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Abstract 
 
Aberrant DNA hypermethylation of promoter CpG islands in the context of a hypomethylated 
genome is a hallmark of cancer. DNA hypomethylation is typically associated with genomic 
instability while CpG island hypermethylation is often linked to gene repression. The 
mechanisms underlying these changes and the role they play in cancer initiation and 
progression remain elusive as they are challenging to study once cancers have progressed, and 
no human experimental models exist to mechanistically investigate this phenomenon.  
We observed that upon reprogramming of primed human embryonic stem cells to the naïve 
state, the acquisition of a globally hypomethylated genome is accompanied by 
hypermethylation of bivalent promoter CpG islands, thus resembling DNA methylation 
patterns characteristic of the human cancer methylome. We dissected the kinetics of these 
DNA methylation changes at high temporal resolution. We found that a subset of bivalent 
genes which are enriched in developmental pathways become hypermethylated, and showed 
that this is mirrored across multiple cancers, suggesting common underlying mechanisms of 
DNA hypermethylation.  
To gain insight into the mechanism of hypermethylation, we investigated the dynamic 
expression of DNA methylation regulators upon reprogramming. We identified the de novo 
DNA methyltransferase DNMT3A as the enzyme primarily responsible for DNA 
hypermethylation, and characterised the consequences of its absence on the naïve pluripotent 
state. Additionally, we demonstrated a role of transcription factors and the pluripotency 
network in coordinating de novo methylation.  
In parallel, we explored the impact of reprogramming on the genomic stability of naïve hESCs 
and investigated a potential relationship between reprogramming and DNA mutations. We 
observed evidence of chromosomal instability upon reprogramming, though the mutation 
frequency appears to remain unchanged. 
The similarities between DNA methylation patterns acquired during reprogramming to naïve 
pluripotency and oncogenic transformation, as well as indications of genomic instability upon 
reprogramming suggest a wider utility for this reprogramming system in understanding cancer 
formation. 
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Introduction 
 
1.1 Primed and Naïve Human Pluripotent States 
 
1.1.1 The origin of Embryonic Stem Cells  
A pluripotent stem cell is a single cell that is able to divide to give rise to all embryonic lineages 
that go on to make up an adult organism, as well as divide to produce daughter cells with 
comparable proliferative and developmental potential to the parent cell (Nichols and Smith 
2009). Such cells can be found in vivo within early mammalian embryos (Nichols and Smith 
2012). Pluripotency can be translated into an in vitro property through the derivation of stem 
cell lines, which can be propagated in culture, and enable maintenance of the pluripotent 
phenotype (Nichols and Smith 2012). The precise developmental stages of the embryo from 
which the stem cells are isolated determine the characteristics of the cells in culture. Typically, 
embryonic stem cells (ESCs) are derived from the inner cell mass (ICM) of the pre-implantation 
blastocyst, while epiblast stem cells (EpiSCs) are derived from the post-implantation epiblast 
(Brons et al. 2007; Tesar et al. 2007). 
 
1.1.2 Human Embryonic Stem Cells in culture 
Human embryonic stem cells (hESCs) are derived from the ICM of pre-implantation human 
blastocysts (Thomson et al. 1998). Their morphology, and their transcriptional and epigenetic 
profiles, however, exhibit more resemblance to murine EpiSCs rather than the more naïve 
mouse embryonic stem cells (mESCs) (Nichols and Smith 2009). It has become increasingly 
common to view pluripotency as a state with fluctuating cellular phenotypes. In vitro, two such 
states, with distinct culture conditions have been defined: naïve pluripotency that represents 
the pluripotent state of cells in the pre-implantation epiblast, and primed pluripotency that 
corresponds to cells primed for differentiation in the post-implantation epiblast (Nichols and 
Smith 2009). More recently, a third stage of formative pluripotency has been proposed as an 
intermediate period between naïve and primed pluripotency, but remains to be tested in vitro 
(Smith 2017). Until recently, the majority of hESC lines have been maintained in the primed 
state, in culture conditions containing fibroblast growth factor (FGF). In these conditions, 
hESCs exist as a population of cells heterogeneous for pluripotency markers, and are primed 
for differentiation (Hackett and Surani 2014). Manipulation of the culture conditions by a 
19 
 
variety of methods enables the reprogramming of primed hESCs to a more naïve state, as well 
as subsequent maintenance and survival of naïve hESCs, as shown in Table 1.1 (Hanna et al. 
2010; Gafni et al. 2013; Chan et al. 2013; Ware et al. 2014; Theunissen et al. 2014; Takashima 
et al. 2014; Chen et al. 2015; Duggal et al. 2015; Qin et al. 2016; Guo et al. 2017). In parallel, 
human preimplantation epiblast cells have been comprehensively characterised at a molecular 
level, providing a guideline for assessing naïve human pluripotency and enabling direct 
comparisons between the in vitro and in vivo naïve pluripotent states (Guo et al. 2014; Smith 
et al. 2014; Yan et al. 2013; Blakeley et al. 2015; Stirparo et al. 2018). 
Each of the naïve state culture conditions involves the use of two small inhibitors (2i) of 
mitogen-activated protein kinase kinase 1/2 (MEK1/2) and glycogen synthase kinase 3 beta 
(GSK3β) in the presence of leukaemia inhibitory factor (LIF). This is based on the knowledge 
that culturing mESCs in 2i+LIF results in a naïve state of pluripotency that better represents the 
cells of the preimplantation epiblast (Ying et al. 2008). Inhibition of the FGF signalling pathway 
that occurs through the use of the MEK1/2 and GSK3β inhibitors has been shown to drive 
genome-wide DNA methylation of mESCs, resulting in a globally hypomethylated state 
representative of the ICM (Ficz et al. 2013; Habibi et al. 2013). Inhibition of GSK3β additionally 
upregulates Wnt signalling which is also activated through other mechanisms and helps to 
sustain the naïve state (Xu et al. 2016). 
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Table 1.1 Culture conditions for the maintenance of naïve hESCs. This table shows the combinations of small 
molecule inhibitors, cytokines and growth factors with varying basal media and oxygen levels, used by different 
groups to reprogram primed hESCs and sustain the survival of naïve hESCs in culture. Some methods additionally 
use transgenes to establish the naïve state. Each approach gives rise to naïve cells that display varying molecular 
profiles, perhaps representing subtly different stages in the transition from primed to naïve pluripotency. 
 
In this thesis, we use the NANOG/Kruppel-like factor 2 (KLF2) overexpression + 2iLGö 
reprogramming method derived by Takashima et al (Takashima et al. 2014), which along with 
the 5iLAF method is considered to give rise to naïve hESCs that most faithfully represent the 
transcriptional profile of the human preimplantation blastocyst (Huang, Maruyama, and Fan 
2014). In this method, primed hESCs are reprogrammed to a naïve state more analogous to 
cells of the ICM (Ying et al. 2008), through transient induced overexpression of NANOG and 
KLF2 transgenes, and inhibition of FGF signalling through the use of two small inhibitors of 
MEK1/2 and GSK3β in the presence of human recombinant leukaemia inhibitory factor (hLIF; 
collectively referred to as 2iL). For long-term propagation of the naïve hESCs, after removal of 
doxycycline (which is used to induce NANOG and KLF2), a pan-protein kinase C (PKC) inhibitor, 
Gö, is used to stabilise the cell state. 
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1.1.3 Differences between primed and naïve human pluripotent states 
Naive hESCs differ from their primed counterparts morphologically, transcriptionally, 
metabolically and epigenetically, as summarised in Figure1.1. Primed hESCs grow as large, flat 
colonies resembling tightly packed cobblestones, while naïve hESCs grow in smaller, dome-
shaped colonies. The gene expression profiles of primed and naïve hESCs have been 
extensively characterised, demonstrating a cohort of pluripotency genes that is enriched in 
naïve hESCs and human preimplantation epiblast cells, though the expression of these genes 
varies to a large degree between various naïve hESC lines derived under different conditions 
(Huang, Maruyama, and Fan 2014) (Figure 1.1a). The naïve gene regulatory network includes 
genes such as KLF4, KLF17, TFCP2L1, and DPPA5, while the primed gene regulatory network 
includes genes such as ZIC2, ZIC3, OTX2 and DUSP6, and both primed and naïve hESCs express 
the core pluripotency genes OCT4, SOX2 and NANOG (Stirparo et al. 2018; Pastor et al. 2016; 
Takashima et al. 2014; Theunissen et al. 2014). In addition to differences in gene expression, 
primed and naïve hESCs can be distinguished based on specific cell surface markers that are 
unique to each cell state (Collier et al. 2017). Primed hESCs, which are primarily glycolytic, 
undergo metabolic realignment upon the transition to the naïve state, through mitochondrial 
activation that enables the use of oxidative phosphorylation (Takashima et al. 2014) (Figure 
1.1b).  
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Figure 1.1 Summary of key changes that occur in the transition from primed to naïve pluripotency. This Figure 
summarizes some of the known key differences between the primed hESCs which grow in large, flattened colonies, 
and the naïve hESCs which grow in smaller, dome-shaped colonies. a) Upon reprogramming, the cells undergo 
transcriptional upregulation of pluripotency factors and a downregulation of genes involved in differentiation 
pathways. b) Primed hESCs are primarily glycolytic, but upon reprogramming, undergo profound mitochondrial 
activation and begin to utilize oxidative phosphorylation in addition to glycolysis (Takashima et al. 2014). c) Upon 
reprogramming, the cells undergo global demethylation alongside some regional hypermethylation (Guo et al. 
2017). The X chromosome also undergoes widespread demethylation and cells display greatly reduced levels of 
repressive histone 3 lysine 27 trimethylation (H3K27me3) (Takashima et al. 2014). 
 
The epigenome undergoes global remodelling as cells transition from the primed to the naïve 
state of pluripotency (Figure 1.1c). Global hypomethylation of the DNA is a hallmark of both 
human and mouse preimplantation embryos, constituting the second wave of global 
epigenetic reprogramming during early mammalian development (Smith et al. 2012; Smith et 
al. 2014; Guo et al. 2014), with the first wave of epigenetic erasure occurring in primordial 
germ cells (Seisenberger et al. 2012) (Figure 1.2). The cells of the ICM from which conventional 
hESCs are derived would therefore be expected to be hypomethylated. Paradoxically, primed 
hESCs in culture display global hypermethylation with levels resembling that of somatic cells 
(Hackett and Surani 2014). Upon reprogramming of primed hESCs to the naïve state, the cells 
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undergo global DNA demethylation across a range of genomic contexts, including 
demethylation of imprints (Takashima et al. 2014; Pastor et al. 2016). Furthermore, female 
naïve hESCs display greatly reduced levels of DNA methylation on the X-chromosome, resulting 
in two active X-chromosomes (Figure 1.1c) (Takashima et al. 2014). 
 
 
Figure 1.2. DNA methylation reprogramming during development. During early development, there are two waves 
of global epigenetic reprogramming. The first wave of erasure takes place upon in primordial germ cells as they 
migrate towards the genital ridge. Following this, the DNA methylation landscapes are established in male and 
female cells at varying rates. The second wave of epigenetic erasure occurs post-fertilisation, once again at distinct 
rates for male and female cells, with the lowest levels of methylation coinciding with the pre-implantation 
blastocyst. hESCs derived from the inner cell mass would be expected to have low levels of methylation, however 
primed hESCs are actually hypermethylated and can be reprogrammed in vitro to a naïve, hypomethylated state. 
Figure adapted from: Smallwood et al (Smallwood and Kelsey 2012). 
 
In this thesis, we will focus primarily on the epigenetic changes occurring between the two 
states, with a specific emphasis on DNA methylation and its interplay with histone 
modifications. In parallel, we will explore the genomic stability of the cells as their epigenomes 
are remodelled during the transition from the primed to the naïve hESC state.  
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1.2 Epigenetic modifications of the DNA and histones 
 
1.2.1 What is epigenetics? 
The term epigenetics was first coined in the 1940s by Conrad Waddington, derived from the 
Greek word “epigenesis”. Epigenetics was defined as “a branch of biology which studies the 
causal interactions between genes and their products which bring the phenotype into being” 
(Waddington 1942, 1968), incorporating all molecular pathways capable of modulating 
genotype and phenotype. Over the years, the definition of the word has narrowed, and the 
current accepted definition is “the study of changes in gene function that are mitotically 
and/or meiotically heritable and that do not entail a change in DNA sequence” (Wu and Morris 
2001). DNA methylation and covalent modifications to the tails of histone proteins are two of 
the most broadly studied classes of epigenetic modifications. 
 
1.2.2 DNA methylation: an epigenetic modification 
DNA methylation, outlined in Figure 1.3a, is the most well characterised epigenetic 
modification that occurs in a cell (Wu and Zhang 2010). Modifications to tails of histone 
proteins, around which the DNA is wrapped, are the other major class of epigenetic 
modifications (Cedar and Bergman 2009) (Figure 1.3a). DNA methylation is carried out by a 
group of proteins called DNA methyltransferases (DNMTs), which catalyse the addition of a 
methyl group to the 5-position of a cytosine (C) residue, using S-adenosyl methionine (SAM) as 
a methyl donor, resulting in 5-methylcytosine (5mC) (Goll and Bestor 2005) (Figure 1.3b). 
Although DNA methylation is a relatively stable epigenetic mark and is maintained across cell 
division and replication, it can be lost from the DNA by both active and passive mechanisms 
(Wu and Zhang 2014). In mammals, DNA methylation typically occurs at a CpG dinucleotide, 
where a cytosine nucleotide is followed by a guanine nucleotide in the 5’-3’ direction. CpG 
sites are underrepresented globally across the genome due to the high mutation rate of 
methylated cytosines (Bird 1980), but 70-80% of those that are present are methylated in 
somatic cells (Ehrlich et al. 1982). Among the globally sparse CpG landscape, short regions of 
high CpG density, called CpG islands (CGIs) are interspersed in the genome, and are commonly 
unmethylated in germ cells, early developmental cell types and somatic cells (Deaton and Bird 
2011; Bird et al. 1985). CGIs are defined as regions with an observed/expected CpG ratio > 0.6 
(Gardiner-Garden and Frommer 1987). Approximately 70% of gene promoters in the human 
genome are associated with a CGI including all housekeeping genes and many developmental 
regulators and tissue-specific genes (Saxonov, Berg, and Brutlag 2006). Tissue specific 
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methylation patterns have been observed at a subset of CGIs associated with developmental 
genes (Illingworth et al. 2008). 
 
 
Figure 1.3. An overview of DNA methylation and histone modifications. a) DNA in the nucleus is wrapped tightly 
around octamers of histone proteins to form chromatin, which is further tightly packed to make up chromosomes. 
Two of the main epigenetic changes that can occur are post-translational modifications to histone tails or direct 
methylation of the cytosine base (depicted in yellow) on the DNA. b) DNA methylation is the addition of a methyl 
group to the 5’ position of a cytosine base by a DNA methyltransferase (DNMT) enzyme, using S-adenosyl 
methionine (SAM) as a methyl donor. 
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1.2.3 Biological functions of DNA methylation in mammalian development 
Large-scale studies of DNA methylation have observed limited heterogeneity in DNA 
methylation patterns between individuals, while the patterns across cell and tissue types 
exhibit greater variation, indicative of a relationship between DNA methylation and 
differentiation (Eckhardt et al. 2006). DNA methylation typically occurs in a tissue and cell type 
specific pattern. Correct patterns of DNA methylation are crucial for early development and 
cell differentiation. At the level of individual genes, the role of DNA methylation in influencing 
gene expression remains a subject of debate. Early studies on DNA methylation dating back to 
1979 provided indirect indications for a role of DNA methylation in silencing gene expression 
(McGhee and Ginder 1979). This was supported by more direct studies showing that the 
perturbation of DNA methylation in mESCs using the cytidine analog 5-azacytidine inhibited 
cell differentiation that was dependent on gene expression changes (Jones and Taylor 1980), 
and that 5-azacytidine could restore the expression of previously silenced genes (Mohandas, 
Sparkes, and Shapiro 1981). Two models evolved to explain the mechanisms by which 5mC 
may operate once added to the DNA. The modified base can inhibit the DNA-binding ability of 
factors that are required for transcription if the methylated cytosine falls within their 
respective DNA sequence recognition motifs (Watt and MoUoy 1988; Zhu, Wang, and Qian 
2016). Alternatively, 5mC can be recognised by methyl-CpG binding domain proteins (MBDs), 
and this evidence initially came from the identification of methyl-CpG binding proteins 1 and 2 
(MECP1 and MECP2) (Meehan et al. 1989). These MBD-containing proteins interact with other 
co-repressor proteins that are able to influence transcriptional regulation and modify 
surrounding chromatin (Jones et al. 1998; Nan et al. 1998), as well as influencing DNA repair 
(Meng et al. 2015). Several studies in later years added to the pool of evidence supporting a 
causal relationship between DNA methylation at gene promoters and transcriptional 
repression, particularly as actively transcribed gene promoters were found to feature very low 
levels of DNA methylation (Siegfried et al. 1999; Boyes and Bird 1991; Naveh-Many and Cedar 
1981). Moreover, studies into the developmental processes of X-chromosome inactivation and 
genomic imprinting have provided evidence for DNA methylation in mediating gene silencing. 
In both of these contexts, DNA methylation has been shown to silence the underlying DNA, 
enabling cells to retain a single active X-chromosome or expression of imprinted genes from a 
single gene copy (Wolf 1984; Li, Beard, and Jaenisch 1993). Interestingly, despite the 
association between de novo methylation and gene silencing, upon global demethylation that 
occurs in primordial germ cells and during conversion of mESCs to the naïve state, DNA 
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methylation and transcription appear to be uncoupled, as the hypomethylated state does not 
result in re-expression of genes (Ficz et al. 2013; Seisenberger et al. 2012). 
On a more global scale, DNA methylation also plays a role, as approximately 70% of the 
genome is methylated in somatic cells, and modern methylation mapping technologies have 
indicated that these highly methylated sequences constitute repetitive elements and 
transposons, satellite DNA, intergenic DNA and gene exons (Li and Zhang 2014). Global DNA 
methylation is key to maintenance of genomic integrity through silencing of retrotransposons 
(Bestor 2004) and it is known that DNA methylation is essential for developmental viability as 
targeted disruption of the DNMTs in mice results in embryonic lethality (Okano 1999; Li, 
Bestor, and Jaenisch 1992). 
 
1.2.4 DNA methylation occurs in different genomic contexts 
Although typically considered a repressive mark associated with transcriptional silencing at CGI 
gene promoters, it has become increasingly evident that DNA methylation can have varying 
outcomes, dependent on the underlying genomic context (Jones 2012). CGIs located at the 
transcriptional start sites (TSS) of genes are commonly unmethylated, and their methylation is 
associated with long-term gene silencing. DNA methylation is typically considered to provide a 
stable lockdown on chromatin that has been silenced by other mechanisms, though there is 
evidence that DNA methylation can also have an instructive role in initiating silencing (Jones 
2012). Genes without CGIs at their TSS can also display substantial variation in the levels of 
promoter methylation, but the functional relationship of this methylation with gene 
expression is less clear (Jones 2012). CGIs also exist within the bodies of genes, and outside of 
genes. Their functions here remain unknown, though it has been postulated that these regions 
may represent orphan or alternative promoters (Illingworth et al. 2010), however DNA 
methylation within gene bodies is not associated with transcriptional repression. Methylation 
of alternative promoters within gene bodies can, however, contribute to the control of 
alternative promoter usage (Maunakea et al. 2010). Variable levels of DNA methylation are 
also detected within gene enhancers and may have an impact upon enhancer activity (Schmidl 
et al. 2009).  
Aside from the genomic context of DNA methylation, studies have shown that the DNA 
sequences up to 2 kilobases (kb) away from the CGIs, termed CGI shores, are prone to large 
variation in DNA methylation levels across tissue types and in disease contexts (Irizarry et al. 
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2009). Moreover, these CGI shores have been shown to be susceptible to changes in 
methylation upon cellular reprogramming (Doi et al. 2009). 
 
1.2.5 Histone modifications: the histone code 
The other well characterised class of epigenetic modifications are post-translational 
modifications to the N-terminal tails of histone proteins, which were first discovered in 1964 
(Allfrey, Faulkner, and Mirksy 1964). The histone tails can be modified in a variety of ways, 
each with a different impact upon chromatin structure, and the various combinations of 
histone modifications can give rise to numerous chromatin states that can influence 
transcription, DNA replication, DNA repair and recombination, by modifying chromatin 
structure or providing a binding platform for transcription factors (Kouzarides 2007). The most 
well characterised post-translational modifications to histone tails include methylation, 
acetylation, phosphorylation and ubiquitination, which can occur on lysine (K), arginine (R), 
serine (S), threonine (T) or tyrosine (Y) residues on any of the variants of histone proteins that 
constitute a histone octamer (Kouzarides 2007). Figure 1.4 depicts the majority of possible 
histone modifications that have been detected to date, though additional modifications are 
continually discovered as technologies advance.  
For this thesis, we will focus primarily on the methylation of lysine residues, specifically those 
occurring on histone H3, as these are particularly involved in the interplay with DNA 
methylation (Cedar and Bergman 2009). Lysine residues can be either mono-, di- or 
trimethylated, which adds further complexity to the histone code and the associated 
functional response (Kouzarides 2007). A combination of the methylation state and the 
position of the lysine residue on the histone tail determines whether the lysine methylation 
confers an active or repressed transcriptional or chromatin state (Hyun et al. 2017). Each 
individual type of histone lysine methylation on histone H3 is written, read and erased by 
distinct proteins (Hyun et al. 2017), which are summarised in Table 1.2. Typically, H3K4, H3K36 
and H3K79 modifications are thought to mark active transcription along with histone 
acetylation, H3K9 and H3K27 are associated with a repressive chromatin state, and H3K4me1 
is enriched at gene enhancers  (Kouzarides 2007).  
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Figure 1.4. Common post-translational modifications associated with histone proteins. Histone octamers 
consisting of H2A, H2B, H3 and H4 make up nucleosomes. DNA (shown in green) is wrapped around nucleosomes. 
This figure depicts the positions of post-translational modifications (phosphorylation, ubiquitination, methylation 
and acetylation) located on each of the histone tails, with the location of the amino acid on the histone tail 
indicated with a number and the type of amino acid indicated with the single letter amino acid code.  
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Histone 
modification 
Writers 
(methyltransferases) 
Methylation 
state 
specificity 
Erasers 
(demethylases) 
Methylation 
state 
specificity 
H3K4 SET1A/B, MLL1/2, 
PRDM9 
me1/2/3 LSD1/2 me1/2 
MLL3/4 me1/2 NO66 me1/3 
SMYD1/2, SET7/9 me1 JARID1A/C/D me2/3 
PRMD9 me1/2/3 JARID1B me1/2/3 
H3K9 SUV39H1/2 me2/3 JHDM2 family, 
PHF8 
me1/2 
G9a, GLP, SETDB1 me1/2 JMHD3 family me2/3 
PRDM family -   
H3K27 EZH1, EZH2 me2/3 UTX, UTY, JMJD3  me2/3 
  PHF8, KIAA1718 me2 
H3K36 SETD2 me3 JHDM1/3 family me1/2 
SETD3, NSD1-3  me1/2 JHMD3 family me2/3 
SMYD2, ASH1L, SETMAR me2   
H3K79 DOT1L me1/2/3 - - 
Table 1.2. Writers and erasers of histone lysine methylation. This table summarises the known human modifiers 
(methyltransferases and demethylases) of histone lysine methylation at histone H3, and their methylation state 
specificities. Information compiled from (Hyun et al. 2017).  
 
In ESCs, regions of co-enrichment of H3K4me3 and H3K27me3 mark regions of DNA termed 
bivalent regions which regulates changes in transcriptional activity from poised to active or 
silenced states upon lineage specification and cell differentiation (Mikkelsen et al. 2007; 
Bernstein et al. 2006; Azuara et al. 2006). Upon differentiation, the resolution of bivalent 
chromatin occurs through removal of either H3K4me3 or H3K27me3, along with changes to a 
number of other histone modifications and DNA methylation, resulting in repressed or active 
chromatin respectively (Figure 1.5). Although bivalency has primarily been studied in ESCs, 
bivalent chromatin is not unique to pluripotent cells as adult stem and progenitor cells such as 
neural progenitors also exhibit chromatin domains marked by H3K4me3 and H3K27me3 
(Mohn et al. 2008; Oguro et al. 2010).  
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Figure 1.5 Resolution of bivalent chromatin domains. Bivalent chromatin at poised promoters in ESCs, marked by 
H3K4me and H3K27me3, is resolved into either a repressed state marked by H3K27me3 or an actively transcribing 
state marked by H3K4me3.  
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1.3 Mechanisms of DNA methylation 
 
1.3.1 The DNA methyltransferase family 
The DNMT family of proteins (Figure 1.6) are responsible for establishing and maintaining DNA 
methylation marks on the DNA.  
 
 
Figure 1.6. Structures of the mammalian DNMT family of proteins. The DNMT family has a number of highly 
conserved C-terminal motifs in the catalytic region, shown as thick black lines (indicated as I–X). DNMT3L does not 
have catalytic activity. Functional domains required for enzymatic regulation are present in the N-terminal regions 
of DNMTs. Sub-domains for DNMT1 include a proliferating cell nuclear antigen binding site (PBD), nuclear 
localisation signal region (NLS), a replication fork targeting domain (RFTD), a cysteine rich CXXC domain (binds DNA 
containing CpG dinucleotides), and two bromo-adjacent homology domains (BAH1/2). For the DNMT3s, domains 
include an ADD (ATRX DNMT3 DNMT3L) domain, and for DNMT3A/B, an additional PWWP domain (highly 
conserved proline–tryptophan–tryptophan–proline motif that is involved in protein–protein interactions).  
Figure taken from: Jelstch and Jurkowska, 2016 (Jeltsch and Jurkowska 2016). 
 
 
There are four main members of the mammalian DNMT family, of which three are 
enzymatically active. DNMT1 shows a stronger preference for methylating hemimethylated 
DNA in vitro, while DNMT3A and DNMT3B do not show a preference for hemimethylated DNA 
compared to unmethylated DNA (Okano 1998; Okano 1999). The third of the DNMT3 family, 
DNMT3L, is catalytically inactive (Figure 1.6). An additional DNMT, DNMT2 shows activity in 
vitro but does not play a role in CpG methylation in mammalian cells (Okano, Xie, and Li 1998; 
Hermann, Schmitt, and Jeltsch 2003). Much of what is known about the functions of these 
enzymes is determined by gene knockout studies in embryos or ESCs, typically in murine cells 
and more recently in human ESCs (Table 1.3). DNMT3A and DNMT3B are thought to primarily 
be responsible for de novo methylation of DNA and are required for establishing DNA 
methylation patterns in the early developing embryo and setting up genomic imprints during 
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germ cell development (Okano 1999). The two proteins have distinct functions throughout 
embryonic development, both temporally and spatially, with DNMT3A being primarily 
responsible for maternal imprinting and DNMT3B for methylation of pericentromeric repeats 
and X-chromosome inactivation (Meng et al. 2015). This suggests that each enzyme has 
regional specificity determined by regulation in their N-terminal domains. DNMT3A and 
DNMT3B are expressed at high levels in the early developing embryo, but their expression 
decreases as cells differentiate. While DNMT3L does not exhibit catalytic activity, it is highly 
expressed in germ cells and in early embryo development, where it is essential for the 
establishment of maternal imprints in the developing oocyte, and as a mandatory cofactor for 
the de novo methyltransferases (Goll and Bestor 2005; Liao et al. 2012). DNMT1 is 
predominantly a maintenance methyltransferase that preserves  established patterns of DNA 
methylation on the daughter DNA strand as cells undergo DNA replication upon dividing (Goll 
and Bestor 2005). DNMT1 is highly expressed in dividing cells and is ordinarily localised to 
replication foci (Leonhardt 1992). DNMT1 is considered to exhibit imperfect fidelity of 
maintenance methylation activity in the absence of de novo methylation activity of DNMT3A 
and DNMT3B (Liao et al. 2015). Additionally, de novo methylation activity of DNMT1 has also 
been reported in various cellular settings (Jair et al. 2006; Fatemi et al. 2002; Vertino et al. 
1996; Bestor 2000).  
The catalytic domain is present in the C-terminal of the DNMT enzymes, with the exception of 
DNMT3L (Figure 1.6). The N-terminal regions of the DNMT proteins differ between DNMT1 and 
the DNMT3 enzymes (Jurkowska, Jurkowski, and Jeltsch 2011). The primary role of the N-
terminal is in regulation and targeting of the enzymes by mediating their interaction with 
chromatin and with other proteins. The N-terminus of DNMT1 contains a number of domains 
that mediate its interaction with replicating DNA (Jurkowska, Jurkowski, and Jeltsch 2011) 
(Figure 1.6). The N-termini of the DNMT3 enzymes contain domains that mediate interactions 
of the enzymes with chromatin. DNMT3A/B/L each possess an ADD domain capable of 
mediating allosteric activation of the enzymatic activity upon interaction with unmethylated 
H3K4 (Otani et al. 2009; Ooi et al. 2007; Guo et al. 2015; Zhang et al. 2010), and both DNMT3A 
and DNMT3B also possess a PWWP domain capable of interacting with H3K36me3 and 
targeting the enzymes to pericentromeric chromatin and gene bodies (Ge et al. 2004; 
Dhayalan et al. 2010; Baubec et al. 2015; Chen, Tsujimoto, and Li 2004). 
Each of the human DNMT genes makes use of splicing and alternative promoter usage, 
generating isoforms of the proteins whose expression can vary with different stages of 
development and in disease. DNMT3A has two main isoforms in human cells: a full length 
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isoform DNMT3A1 that has an extended N-terminal region and is typically expressed in 
somatic cells, and a shorter isoform DNMT3A2, whose expression is typically restricted to early 
developmental cell types (Chen et al. 2002). DNMT3B has multiple isoforms identified in 
various cell types (Duymich et al. 2016; Ostler et al. 2007). The main isoform expressed in 
developmental cells is DNMT3B1. Levels of DNMT3B1 decrease sharply during differentiation, 
as cells begin to express an alternative, inactive isoform of the protein (Gifford et al. 2013; 
Gordon, Hartono, and Chedin 2013). 
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Gene DNA Specificity Major Function Mouse knock-out 
phenotype 
Human ESC 
knockout 
phenotype 
DNMT1 Hemimethylated 
DNA 
Maintenance 
methyltransferase 
Genome-wide loss of 
DNA methylation, 
embryonic lethality at 
embryonic day 9.5 
(E9.5), abnormal 
imprinted gene 
expression, activation 
of silent 
retrotransposons (Li, 
Bestor, and Jaenisch 
1992; Howell et al. 
2001) 
Immediate lethality. 
Homozygous mutants 
rescued with ectopic 
DNMT1 show that 
acute DNMT1 loss 
results in rapid global 
demethylation in 1 
week (Liao et al. 
2015) 
DNMT3A Equal preference for 
hemimethylated and 
unmethylated DNA 
De novo DNA 
methyltransferase 
Postnatal lethality at 
4–8 weeks, failure to 
establish methylation 
imprints in both male 
and female germ cells 
(Okano 1999) 
Viable. Gradual loss 
of methylation at a 
subset of CpGs, retain 
up to 65% of original 
global methylation 
levels (Liao et al. 
2015) 
DNMT3B Equal preference for 
hemimethylated and 
unmethylated DNA 
De novo DNA 
methyltransferase 
Demethylation of 
minor satellite DNA, 
embryonic lethality 
around E14.5 days 
(Okano 1999) 
Viable. Gradual loss 
of methylation at a 
subset of CpGs, retain 
up to 65% of original 
global methylation 
levels (Liao et al. 
2015) 
DNMT3L N/A Cofactor required 
for de novo 
methyltransferase 
activity in ESCs 
Lack of appropriate 
methylation of 
maternal allele and 
lack of sperm in 
homozygous males 
(Webster et al. 2005). 
Not Reported 
Table 1.3 Specificities, roles and knockout phenotypes of DNMTs. This table summarises the properties of DNMT 
proteins deduced from a number of knockout studies in mouse and human cells. 
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1.3.2 Cross-talk between DNA methylation and histone modifications 
To carry out DNA methylation, the DNMTs must be targeted to the correct regions of the DNA. 
Mammalian DNA methyltransferases themselves have little or no innate sequence specificity 
beyond the CpG dinucleotide (Goll and Bestor 2005), although it has been shown that both 
DNMT3A and DNMT3B are sensitive to the sequences flanking their target CpG sites (Handa 
and Jeltsch 2005; Lin et al. 2002). Additionally, mechanisms must be in place to prevent CGIs 
that do not require methylation from becoming de novo methylated. Deposition of DNA 
methylation within the genome is generally not considered to occur randomly, and several 
studies have highlighted a relationship between DNA methylation and modifications to histone 
tails. This relationship may work in both directions, with histone methylation directing DNA 
methylation patterns in certain contexts, and DNA methylation guiding histone modifications 
in other contexts such as upon DNA replication. Methylation of histone H3, particularly at 
lysine 4 (H3K4), 9 (H3K9), 27 (H3K27) and 36 (H3K36) is particularly involved in the interplay 
with DNA methylation, and histone acetylation negatively correlates with DNA methylation 
(Cedar and Bergman 2009). There is evidence to suggest that some of this cross-talk may be 
brought about through direct interactions between the proteins responsible for carrying out 
DNA methylation and histone lysine methylation, rather than through the modifications 
themselves (Cedar and Bergman 2009).   
DNMT1 is recruited to the DNA by ubiquitin-like with PHD and RING finger domain-containing 
protein 1 (UHRF1), a member of the Ring finger-type E3-ubiquitin ligase family, which also 
regulates the degradation and stability of DNMT1 (Sharif et al. 2007; Bostick et al. 2007; Qin, 
Leonhardt, and Spada 2011) (Figure 1.7a). UHRF1 associates directly with dimethylated or 
trimethylated H3K9 (H3K9me2/3), present in regions of heterochromatin, as well as binding to 
hemimethylated CpGs during the S phase of DNA replication (Liu et al. 2013; Rothbart et al. 
2012). It thereby brings DNMT1 into proximity of the hemimethylated DNA, enabling DNMT1 
to copy methylation onto the daughter DNA strand. This is further assisted by the interaction 
of DNMT1 with proliferating cell nuclear antigen (PCNA) through its N-terminal PCNA binding 
domain (Figure 1.7a). PCNA is an auxiliary factor involved in DNA replication and repair, so this 
interaction enhances methylation maintenance at DNA replication forks (Chuang et al. 1997). 
In vivo, studies have also shown that the DNMT1-UHRF1 complex interacts with ubiquitin 
carboxyl-terminal hydrolase 7 (USP7), which stimulates the activity of DNMT1 and regulates 
the stability of UHRF1 (Felle et al. 2011). Other studies have shown that the H3K9me2-specific 
methyltransferase G9a/GLP interacts directly with DNMT1 and may be required for DNA 
methylation at some loci (Esteve et al. 2006).  
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The lysine methyltransferase G9a/GLP has been reported to interact with DNMT3A, mediated 
by the M-phase phosphoprotein 8 (MPP8) (Chang et al. 2011). The H3K9 methyltransferase 
SETDB1 has also been shown to interact with DNMT3A, and SUV39H1 has been reported to 
interact with both DNMT3A and DNMT3B (Li et al. 2006; Fuks, Hurd, Deplus, et al. 2003). 
Collectively, this points to coordination of H3K9me2 and DNA methylation in regions of 
heterochromatin (Figure 1.7b). Once DNA methylation has been established in regions of 
heterochromatin, MBDs such as MECP2 can bind to methylated DNA and recruit histone 
deacetylases (HDACs) (Jones et al. 1998) to repress transcription, as well as interacting with 
H3K9 methyltransferases to further maintain the repressive chromatin state (Fuks, Hurd, Wolf, 
et al. 2003). 
Trimethylated H3K27 (H3K27me3), like DNA methylation is associated with repressed DNA. 
The relationship between the two marks, however, is complex, as one or the other can 
precede (Mohn et al. 2008), indicating that DNA methylation can act as either a leader or a 
sealant in the silencing of chromatin (Ficz 2015). During development, however, H3K27me3 
and DNA methylation are considered to be mutually exclusive at CpG rich regions (Brinkman et 
al. 2012). However, many of these regions undergo silencing and gain DNA methylation upon 
differentiation, suggesting a cell context dependent cross-talk between H3K27me3 and DNA 
methylation (Mohn et al. 2008; Meissner et al. 2008). It has been demonstrated that the 
polycomb repressive complex 2 (PRC2), which includes the H3K27me3 methyltransferase 
Enhancer of Zeste homolog 2 (EZH2), can directly interact with the DNMTs to direct DNA 
methylation (Vire et al. 2006). However, recent studies suggest that while PRC2 can recruit 
DNMT3A to the DNA, it is not sufficient to trigger de novo DNA methylation, indicating that 
additional factors are required (Rush et al. 2014). Additionally, deletion of PRC2 components 
does not lead to changes in DNA methylation (Hagarman et al. 2013; Boulard, Edwards, and 
Bestor 2015).  
CGIs enriched with trimethylated H3K4 (H3K4me3), a mark of active gene promoters 
(Guenther et al. 2007), are typically protected from DNA methylation. This is supported by the 
finding of a strong anti-correlation between DNA methylation and H3K4me3 in many cellular 
contexts (Weber et al. 2007). The proteins Cfp1 and KDM2A are both able to bind specifically 
to unmethylated CpGs via their CXXC domains (Blackledge et al. 2010), and subsequently 
recruit the H3K4 methyltransferase SETD1 to the chromatin (Thomson et al. 2010) (Figure 
1.7c). Additionally, it has also been shown that ten-eleven translocase 1 (TET1) can contribute 
to the protection of CGIs from DNA methylation (Williams et al. 2011; Wu et al. 2011; Verma et 
al. 2018), as can the lysine demethylase FBXL10 (also known as KDM2B or JHDM1B) (Boulard, 
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Edwards, and Bestor 2015).  In certain developmental contexts, DNMT3A and DNMT3B 
function in complex with DNMT3L, which facilitates their enzymatic activity (Ooi et al. 2007) 
(Figure 1.7c). The ADD domain of DNMT3L selectively recognises unmethylated H3K4, and 
enhances access of either DNMT3A or DNMT3B to CGIs that require methylation (Ooi et al. 
2007). The ADD domain of DNMT3A and DNMT3B is also able to directly interact with 
unmethylated H3K4, resulting in DNA methylation of chromatin with this modification state 
(Zhang et al. 2010).  
Trimethylation of H3K36 (H3K36me3) is associated with the gene bodies of genes that are 
actively transcribed, and correlates with an enrichment of DNA methylation (Wagner and 
Carpenter 2012). The PWWP domains of DNMT3A and DNMT3B preferentially bind to 
H3K36me3, hence directing DNA methylation to gene bodies (Dhayalan et al. 2010; Baubec et 
al. 2015), as well as to pericentromeric heterochromatin (Figure 1.7c) (Chen, Tsujimoto, and Li 
2004; Ge et al. 2004). 
While the above mechanisms give us a general overview of how the DNMTs gain access to the 
DNA during early development, they do not shed light on how the enzymes are targeted more 
specifically both spatially and temporally to give rise to cell-specific epigenetic patterns. 
Various ideas have been reported, such as the interaction of DNMTs with transcription factors 
(Hervouet, Vallette, and Cartron 2010; Hervouet, Vallette, and Cartron 2014), the local 
influence of DNA-binding factors (Stadler et al. 2011), and the influence of micro RNAs (Denis, 
Ndlovu, and Fuks 2011), but a unified targeting mechanism applicable to both development 
and disease is yet to be described. 
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Figure 1.7. Cross-talk between DNA methylation and histone modifications. a) DNMT1 is recruited to replicating 
DNA by UHRF1, which recognises both H3K9me2/3 and hemimethylated DNA and interacts with PCNA. b) At regions 
of heterochromatin, DNMT3A and DNMT3B interact with the H3K9 methyltransferases SETDB1, SUV39H1 and G9a 
to coordinate DNA methylation and H3K9me3. MECP2 binds to methylated DNA and recruits more H3K9 
methyltransferases to maintain the repressive state. c) At gene promoters marked by H3K4me3, the binding 
between the ADD domain of DNMT3s and unmethylated H3K4 is abrogated. CFP1 and KDM2A bind unmethylated 
CpGs through their CXXC domains and recruit SETD1 to methylated H3K4. Gene bodies are marked by H3K36me3, 
which is recognised by the PWWP domains of DNMT3A and DNMT3B to direct DNA methylation.   
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1.3.3 Epigenetic mechanisms during development 
The global methylation of CpGs across the genome, with unmethylated CGIs results in a 
bimodal distribution of DNA methylation. During early mammalian development, cells undergo 
two waves of global erasure of DNA methylation. The first wave occurs in primordial germ cells 
and the second wave occurs in the early blastocyst upon fertilisation (Figure 1.2) (Seisenberger 
et al. 2012; Smith et al. 2012; Smith et al. 2014; Guo et al. 2014). DNA methylation patterns are 
subsequently re-established following implantation of the embryo by a wave of de novo 
methylation by the de novo methyltransferases DNMT3A and DNMT3B, in complex with 
DNMT3L (Okano 1999). It is possible that H3K4me3 patterns are established first and protect 
CGIs from this wave of re-methylation, allowing them to remain unmethylated (Ooi et al. 
2007). Additionally cis-acting DNA-binding sequences play a role in protecting CGIs from de 
novo methylation, as has been demonstrated for specificity protein 1 (Sp1) elements (Brandeis 
et al. 1994; Macleod et al. 1994). The wave of de novo methylation re-instates the bimodal 
distribution of DNA methylation in the developing embryo.  
Later in development, the genome undergoes further alterations to DNA methylation patterns. 
In particular, upon the formation of the germ layers during gastrulation, genes responsible for 
the maintenance of pluripotency are no longer protected from DNA methylation and instead 
are targeted for de novo methylation and repression (Gidekel and Bergman 2002). Unlike the 
global wave of de novo methylation upon implantation, de novo methylation of the 
pluripotency genes requires specific targeting of the DNMTs to pluripotency gene promoters. A 
multi-step mechanism has been outlined for the pluripotency gene Oct3/4, and is relevant for 
the control of other pluripotency genes (Epsztejn-Litman et al. 2008). The direct interaction of 
repressor molecules with the gene promoter can silence transcription, and this is followed by 
recruitment of the H3K9 methyltransferase G9a and HDACs by transcription factors. Following 
deacetylation of lysine residues and methylation of H3K9, the heterochromatin protein 1 (HP1) 
binds and facilitates formation of heterochromatin, and DNMT3A and DNMT3B are recruited 
as part of the G9a complex to carry out de novo methylation of the Oct3/4 promoter for stable 
gene repression (Fuhrmann et al. 2001; Feldman et al. 2006; Epsztejn-Litman et al. 2008).  
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1.4 Mechanisms of DNA demethylation 
 
1.4.1 Active demethylation 
Although patterns of DNA methylation are relatively stable in terminally differentiated cells, 
the genome can lose DNA methylation by both active and passive mechanisms of DNA 
methylation. These processes are at play during developmental cellular reprogramming (Wu 
and Zhang 2010). Unlike the machinery involved in regulating histone post-translational 
modifications, a dedicated DNA demethylase has not been identified. Instead the mechanisms 
that regulate removal of 5mC involve further modification to the base, or passive dilution of 
the base across cell divisions.  
Like DNA methylation, the targeting of the active mechanisms of demethylation can be global 
or loci-specific. There are three members of the ten-eleven translocation methylcytosine 
dioxygenase (TET) family of proteins (Figure 1.8), each with cell-specific expression patterns 
and specific, non-overlapping target genes or genomic regions (Wu and Zhang 2011).  
 
 
Figure 1.8. The ten-eleven translocation methyltransferase dioxygenase (TET) family. There are three members of 
the TET family. All three TETs have a double-stranded helix fold (DSBH) and a cysteine rich domain, and TET1 and 
TET3 have an additional CXXC domain which TET2 lacks. 
Figure taken from: Meng et al. (Meng et al. 2015) 
 
 
TET enzymes can oxidise 5mC to 5-hydroxymethylcytosine (5hmC), which can subsequently be 
further oxidised to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Tahiliani et al. 2009; 
Kriaucionis and Heintz 2009; Ito et al. 2011), as shown in Figure 1.9a. Once converted, these 
marks are not recognised by DNMT1 during DNA replication (Valinluck and Sowers 2007), 
leading to loss of DNA methylation as cells divide. Additionally, the 5mC oxidation products 
may however be cleaved by the thymine-DNA glycosylase (TDG) and activate the base excision 
repair (BER) pathway (Maiti and Drohat 2011) (Figure 1.9a).  Alternatively, 5mC or 5hmC can 
be deaminated by the activation induced cytidine deaminase (AID/AICDA) or related APOBEC 
proteins to form thymine and 5-hydroxymethyluracil (5hmU), both of which can subsequently 
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also undergo excision by TDG and other glycosylases, and activate the BER pathway (Figure 
1.9a) (Bhutani et al. 2010; Guo et al. 2011; Popp et al. 2010). Though the role of AID in active 
demethylation is controversial, an in vivo study in mice reported that AID-deficient primordial 
germ cells were up to three times more methylated than their wildtype counterparts (Popp et 
al. 2010), suggesting that AID may play a role in active DNA demethylation through 
deamination. Additionally, overexpression of AID in B-cell lymphomas leads to increased 
epigenetic heterogeneity driven by AID-driven demethylation rather than mutation (Teater et 
al. 2018). 
Although 5hmC, 5fC and 5caC are intermediates in active demethylation, each of the modified 
bases can be identified in tissues, implying that they are stable bases and may have functions 
beyond acting as intermediates in the process of demethylation (Bachman et al. 2014; 
Bachman et al. 2015). Levels of 5hmC vary across tissue types and are most abundant in brain 
tissue and in ESCs, where they can be found at levels approximately 10-fold lower than 5mC 
(Nestor et al. 2012; Munzel, Globisch, and Carell 2011). Both 5fC and 5caC can be detected at 
levels approximately 10-100 fold lower than that of 5hmC (Bachman et al. 2015; Pfaffeneder et 
al. 2011). In ESCs, 5hmC is prevalent in euchromatin, particularly at transcriptional start sites, 
promoters, exons, gene bodies and active enhancers, and is typically found at genomic regions 
with intermediate CpG density (Shen and Zhang 2013; Ficz et al. 2011). Additionally, 5hmC is 
primarily enriched at developmental genes marked by bivalent histone modifications or 
polycomb target genes (Pastor et al. 2011). This correlates with the genome-wide pattern of 
TET1 enrichment which is proposed to protect bivalent CGIs from de novo DNA methylation 
(Williams et al. 2011; Wu et al. 2011). 5fC exhibits a similar pattern of enrichment to 5hmC in 
ESCs, but its enrichment at gene promoters correlates with active gene expression (Neri et al. 
2015). Evidence from recent years indicates that each of these modified bases may exert their 
own regulatory functions on the DNA through binding to or recruitment of other factors (Song 
and He 2013). 5hmC is known to inhibit the binding of MBDs and has also been shown to 
recruit chromatin remodelling complexes to 5hmC-marked genes (Yildirim et al. 2011; 
Valinluck et al. 2004), and 5fC has also been shown to interact with transcription and 
chromatin regulating factors (Iurlaro et al. 2013; Spruijt et al. 2013). 
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Figure 1.9. Mechanisms of DNA demethylation. a) DNA demethylation can occur actively through oxidation of 5-
methylcytosine (5mC) by the ten-eleven translocation methylcytosine dioxygenase (TET) enzymes to 5-
hydroxymethylcytosine (5hmC), and further on to 5-formylcytosine and 5-carboxylcytosine (5caC). The modified 
bases may be removed by thymine-DNA glycosylase (TDG), resulting in an abasic site and activation of the base 
excision repair (BER) pathway and replacement of an unmodified cytosine base. Alternatively, deamination of 5mC 
of 5hmC by activation induced cytidine deaminase (AID) and related proteins results in a thymine or 5-
hydroxyuridine (5hmU) base that causes a mismatch and activates the base excision repair pathway. b) 
Demethylation can also occur passively through dilution of DNA methylation upon DNA replication across cell 
divisions in the absence of faithful methylation maintenance by DNMT1. 
 
 
1.4.2 Passive demethylation 
As well as active removal of 5mC, DNA demethylation can occur passively by dilution of 
methylation over cell divisions if it is not faithfully maintained by the maintenance 
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methyltransferase DNMT1 upon DNA replication (Wu and Zhang 2010) (Figure 1.9b). This could 
be as a result of absence or downregulation of the protein, or inactivity of its enzymatic 
function. In mESCs grown in 2i conditions, impairment of DNA methylation maintenance as a 
result of both downregulation of UHRF1 and globally reduced H3K9me2 has been identified as 
the primary mechanism of global demethylation (von Meyenn et al. 2016). Unlike active 
demethylation mechanisms, which are likely targeted to specific regions of the DNA in 
response to cellular stimuli, passive demethylation is likely more unspecific and would result in 
genome-wide loss of methylation. 
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1.5 Epigenetic changes in cancer 
 
1.5.1 Aberrant DNA methylation patterns in cancer 
DNA methylation patterns are commonly altered in a number of human diseases. Disruption of 
canonical DNA methylation patterns is a hallmark of human cancers, typically characterised by 
loss of global genomic DNA methylation accompanied by site-specific hypermethylation (Figure 
1.10) (Jones and Baylin 2007; Baylin and Jones 2011; Esteller et al. 2001; Feinberg, Ohlsson, 
and Henikoff 2006; Ehrlich 2002). DNA hypomethylation is typically associated with genomic 
instability (Eden et al. 2003; Gaudet et al. 2003), while site-specific DNA hypermethylation 
occurs at promoter CpG islands and is often associated with repression of tumour suppressor 
genes in cancer cells (Jones and Baylin 2002). Whether DNA methylation changes are a cause 
of consequence of tumourigenesis remains a recurrent controversial question in the field, but 
emerging research is beginning to answer this question.  
 
 
Figure 1.10. DNA methylation patterns in cancer. Typically, cancer cells exhibit genome-wide hypomethylation 
accompanied by hypermethylation of specific gene promoters compared to their normal counterparts. Genome-
wide hypomethylation is associated with genomic instability, while promoter hypermethylation has been associated 
with transcriptional repression. Each black lollipop represents a methylated cytosine, while the black lines represent 
unmethylated cytosines. 
 
 
1.5.2 DNA hypermethylation in cancer 
Early experiments based on the study of individual genes indicated that it was primarily 
tumour-suppressor genes that underwent aberrant DNA hypermethylation in cancer (Jones 
and Baylin 2002). Multiple tumour suppressor genes, such as CDKN2A and BRCA1, that are 
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commonly mutated in cancers were found to by hypermethylated in various cancer types 
(Dobrovic and Simpfendorfer 1997; Merlo et al. 1995). Moreover, in some cases, such as with 
MLH1, hypermethylation was detected in the absence of any mutations to the gene, resulting 
in loss of function analogous to MLH1 gene mutations and a driving role in tumourigenesis 
(Kane et al. 1997; Herman et al. 1998). Hypermethylation of single tumour suppressor genes 
was thought to be propagated in cancer cells as a result of cellular selection due to the 
inhibition of tumour suppressor activity, as these genes are typically involved in pathways such 
as DNA repair and genomic stability, cell cycle and cell division, and metabolism (Llinas-Arias 
and Esteller 2017). Experiments carried out with more advanced DNA methylation mapping 
technologies showed that this phenomenon is more widespread and that a large number of 
CGIs are hypermethylated in cancer (Costello et al. 2000; Jones and Baylin 2007). While several 
studies have shown clear repressive roles of hypermethylation for individual tumour 
suppressor genes (Jones and Baylin 2002), many of the large number of loci hypermethylated 
in cancers are not tumour suppressor genes. It remains less well understood what the purpose 
of hypermethylation of a large number of loci might be. Many of the genes that are 
hypermethylated are shared across cancer types, while a number of them are tumour or 
tissue-type specific (Costello et al. 2000). Different cancer types display different levels of CGI 
hypermethylation, with a sub-group of cancers displaying a particularly high degree of 
hypermethylation at a specific subset of gene promoters, known as the CpG island methylator 
phenotype (CIMP) (Toyota et al. 1999). Moreover, many of the genes that undergo 
hypermethylation are already repressed in the normal tissue prior to transformation, and their 
expression is further attenuated upon hypermethylation (Keshet et al. 2006; Sproul et al. 2012; 
Easwaran et al. 2012). Developmental genes have been found to be frequently 
hypermethylated across cancer types, therefore it has been proposed that aberrant 
hypermethylation in cancer may act to block cellular differentiation and enable cancer cells to 
continue to propagate in their more primitive states (Widschwendter et al. 2007; Easwaran et 
al. 2012; Pfeifer 2018). Alternatively, it has been proposed that cancer hypermethylation may 
act to block cancer progression, by restricting the stochastic activation of genes that may 
enable adaptation of the cancers to environmental stimuli (Sproul and Meehan 2013). 
There is some evidence that aberrant de novo methylation occurs early in tumourigenesis, as 
DNA hypermethylation can be detected in premalignant lesions (Chan et al. 2002; Hanley et al. 
2017). Many of the genes that are hypermethylated in cancer are also hypermethylated during 
normal human ageing, which is perhaps unsurprising as cancer is a disease strongly associated 
with age, and this suggests that the two processes are driven by common epigenetic 
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mechanisms or that ageing predisposes to neoplasia (Rakyan et al. 2010; Teschendorff et al. 
2010). Whether such DNA hypermethylation changes are a cause of consequence of 
tumourigenesis remains a recurrent controversial question in the field, but some recent 
studies have shed light on this. One recent study showed that targeting DNA hypermethylation 
to the CDKN2A gene promoter in normal cells initiates aberrant cellular processes (Saunderson 
et al. 2017), and a second study demonstrated that ageing and cancer associated DNA 
hypermethylation accelerates cellular transformation in a BrafV600E mouse colon organoid 
system, through suppression of Wnt signalling regulators in a progressive manner (Tao et al. 
2019). This study functionally links promoter CGI hypermethylation with oncogenic 
transformation, demonstrating a causal relationship.  
The majority of the observations of aberrant DNA methylation have been made in cancer cell 
lines or primary cancer cells, but they are not fully representative of the processes occurring 
during the transition of normal cells into cancer cells. The underlying mechanisms that give rise 
to these opposing patterns of genomic DNA methylation in early stages of human cancer 
development remain elusive, as does the timing of such events in cancer initiation and 
progression. More specifically, while it has been postulated that recruitment of de novo 
DNMTs may be assisted by a chromatin- or DNA-binding factor, how de novo DNA 
methyltransferase activity is preferentially targeted to specific regions of the genome in the 
context of aberrant cancer methylation remains largely a mystery.  
It has been proposed that de novo methylation of DNA in cancer operates through an 
instructive mechanism driven by cis-acting DNA sequences and trans-acting protein complexes 
that are capable of recruiting DNMTs (Keshet et al. 2006). In line with this, various studies have 
used computational models to show that sites prone to de novo DNA methylation in cancer 
can be predicted based on nearby DNA sequence motifs, and those that are protected from 
methylation are enriched for alternative motifs, such as zinc-finger protein binding sites (Feltus 
et al. 2003, 2006; Fan et al. 2007; Kim et al. 2008; McCabe, Lee, and Vertino 2009). However, 
there is limited consensus between the sequence motifs identified as being predictive for DNA 
methylation by each individual computational approach. A more recent hypothesis suggested 
that CGIs that become hypermethylated in cancer are typically associated with developmental 
genes and are regulated by tissue-specific transcription factors which are not ubiquitously 
expressed. CGIs that are resistant to de novo methylation in cancer typically reside within 
genes involved in basic cellular processes and are bound by combinations of ubiquitously 
expressed transcription factors which contribute to protection from DNA methylation 
(Gebhard et al. 2010).   
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A number of independent studies have observed the preferential susceptibility of loci marked 
by H3K27me3 or bound by polycomb to gain DNA methylation in cancer (Ohm et al. 2007; 
Schlesinger et al. 2007; Widschwendter et al. 2007; Nejman et al. 2014). Similarly, other 
studies have reported that hypermethylation in cancer occurs at the promoters of 
developmental genes and transcription factors which are marked by bivalent histone 
modifications in hESCs (Bernhart et al. 2016; Easwaran et al. 2012; Court and Arnaud 2017). 
Other studies have demonstrated site-specific recruitment of DNMTs to loci that undergo 
hypermethylation by DNA-binding factors, but thus far this has only been shown for individual 
genes or loci (Suzuki et al. 2006; Fuks et al. 2001; Di Croce et al. 2002; Brenner et al. 2005).  
The process of inflammation, often as a result of bacterial or viral infection has also been 
linked to de novo methylation and carcinogenesis. It is thought that this association may arise 
either as a result of increased proliferation of inflammatory tissues or by means of epigenetic 
reprogramming induced by the infection (Niwa et al. 2010; Su et al. 2007; Ferrari et al. 2008). 
In line with this, associations have been made between DNA methylation and the processes of 
DNA damage and repair, which are known to play a role in carcinogenesis. Various studies 
have demonstrated de novo DNA methylation of CGIs at sites of DNA double-strand break 
repair or sites of oxidative damage. In each case, the DNA repair proteins responsible for 
repairing the damaged DNA recruit DNMTs to the DNA, thus linking DNA repair to de novo DNA 
methylation (Xia et al. 2017; O'Hagan, Mohammad, and Baylin 2008; Ding et al. 2015; Cuozzo 
et al. 2007).  
 
1.5.3 Global hypomethylation and genomic instability 
Cancer cells commonly exhibit reduced global levels of DNA methylation compared to normal 
somatic cells (Ehrlich 2002, 2009). More recently, it has also become evident that cancer cells 
also display reduced global levels of 5hmC (Ficz and Gribben 2014). Hypomethylation is likely 
an early event in cancer as it has been detected in pre-malignant tissue (Desrosiers et al. 
1985). Global methylation in cancer is typically disrupted at repetitive DNA elements, and 
these can become overexpressed as a result of loss of silencing mechanisms (Ting et al. 2011). 
The presence of DNA methylation across the genome is beneficial in maintaining genomic and 
chromosomal stability (Chen et al. 1998). Global hypomethylation in cancer is often associated 
with genomic instability including chromosomal instability (Ehrlich 2009; Eden et al. 2003; 
Karpf and Matsui 2005; Chen et al. 1998; Sheaffer, Elliott, and Kaestner 2016). 
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Whether DNA hypomethylation is a cause or simply a consequence of carcinogenesis remains 
a question under investigation. Several studies have reported chromosomal breakages, 
fusions, aneuploidy, and re-activation of silenced DNA elements, in relation to DNA 
hypomethylation and downregulation or mutations of the DNMTs, and such instability may 
promote tumour initiation or progression (Eden et al. 2003; Gaudet et al. 2003; Sheaffer, 
Elliott, and Kaestner 2016; Dodge et al. 2005; Karpf and Matsui 2005). The absence of DNA 
methylation at certain genomic regions such as heterochromatic repetitive elements may lead 
to incorrect chromosome segregation that gives rise to chromosomal aberrations (Monier, 
Mouradian, and Sullivan 2006). Mice with a hypomorphic mutation of DNMT1 display greatly 
reduced levels of DNA methylation and develop aggressive T-cell lymphomas with a high 
frequency of chromosome 15 trisomy, suggesting that DNA methylation contributes to 
tumourigenesis by causing chromosomal instability that results in aneuploidy (Gaudet et al. 
2003; Karpf and Matsui 2005). Inactivation of DNMT3B or mutations in DNMT3B which cause 
the immunodeficiency, centromere instability and facial anomalies (ICF) syndrome both result 
in DNA hypomethylation and chromosomal aberrations and aneuploidy (Ehrlich 2003; Dodge 
et al. 2005). Additionally, as DNA methylation is involved in the silencing of retrotransposons 
during development (Bestor 2004), hypomethylation may result in increased 
retrotransposition and re-expression of such elements, which may play an active role in 
tumorigenesis (Daskalos et al. 2009).  
As well as global disruption of methylation at repetitive DNA sequences, hypomethylation can 
also result in the derepression of imprinted genes (Li, Beard, and Jaenisch 1993). Loss of 
imprinting is a commonly observed phenomenon across cancer types and is also thought to 
occur early on in tumourigenesis, with a putative driving role in predisposing cells to cancer 
development (Jelinic and Shaw 2007; Holm et al. 2005). 
 
1.5.4 Disruption of epigenetic regulators in cancer 
Large-scale sequencing studies have enabled the identification of the landscape of mutations 
across cancer types. Among these landscapes, several mutations have been identified that 
affect epigenetic regulators (Plass et al. 2013), suggesting that epigenetic abnormalities may lie 
downstream of genetic events. However, while aberrant DNA methylation patterns including 
both genomic hypomethylation and CGI hypermethylation are a hallmark of cancer, mutations 
to the epigenetic modifiers of DNA methylation, the DNMTs, are less frequent. Nevertheless, 
mutations in DNMT3A are frequent in haematological malignancies (Yan et al. 2011; Ley et al. 
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2010), though the resulting hypermethylation is considered to be a consequence of the 
malignancy rather than a contributor to development of the malignancy (Spencer et al. 2017). 
Mutations in the TET genes, in particular TET2, are also an early event in haematological 
malignancies (Lorsbach et al. 2003; Langemeijer et al. 2009). Notably, both these types of 
mutations are present at considerable frequencies in the blood of healthy, ageing individuals 
(Desai et al. 2018; Abelson et al. 2018; Xie et al. 2014), and both types of mutations are 
predominantly found in haematological malignancies rather than solid tumours. Mutations in 
DNMT1 have been identified in colorectal cancers (Kanai et al. 2003). Aside from mutations to 
the DNMTs, many cancers exhibit aberrant overexpression of DNMT3B. Many studies have 
observed correlations between aberrant DNMT3B expression and CGI hypermethylation in 
cancer, but a direct causal role in establishing aberrant DNA methylation patterns has not been 
demonstrated (Roll et al. 2008; Linhart et al. 2007).  
Though the writers and erasers of DNA methylation themselves may not be frequently 
mutated in cancer, mutation of readers and writers of histone modifications as well as 
chromatin remodelers is a common feature of many cancer types (Plass et al. 2013; Baylin and 
Jones 2011). Given the interplay between DNA methylation and the chromatin, such 
abnormalities may contribute to the aberrant DNA methylation patterns frequently observed 
in cancer. Alternatively, it is possible that aberrant DNA methylation patterns arise 
independently of genetic mutations to the epigenetic modifiers themselves. In line with this, it 
has been proposed that disruption of epigenetic ‘modulators’ or ‘mediators’, which can act 
either upstream or downstream of the epigenetic modifiers may also impact the epigenome in 
cancer (Feinberg, Koldobskiy, and Gondor 2016). Finally, given the commonality in aberrant 
DNA methylation patterns across different cancers that each have different driver mutations, it 
is also possible that the initial disruption of canonical DNA methylation patterns occurs 
independently of genetic mutations altogether.  
 
1.5.5 DNA methylation and mutation 
Cytosine (C) can deaminate spontaneously to give uracil (U), which causes a mismatch with 
guanine (G). This mismatch is recognised by uracil DNA glycosylases, and the uracil base is 
efficiently eliminated and replaced with cytosine. 5mC, however, is deaminated to give 
thymine (T) (Bird 1980). Compared to unmodified C, 5mC has increased susceptibility to 
spontaneously deaminate (Shen, Rideout, and Jones 1994). Aside from spontaneous 
deamination, AID is thought to mediate hydrolytic deamination of 5mC into T and C to U. The 
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U:G mismatch, if replicated over, will give rise to C to T mutations unless the U is excised by 
the uracil-N-glycosylase enzyme (UNG) (Perez-Duran et al. 2012). The T is repaired if AID 
activity is coupled to DNA repair, resulting in active demethylation. Unlike U, however, 
because T is a natural base, the mutant base can persist through DNA replication, and upon 
cell division, it can be passed on to daughter cells as a C to T transition mutation (Schmutte et 
al. 1995). Despite the existence of MBD4, a dedicated thymine DNA glycosylase that can 
selectively remove T from a T:G mismatch, these mismatches are repaired with reduced 
efficiency (Schmutte et al. 1995; Hendrich et al. 1999).  
CpG sites are underrepresented globally across the genome due to the high mutation rate of 
methylated cytosines (Bird 1980). Moreover, methylated CpGs are considered to be hotspots 
for disease-related DNA mutations, supported by the fact that C to T mutations are the most 
frequent in human disease, constituting a third of all point mutations (Cooper and Youssoufian 
1988). These mutations may occur in the coding regions of genes (Rideout et al. 1990), or on 
regulatory regions of DNA, hence altering binding sites of transcription factors and other 
proteins (Zemojtel et al. 2011). C to T mutations that occur in early-replicating DNA are likely 
to be repaired by BER machinery, but mutations that occur in late-replicating DNA where BER 
operates with reduced efficiency are more likely to result in a mutation that is propagated 
upon cell division (Blokzijl et al. 2016; Tomkova et al. 2018). Interestingly, while 5mC shows 
increased mutability compared to unmethylated C, 5hmC has in fact been shown to be 
protective against mutagenesis (Tomkova et al. 2016), and enrichment of 5hmC at sites of DNA 
damage has in fact been shown to promote genome stability by ensuring chromosome 
segregation occurs correctly (Kafer et al. 2016).  
Some of the most frequently seen mutational signatures in human cancers feature high rates 
of C to T mutations, and are attributed to the deaminase hyperactivity of AID or APOBEC 
enzymes at methylated CpG dinucleotides, possibly coupled with inefficient BER pathway 
activity (Alexandrov et al. 2013). Recent reports suggest that tissue-specific mutations 
accumulate in normal adult stem cells during life. These patterns are similar between the 
normal stem cells of a given tissue and cancers that arise from those tissues, suggesting that 
intrinsic, non-random mutational processes such as that described above may be responsible 
for initiating tumourigenesis (Blokzijl et al. 2016).  
While 5mC is susceptible to DNA mutation, a global loss of methylation has been associated 
with an overall increased mutation frequency (Chen et al. 1998). This suggests that the 
interplay between CpG methylation and mutation is two-fold, in that global DNA methylation 
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maintains genomic stability, but methylated CpG dinucleotides individually have increased 
susceptibility to mutation compared to unmethylated CpGs.  
 
1.6 Epigenetic reprogramming 
 
1.6.1 Somatic cell reprogramming 
Aside from the two waves of epigenetic reprogramming that take place in vivo during early 
mammalian development, it is now known that molecular reprogramming of human somatic 
cells can be induced by ectopically overexpressing a combination of four pluripotency 
transcription factors. The overexpression of OCT4, SOX2, KLF4 and c-MYC (collectively referred 
to as OSKM) in differentiated cells reprograms the cells, albeit with low efficiency, resulting in 
the generation of induced pluripotent stem (iPS) cells. (Takahashi and Yamanaka 2006; Okita, 
Ichisaka, and Yamanaka 2007; Takahashi et al. 2007). While iPS cells and ESCs share 
characteristics such as their pluripotency and differentiation potency, their molecular profiles 
are similar, yet distinct, and the molecular similarity between the two cell types remains a 
topic of controversy as iPS cells often exhibit molecular profiles attributable to somatic 
memory (Hochedlinger and Jaenisch 2015). Recently, it has been shown that the OSKM 
pluripotency transcription factors can be replaced with combinations of lineage-specific 
transcription factors to generate iPS cells, suggesting that cellular reprogramming may be 
influenced by the equilibrium between transcription factors controlling opposing cellular states 
rather than the direct specification of a pluripotent state by OSKM (Montserrat et al. 2013). 
Such reprogramming of mature cells into a pluripotent state challenges the unidirectional 
depiction of development proposed by Conrad Waddington, as does the further 
reprogramming of primed hESCs to the naïve state of pluripotency (Figure 1.11). Recently, it 
has also been demonstrated that naïve human iPS cells can be generated directly from somatic 
cells directly, without a primed intermediate, through OSKM induction and maintenance in 
2iLGö media (Kilens et al. 2018). 
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Figure 1.11. Cell state changes and Waddington’s landscape. This figure shows that during development, 
pluripotent cells (primed or naïve) commit to various somatic cell lineages via intermediate progenitor states. Using 
direct or indirect reprogramming, differentiated, somatic cells can be converted into alternative lineages or 
reprogrammed into a pluripotent cell state. 
Figure from: Takahashi & Yamanaka, 2015 (Takahashi and Yamanaka 2015) 
 
 
The nuclear reprogramming induced by the OSKM factors resets the epigenetic landscape of 
somatic cells into that of a pluripotent cell, and this is accompanied by global reprogramming 
of the transcriptome (Maherali et al. 2007). During reprogramming of somatic cells to iPS cells, 
certain components of the chromatin landscape are rapidly altered in a loci-specific manner to 
enable the first wave of transcriptional reprogramming that primarily involves silencing of 
somatic genes, and this is driven by transcription factors (Koche et al. 2011). Additionally, the 
early stages of iPS reprogramming involve the transient re-activation of developmental 
regulators (Cacchiarelli et al. 2015). The activation of pluripotency genes occurs at a later 
stage, as a final wave of transcriptional reprogramming (Polo et al. 2012). The majority of 
epigenetic modifications are not altered globally until the later stages of iPS reprogramming, at 
which stage global chromatin decompaction occurs and bivalency is established at 
developmental gene promoters (Mikkelsen et al. 2008). Global DNA demethylation occurs 
particularly late during reprogramming (Polo et al. 2012) and is a bottleneck for efficient 
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reprogramming, as it may trap cells in a partially reprogrammed state. In line with this, it has 
been shown that manipulation of DNMT1 levels or use of DNA demethylating agents increases 
the efficiency of cellular reprogramming. (Mikkelsen et al. 2008). Conversely, DNMT3A and 
DNMT3B are not required for efficient iPS reprogramming, indicating that de novo DNA 
methylation is dispensable for reprogramming (Pawlak and Jaenisch 2011).   
Despite the dispensability of the de novo methyltransferases for efficient reprogramming of 
somatic cells into iPS cells, there have been several reports of aberrant DNA hypermethylation 
observed during reprogramming (Ruiz et al. 2012; Nishino et al. 2011). A number of these 
aberrantly hypermethylated sites have been shown to overlap with bivalent chromatin marks, 
as well as overlapping regions that are hypermethylated in cancer (Doi et al. 2009; Ohm et al. 
2010). These observations insinuate that the process of reprogramming gives rise to epigenetic 
changes that are characteristic of neoplasia. Additionally, it has also been demonstrated that 
transient expression of OSKM in mice enables reprogramming to occur in vivo, resulting in the 
formation of teratomas in multiple organs (Abad et al. 2013). Moreover, partial or incomplete 
in vivo reprogramming using OSKM can result in a dysplastic phenotype resembling Wilms 
tumours when reprogramming is prematurely terminated, in the absence of any identifiable 
cancer-driving mutations (Ohnishi et al. 2014). This also implicates epigenetic reprogramming 
as a driver of carcinogenesis in the absence of cancer-causing mutations.  
 
1.6.2 Cellular reprogramming and the pluripotency network 
Of the four transcription factors that constitute the OSKM combination, OCT4, SOX2 and 
NANOG are considered to be part of the ‘core’ pluripotency network (Boyer et al. 2005; Wang 
et al. 2006). The core pluripotency network is known to interact with histone and chromatin 
modifying complexes, though the extent of the interactions and whether they are direct or 
indirect is less well characterised. OCT4, SOX2 and NANOG all associate with components of 
the Brg/Brahman-associated factors (BAF) complex, which is responsible for remodelling 
nucleosomes, and Oct4 and NANOG additionally associate with the nucleosome remodelling 
deacetylase (NuRD) complex (Ho et al. 2009; Orkin and Hochedlinger 2011). The core 
pluripotency factors also associate with HDAC complexes as well as chromatin scaffold 
proteins such as transcription intermediary factor-1b (TIF1b) (Seki et al. 2010; Wang et al. 
2006). Moreover, the gene expression control of several histone modifying enzymes is under 
the control of pluripotency transcription factors. The H3K9 demethylases JMJD1A (KDM3A) 
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and JMJD1B (KDM3B), both of which are part of the JHDM2 family, are directly controlled by 
OCT4 (Loh et al. 2007).  
 
1.6.3 Reprogramming and genomic stability 
Although stem cells are constantly exposed to endogenous sources of DNA damage as a result 
of their rapid proliferation, stem cells are considered to be very sensitive to DNA damage, in 
that they activate robust DNA repair mechanisms against even low levels of DNA damage in 
order to maintain their genomic integrity (Fu et al. 2017; Seifert, Dejosez, and Zwaka 2017). 
However, the process of cellular reprogramming and generating iPS cells has been associated 
with genomic instability. Human iPS cells cultured for multiple passages display increased 
double-strand breaks and chromosomal aberrations and reduced DNA repair efficiency (Simara 
et al. 2017; Mayshar et al. 2010). Additionally, various studies have reported increased 
numbers of somatic mutations and copy number variation upon iPS reprogramming (Gore et 
al. 2011; Hussein et al. 2011; Ji et al. 2012). The OSKM reprogramming factors are thought to 
induce replication stress which ultimately leads to increased DNA damage and reduced 
genomic stability, and lowering the replication stress through either genetic or chemical 
manipulation during reprogramming can reduce the levels of genomic instability (Ruiz et al. 
2015).  
Moreover, naïve hESC lines generated through various methods of primed hESC 
reprogramming, as well as naïve hESCs generated directly through iPS reprogramming show an 
aberrant karyotype following multiple passages (Kilens et al. 2018; Theunissen et al. 2014; 
Pastor et al. 2016; Guo et al. 2017). It has been shown that this loss of genomic stability is 
attributable to the MEK1/2 inhibitor used as part of the 2i combination (Choi et al. 2017), and 
that reduction of MEK inhibition can reduce the genomic instability observed in naïve hESCs 
generated using the 5iLAF method of reprogramming (Di Stefano et al. 2018). 
 
1.6.4 Reprogramming and cancer 
The process of oncogenic transformation, whereby a normal becomes neoplastic, bears 
resemblance to the process of reprogramming, as both processes involve the acquisition of an 
altered developmental state and transcriptional programme along with enhanced self-renewal 
potential, with or without any changes to the DNA sequence (Suvà, Riggi, and Bernstein 2013; 
Ben-Porath et al. 2008). In particular, the loss of cellular identity, either through 
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dedifferentiation or transdifferentiation is considered to be an early event across many cancer 
types (Roy and Hebrok 2015). During both cellular reprogramming and malignant 
transformation, it has been observed that there is an inverse correlation between the 
differentiation state of the cell of origin and its reprogramming efficiency or transformation 
potential, with stem and progenitor cells being more receptive to pluripotent reprogramming 
and oncogene-induced transformation (Eminli et al. 2009; Silva et al. 2008; Morel et al. 2017; 
Cobaleda et al. 2000). 
Each of the four factors that constitute the OSKM combination used in iPS reprogramming are 
also implicated in carcinogenesis. OCT3/4 has been shown to play a role in the generation of 
germ cell tumours (Gidekel et al. 2003), and SOX2 has been implicated as an oncogene in lung 
and oesophageal squamous cell carcinomas and small-cell lung carcinomas, as well as helping 
to support the cancer stem cell populations in Ewing sarcoma and a number of other cancer 
types (Bass et al. 2009; Rudin et al. 2012; Riggi et al. 2010). KLF4 has been shown to promote 
the development of various solid tumours such as breast and skin cancer (Rowland and Peeper 
2006), and c-MYC is a well-known oncogene in a wide range of human cancers, functioning 
through its influence on gene expression programmes (Dang 2012; Lin et al. 2012). 
Furthermore, NANOG, which is able to substitute some of the original OSKM factors and is 
used in alternative combinations of reprogramming factors (Jung et al. 2014) is frequently 
detected in the stem-like compartments of multiple human malignancies (Jeter et al. 2015). 
Moreover, it was recently shown that the induction of pluripotency regulators in cancers 
promotes their survival and resistance to therapy, conferring poor clinical outcomes (Hepburn 
et al. 2019). Finally, the finding that transient expression of OSKM in mice enables 
reprogramming to occur in vivo, resulting in the formation of teratomas in multiple organs 
(Abad et al. 2013) and that partial or incomplete in vivo reprogramming using OSKM can result 
in a dysplastic phenotype in the absence of any identifiable cancer-driving mutations (Ohnishi 
et al. 2014) implicates epigenetic reprogramming as a driver of carcinogenesis in the absence 
of cancer-causing mutations. The identification of pluripotency factors in cancers has driven 
hypotheses regarding the origins of cancer, such as the cancer stem-cell hypothesis (Beck and 
Blanpain 2013). 
Aside from the pluripotency transcription factors themselves, reprogramming of the 
epigenome is a process common to both iPS reprogramming and cancer transformation which 
has led to the hypothesis that cancer initiation may involve a process of dedifferentiation that 
is analogous to cellular reprogramming. The epigenetic progenitor model of cancer was 
proposed as an alternative route of cancer initiation to the classical clonal genetic model of 
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cancer formation, which is based on a series of mutations and selection events (Feinberg, 
Ohlsson, and Henikoff 2006). The epigenetic progenitor model proposes that epigenetic 
reprogramming or alterations may first occur in stem or progenitor cells within tissues, 
resulting in the expansion of an epigenetically altered pool of progenitor cells that is refractory 
to differentiation. This altered progenitor pool can subsequently give rise to cancer by means 
of further mutations as well as epigenetic and genetic instability (Feinberg, Ohlsson, and 
Henikoff 2006). It has also been hypothesised that cancer cells follow an evolutionary 
trajectory towards a stem cell state, which allows for both self-renewal and differentiation that 
generate cellular hierarchies in cancer (Chen and He 2016). This convergent evolution could 
explain how cancers with largely varied mutational profiles still exhibit common phenotypic 
hallmarks (Hanahan and Weinberg 2011). 
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1.7 Project Aims 
 
While it is well established that aberrant DNA methylation patterns are a hallmark of cancer, 
the underlying mechanisms that give rise to global hypomethylation and gene promoter 
hypermethylation in early stages of human cancer development remain elusive, as does the 
timing and biological function of such events in cancer initiation and progression. In particular, 
how de novo DNA methyltransferase activity is preferentially targeted to specific regions of the 
genome in the context of aberrant cancer methylation remains largely a mystery. Moreover, 
the relationship between DNA demethylation and genomic instability, alongside the increased 
mutability of methylated CpGs has not been extensively explored. 
It has been hypothesised that cancer cells follow an evolutionary trajectory towards a stem cell 
state, which allows both self-renewal and differentiation, and several molecular parallels have 
been drawn between the acquisition of pluripotency during cellular reprogramming and 
molecular processes occurring during oncogenesis (Chen and He 2016; Suvà, Riggi, and 
Bernstein 2013). This suggests that common mechanisms may drive the two processes and 
that molecular dissection of epigenetic reprogramming may shed light on processes occurring 
during tumourigenesis. In line with this, for this thesis we use the recently developed 
NANOG/KLF2 overexpression + 2iLGö method of primed to naïve human embryonic stem cell 
reprogramming (Takashima et al. 2014) as a model system to explore mechanisms of DNA 
methylation and the relationship between changing DNA methylation patterns and genomic 
stability. The aims of the project were to: 
 
 Temporally characterise the dynamics of DNA methylation during the transition from 
primed to naïve pluripotency in hESCs. 
 Identify the epigenetic factors responsible for carrying out hypermethylation as well as 
identifying upstream mechanisms involved in targeting these factors to specific regions 
of the DNA. 
 Determine whether the global demethylation observed upon resetting primed hESCs 
to the naïve state gives rise to genomic instability or an increased mutation frequency. 
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Chapter 2: Materials and Methods 
 
2.1 Cell Culture 
 
2.1.1 Cell culture reagents 
Name Source Catalogue Number 
DMEM/F-12 Ham Sigma Aldrich D6421 
DMEM, high glucose ThermoFisher Scientific 11965-092 
DPBS ThermoFisher Scientific 14190-094 
KnockOut serum replacement (KSR) ThermoFisher Scientific 10828-028 
Fetal bovine serum (FBS) ThermoFisher Scientific 11965-092 
Neurobasal ThermoFisher Scientific 21103-049 
L-glutamine ThermoFisher Scientific 25030-024 
MEM Non-essential amino acids solution ThermoFisher Scientific 11140-035 
2-Mercaptoethanol (2-ME) Sigma Aldrich M3148 
Doxycycline Sigma Aldrich D9891 
N-2 Supplement ThermoFisher Scientific 17502-048 
B-27 Supplement ThermoFisher Scientific 17504-044 
Recombinant human FGF-basic (bFGF) Peprotech 100-18B 
Recombinant human LIF (hLIF) Peprotech 300-05 
PD0325901 Stem Cell Technologies 72182 
CHIR99021 Stem Cell Technologies 72052 
Y-27632 dihydrochloride (ROCKi) Sigma Aldrich Y0503 
Gö6983 (PKCi) Sigma Aldrich G1918 
Penicillin-Streptomycin ThermoFisher Scientific 15140122 
Gelatine solution Sigma Aldrich G1393 
Accutase solution Sigma Aldrich A6964 
Trypsin-EDTA ThermoFisher Scientific 25200-072 
Defined Trypsin Inhibitor (DTI) ThermoFisher Scientific R-007-100 
Trypsin ThermoFisher Scientific 15090-046 
Collagenase, type IV ThermoFisher Scientific 17104-019 
FresR-S Stem Cell Technologies 05859 
Stem-Cell Banker Takara Bio 11890 
Table 2.1 Cell Culture Reagents  
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2.1.2 Cell lines 
WA09/H9 NK2 primed human embryonic stem cells (hESCs): kindly provided by Austin Smith 
(Takashima et al. 2014) with permission from WiCell.  
Primary mouse embryonic fibroblasts (MEF): Isolated from wild-type E12.5 mouse embryos. 
 
2.1.3 Isolation of Mouse Embryonic Fibroblasts 
Primary mouse embryonic fibroblasts (MEF) were isolated from wild-type mouse embryos at 
embryonic day 12.5 (E12.5). Primary MEFs were expanded for two passages, before being 
irradiated at 35Gy in a biological X-ray irradiator. Irradiated MEFs (iMEF) were frozen into 
stocks. Irradiated MEF (iMEF) were seeded at a density of 1x106 cells on 0.1% gelatine-coated 
6-well plates in DMEM supplemented with 10% foetal bovine serum (FBS) and 100U/ml 
Penicillin-Streptomycin. After 24 hours, media was aspirated, wells were washed with DPBS, 
and then hESCs were seeded on iMEF plated wells.  
 
2.1.4 Human embryonic stem cell culture 
Human H9-NK2 human embryonic stem cells (hESCs) containing doxycycline-inducible KLF2 
and NANOG transgenes coupled to Venus (H9-NK2) were maintained in conventional medium 
(KSR/FGF) comprised of DMEM/F-12 Ham with 20% KnockOut Serum Replacement (KSR) and 
10ng/ml basic fibroblast growth factor (bFGF), supplemented with 2mM L-glutamine, 100uM 
2-mercaptoethanol (2ME), 1% MEM non-essential amino acids, and 100U/ml Penicillin-
Streptomycin. Cultures were passaged every 5-6 days as small clumps by dissociation with a 
buffer containing 1mg/ml Collagenase IV, 0.025% Trypsin, 1mM CaCl2 and KSR at a final 
concentration of 20% in DPBS. Medium was changed daily. Cells were frozen in FresR-S 
freezing solution.  
Resetting to the naïve state was carried out as previously described (Takashima et al. 2014). 
H9-NK2 cells were dissociated to single cells with trypsin-EDTA, trypsin inactivated using the 
Defined Trypsin Inhibitor (DTI), and re-plated in the presence of 10µM Rho-associated kinase 
inhibitor (ROCK inhibitor [Y-27632]). After 24 hours, media was changed to primed media with 
1µM doxycycline. The following day, media was changed to 2iL+dox media composed of 50% 
DMEM/F12 and 50% Neurobasal supplemented with 2mM L-glutamine, 100µM 2ME, N2, B27, 
1µM PD0325901 (MEK inhibitor), 1µM CHIR99021 (GSK3β inhibitor), 20ng/ml human 
recombinant LIF (hLIF), 100U/ml Penicillin-Streptomycin and 1µM doxycycline. Media was 
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changed daily. Cells were split every 4-5 days after dissociation to single cells using Accutase. 
After 2 weeks, doxycycline was withdrawn and PKC inhibitor Gö6983 was added at a 
concentration of 5µM. Cells in 2iL+Gö were split every 4-5 days after dissociation to single cells 
using Accutase. Cells were frozen in Stem-Cell Banker freezing solution. All hESCs were 
cultured on irradiated mouse embryonic fibroblasts (iMEF). All hESCs were maintained in 5% 
O2, 7% CO2 at 37°C in a humidified incubator. 
 
2.1.5 HEK293T cell culture 
Human embryonic kidney 293T (HEK293T) cells were maintained in DMEM supplemented with 
10% FBS and 100U/ml Penicillin-Streptomycin. Cells were maintained in 5% CO2 at 37°C in a 
humidified incubator.  
 
2.1.6 Brightfield Microscopy of cells in culture 
Brightfield images of cells in culture were captured on the EVOS XL Core Cell Imaging System 
(ThermoFisher Scientific). 
 
2.2 Embryoid body generation 
Embryoid body generation was performed as previously described (Takashima et al. 2014). 
Briefly, 10,000 naïve hESCs dissociated with Accutase were plated per well of a 96-well clear 
black round bottom ultra-low attachment spheroid microplate (Corning) in N2B27 with 10% 
KSR. Medium was changed every second day. RNA was isolated from cells from embryoid 
bodies harvested at days 0 and 5. 
 
2.3. Immunofluorescence  
 
2.3.1 Immunostaining 
Cells grown on coverslips were washed with PBS and then fixed in 4% paraformaldehyde (PFA) 
for 15 minutes at room temperature. Fixed cells were blocked with 2% FBS/PBS + 0.1% BSA + 
0.1% Triton (PBSBT) for 2 hours. Primary antibodies were diluted in PBSBT and incubated at 
overnight at 4°C. Cells were washed in excess PBSBT for 2 hours and incubated for 1 hour at 
room temperature in the dark in either goat anti-mouse or goat anti-rabbit Alexa Fluor (AF) 
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488 (A11029 and A11008; ThermoFisher Scientific) secondary antibodies at a 1:1000 dilution. 
Cells were washed in excess PBSBT for 2 hours before being counterstained with Vectashield 
Antifade Mounting Medium with 4’,6-diamidino-2-phenylindole (DAPI) (VectorLabs) and 
mounted onto polysine® adhesion slides (VWR). Staining of 5-methylcytosine (5mC) was 
performed as previously described (Ficz et al. 2013). Briefly, fixed cells were permeabilised in 
PBS + 0.5% Triton for 1 hour at room temperature. Cells were incubated in 2N hydrochloric 
acid for 30 minutes before being blocked in PBSBT for 2 hours, and stained as above.  
For staining of DNA damage markers, cells grown on coverslips were fixed with PTEMF (0.2% 
Triton X-100, 0.02 M PIPES [pH 6.8], 0.01 M EGTA, 1 mM MgCl2, and 4% formaldehyde) for 10 
minutes at room temperature. After blocking with 3% BSA, cells were incubated with primary 
antibodies for 1 hour at room temperature. Secondary antibodies used were goat anti-mouse 
Alexa Fluor 488 (A11017; Invitrogen), goat anti-rabbit AF594 and AF488 (A11012 and A11008; 
Invitrogen), and goat anti-human AF647 (109-606-088-JIR [Stratech] or A21445 [Invitrogen]). 
Each secondary antibody was used at a 1:100 dilution for 30 minutes at room temperature, 
protected from light. DNA was stained with DAPI (Roche), and coverslips were mounted in 
Vectashield (Vector H-1000; Vector Laboratories) onto SuperFrost microscope slides 
(ThermoFisher Scientific). 
Primary antibody details are listed in Table 2.2. 
Table 2.2 Primary antibodies used for immunostaining 
 
Antibody target Species Source Catalogue number Dilution 
KLF4 Rabbit Santa Cruz 
Biotechnology 
sc-20691 1:200 
THY1 Mouse Merck Millipore  CBL415 1:200 
5mC Mouse Active Motif 39649 1:200 
UHRF1 Mouse Merck Millipore MABE308 1:1000 
DNMT1 Mouse Abcam ab13537 1:1000 
Centrin 3 Mouse Abcam ab54531 1:250 
CREST Human Antibodies Inc 15-234-0001 1:200 
γ-H2AX Mouse Merck Millipore 05-636 1:250 
53BP1 Rabbit Santa Cruz 
Biotechnology 
sc-22760 1:250 
RPA70 Rabbit Abcam ab79398 1:250 
Beta-tubulin Rabbit Abcam ab6046 1:250 
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2.3.2 Microscopy 
For staining of epigenetic regulators and markers of pluripotency, slides were visualised and 
imaged on the Nikon Eclipse Ci fluorescence microscope.  
For staining of DNA damage markers, images were acquired using an Olympus DeltaVision RT 
microscope (Applied Precision) equipped with a Coolsnap HQ camera. Three-dimensional 
image stacks were acquired in 0.2 mm steps, using Olympus 1003 (1.4 numerical aperture), 
603, or 403 UPlanSApo oil immersion objectives. Deconvolution of image stacks and 
quantitative measurements was performed with SoftWorx Explorer (Applied Precision). 
Imaging analysis was performed using Softworx Explorer and ImageJ (for CREST spot counting 
only). Statistical analysis was performed using Prism v7.04 (GraphPad). 
  
2.4 Flow cytometry 
Cells were dissociated to single cells with Accutase and washed in PBS. Cells were fixed in 
0.25% paraformaldehyde (PFA) at 37°C for 10 minutes, cooled at 4°C for 10 minutes and then 
permeabilised in ice-cold 88% methanol at -20°C for 10 minutes. Following fixation and 
permeabilisation, cells were washed in PBS/ 0.1% Tween-20/ 1% bovine serum albumin (PBST-
BSA) and then blocked in 10% FBS in PBST-BSA for 30 minutes at 37°C. Cells were stained with 
an anti-feeder antibody conjugated to the fluorophore allophycocyanin (APC) for 10 minutes at 
4°C in the dark, and with an anti-CD90 antibody conjugated to the fluorophore phycoerythrin 
(PE) for 30 minutes at room temperature in the dark. Alternatively, cells were stained with the 
anti-feeder APC antibody and then with DAPI for 15 minutes at 4°C in the dark. Samples were 
analysed on an LSR Fortessa cell analyser (BD Biosciences). Flow cytometry data analysis was 
carried out using FlowJo Version 10 software. 
 
2.5 Reverse Transcription Quantitative Real-time PCR (rt-qPCR) 
Cells were dissociated to single cells using Accutase and serially plated onto 6-well plates for 2 
hours to eliminate excess iMEFs. Total RNA was isolated from pelleted hESCs using the Direct-
zol RNA mini-prep kit (Zymo) as per manufacturer’s instructions, and treated with the DNA-
free™ DNA removal kit (ThermoFisher Scientific). Complementary DNA (cDNA) was made using 
the High-capacity RNA to cDNA™ kit (ThermoFisher Scientific). Real-time PCR was carried out 
using Sso advanced™ Universal SYBR® Green Supermix (Bio-Rad) on the CFX384 Touch™ Real 
Time PCR detection system (Bio-Rad). An endogenous control (GAPDH) was used to normalise 
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expression. Primers were designed using Primer-BLAST (which uses Primer3 for design and 
BLAST to ensure target specificity) and are listed in Table 2.3. 
 
Table 2.3 Primer Sequences used for rt-qPCR 
 
Gene Primer Sequence (5’ – 3’) 
GAPDH GATTTGGTCGTATTGGGCGC 
TTCCCGTTCTCAGCCTTGAC 
KLF4 TCTCCAATTCGCTGACCCAT 
CGGATCGGATAGGTGAAGCT 
DNMT3A AGTACGACGACGACGGCTA 
CACACTCCACGCAAAAGCAC 
DNMT3B GAGTCTGCACGGGACCTATT 
GTCACGGGGAGGGATTTAGC 
DNMT3L CATAGCCTGGTGACCTCTGG 
CTGGTGGGTTCAAGGTTCCA 
DNMT3A1 ACTACATCAGCAAGCGCAAG 
CACAGCATTCATTCCTGCAA 
DNMT3A2 GCTGCACCTGGCCTTATG 
CGTCTTTCAGGCTACGATCC 
TET1 CGAGTTGGAAAGTTTGCCCG 
CACAAGGTTTTGGTCGCTGG 
TET2 AATTTGCAAGCTCCTGGTGG 
GCAATTGTGATGGTGGTGGT 
TET3 CAAGACACCTCGCAAGTTCC 
CGTTGGTCACCTGGTTCTGAT 
DNMT1 GACCACGGTTCCTCCTTCTG 
CGGCCTCGTCATAACTCTCC 
UHRF1 TCAGACAAGTCCTCCACCCA 
TGTACAGCCCCAATTCCGTC 
FOXC1 GCTGTCAAATGGCCTTCCCT 
TCCTGCTTTGGGGTTCGATT 
ZFHX3 CTTCCAGAGGAGGACGAGGA 
AATGGCTTCTTCTGGGTCCG 
SOX15 GGCTTTGGGTACAGACCCC 
GTTTGCAGTGGGAAGAGCCAT 
NFKB1 GCTTAGGAGGGAGAGCCCA 
CTGCCATTCTGAAGCCGGG 
MECP2 TGTTAGGGCTCAGGGAAGAAAAG 
AACTTGAGGGGTTTGTCCTTGA 
DPPA4 ATAGCAATCTTGGGGCAGGG 
TCTGTGGAGGTCCACTCCTT 
AICDA GGGAGGCAAGAAGACACTCT 
GGTCCCAGTCCGAGATGTAG 
NANOG GCTACAAACAGGTGAAGACC 
CCTGCGTCACACCATTG 
TFCP2L1 ATGAAGAGACGCTGACCTAC 
ACACGGATGATGCTCTTG 
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2.6 Western Blotting 
2.6.1 Protein Isolation  
Cells to be processed for protein analysis were dissociated from growth plates using Accutase, 
followed by centrifugation to obtain cellular pellets. Whole cell lysates were extracted in 
radioimmunoprecipitation assay buffer (RIPA buffer; Sigma Aldrich), with protease inhibitor 
cocktail (Sigma Aldrich). The suspension was centrifuged at 10,000g at 4°C for 15 minutes to 
pellet cell debris. The supernatant containing the protein was transferred into a new 
microcentrifuge tube and the pellet discarded. Protein lysates were subsequently stored at -
80°C until required. 
 
2.6.2 Protein Quantification 
Proteins concentration was determined using the Pierce™ BCA Protein Assay kit (ThermoFisher 
Scientific) according to manufacturer’s instructions. In a 96-well plate, 25μl of albumin protein 
standards (dilutions of 25-2000μg/ml prepared using serial dilution) and test protein samples 
were loaded in triplicate. 200μl of bicinchoninic acid (BCA) reagent was added to each well. 
This begins a two-step reaction, starting with the biuret reaction which involves chelation of 
copper with protein in an alkaline environment to form a light blue complex. The second step 
of the reaction involves the reaction of BCA with the reduced cuprous cation formed in step 
one, resulting in the formation of a water soluble complex that exhibits a strong linear 
absorbance at 562nm with increasing protein concentrations. The reaction is strongly 
influenced by the amino acid sequence of the protein. The absorbance of each well was 
quantified using the FLUOstar Omega Microplate reader (BMG Labtech) using an excitation of 
595nm. The concentration of the BCA standards was plotted against their absorbance, and an 
equation for the standard curve was generated. Protein concentrations for the test samples 
were calculated based on the standard equation. 
 
2.6.3 Gel Electrophoresis 
25µg of protein was diluted in distilled water to a final volume of 13μl per sample. To this, 2μl 
of sample reducing agent (ThermoFisher Scientific) and 5μl of 4x NuPAGE LDS Sample loading 
buffer (ThermoFisher Scientific) were added, and samples were placed in a heat block at 99°C 
for 5 minutes. Denatured proteins were separated by electrophoresis on a 4-12% Bis-Tris gel in 
MOPS running buffer (ThermoFisher Scientific) at 200 Volts for 55 minutes, alongside the 
colour pre-stained broad range protein standard (NEB). 
66 
 
2.6.4 Western Blot Transfer 
Resolved proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Merck 
Millipore) using the Mini Trans-Blot® Electrophoretic transfer cell system (Bio-Rad). PVDF 
membranes were equilibrated in methanol for 1 minute. Cassettes were prepared in a plastic 
tray filled with 1L of Transfer Buffer. A sponge and 2 pieces of filter paper were placed on the 
negative side of the cassette, followed by the gel, the PVDF membrane, 2 further pieces of 
filter paper and another sponge. Throughout the procedure, each layer was rolled gently with 
a roller to ensure no air bubbles remained within the stack. The cassette was closed and 
placed in the transfer tank along with an ice block to prevent overheating during the transfer 
process. The transfer buffer was poured into the tank and transfer was carried out at 22 Volts 
overnight for 16 hours at 4°C. 
 
2.6.5 Detection 
Following transfer of proteins, PVDF membranes were removed from the cassettes and 
blocked with 5% skimmed milk for 45 min at room temperature. Membranes were then 
incubated overnight at 4°C with primary antibody in blocking buffer, with gentle rolling. The 
following day, membranes were washed three times in 0.1% Tween-20 in PBS (PBST) for 5 
minutes each, before being incubated for 1 hour at room temperature with horseradish 
peroxidase-conjugated secondary antibodies: sheep-anti-mouse IgG or sheep-anti-rabbit IgG 
(1:5,000; GE Healthcare). Membranes were washed a further three times for 5 minutes each in 
PBST.  Detection was performed with enhanced chemiluminescence (ECL; ThermoFisher 
Scientific), by adding 5ml of ECL reagent (a 1:1 mixture of peroxide solution and Luminol 
enhancer) to the membrane for 5 minutes. Visualisation of chemiluminescence was performed 
on the Amersham Imager 600 (GE Healthcare). Primary antibodies used are detailed in Table 
2.4 
Antibody target Species Source Catalogue number Dilution 
DNMT1 Mouse Abcam ab13537 1:1000 
UHRF1 Mouse Merck Millipore  MABE308 1:5000 
GAPDH Rabbit Cell Signalling Technology 2118S 1:2500 
Alpha-tubulin Mouse Abcam ab7291 1:5000 
TET1 Rabbit GeneTex GTX124207 1:1000 
P53 Mouse Santa Cruz Biotechnology sc-126 1:1000 
Table 2.4 Primary antibodies used for Western Blotting 
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2.7 Alkaline phosphatase assay 
To perform an alkaline phosphatase assay, the Amplite™ Colorimetric Alkaline Phosphatase 
Assay Kit (Stratech) was used according to manufacturer’s instructions. Briefly, equal numbers 
of hESCs were seeded on wells of 0.1% gelatine and iMEF coated 96 well plates. After 24 hours, 
media was aspirated and wells were washed with DPBS. 50μl of each alkaline phosphatase 
standard solution (prepared by serial dilution) was plated on the same plate. P-nitrophenyl 
phosphate (pNPP) working solution was prepared and 50μl was added to each well of 
standards and 100μl to each test well containing cells. Plates were incubated at 37°C for 30 
minutes in the dark, following which the absorbance increase was measured with the FLUOstar 
Omega Microplate reader (BMG Labtech) using the absorbance plate reader detection mode at 
400nm.  
 
2.8 Stable shRNA knockdown cell line generation 
 
2.8.1 Acquisition and preparation of shRNA plasmids 
Short hairpin RNA (shRNA) constructs were obtained from Dharmacon in The RNA Consortium 
(TRC) pLKO.1 HIV-based lentiviral vector. Constructs were obtained as glycerol stocks of 
plasmid DNA in DH5α E.Coli bacteria. Bacteria containing each construct was streaked onto an 
LB agar plate containing 100µg/ml Ampicillin and incubated overnight at 37°C. The following 
day, colonies were picked from the agar plate and 3ml of LB broth medium (containing 
100µg/ml Ampicillin) was inoculated with each colony. Cultures were incubated at 37°C for 16 
hours with vigorous shaking, following which plasmid DNA was purified from pelleted cultures 
using the Zyppy plasmid miniprep kit (Zymo Research), following manufacturer’s instructions. 
shRNA sequences and identifiers are listed in table 2.5. 
 
2.8.2 Generation of lentiviral particles 
To generate lentiviral particles, HEK293T cells in a 6-well plate at 70% confluency were 
transfected with 3µg of the shRNA plasmid for a target gene, 2µg of the packaging construct 
pCMV Δ8.91, and 1µg of the vesicular stomatitis virus glycoprotein (VSV-G) containing 
envelope expressing plasmid pMD2.G, using jetPrime (Polyplus) at a ratio of 1:2. 48 hours 
later, media containing viral particles was collected and filtered through a 0.22µm filter. 
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2.8.3 Transduction of hESCs and generation of stable knock down cell lines 
Primed hESCs were treated with 6µg/ml polybrene (Sigma Aldrich) for 15minutes, followed 
by transduction with filtered lentiviral particles. Stable hESC knock down cell lines were 
generated by puromycin selection (1µg/ml) of successful integrants for 48 hours.   
Table 2.5 shRNA sequences used to generate knock down cell lines 
 
  
Target 
Gene 
Mature antisense sequence Identifier Catalogue Number 
DNMT3A AATAATCTCCTTGACCTTGGG TRCN0000035754 RHS3979-201764981 
TTATTAGCGAAGAACATCTGG TRCN0000035757 RHS3979-201764984 
DNMT3B TATAGCAATTTGTCTTGAGGC TRCN0000035684 RHS3979-201764911 
ATTTGAGAGATCGTTGCATGG TRCN0000035686 RHS3979-201764913 
DNMT3L TTGTCCACGAACATCCAGAAG TRCN0000019683 RHS3979-201750800 
TTCTTCTTCCGAAACCAGAGC TRCN0000019680 RHS3979-201750797 
DNMT3A 
isoform 1 
ATTGGGTAATAGCTCTGAGGC TRCN0000035756 RHS3979-201764983 
FOXC1 AGGGTGATCTTCTTGTCCGGG TRCN0000013964 RHS3979-201745542 
TTCAGGTACCACGAGGTGAGG TRCN0000013965 RHS3979-201745543 
ZFHX3 ATTCTCATAATTCTTCCTGGC TRCN0000013558 RHS3979-201745136 
TTAGCTGTGGAAACTAAAGGG TRCN0000013560 RHS3979-201745138 
SOX15 TTCCAGTTTGCAGTGGGAAGA TRCN0000019150 RHS3979-201750357 
TAGTGGGTATAGGTGGGCAGC TRCN0000019151 RHS3979-201750358 
NFKB1 ATCATCAGATGTAAACTCTGG TRCN0000006518 RHS3979-201738791 
TTCAGGATAGTAGAGGAAAGG TRCN0000006520 RHS3979-201738793 
Non-
targeting 
control 
N/A N/A 
 
RHS6848 
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2.9 Stable overexpression cell line generation 
 
2.9.1 Acquisition of entry clones of target genes  
Entry clones for overexpression of genes, listed in Table 2.6, were obtained from Harvard 
PlasmID Repository. These were made up of full length sequences for the target gene in the 
pENTR223 gateway cloning compatible vector.  
 
2.9.2 Generation of expression vectors for target genes 
To generate expression vectors, a recombination reaction was performed with 100ng of the 
entry clone for each target gene and 150ng of the pLenti CMV puro DEST (w118-1) destination 
vector with Gateway LR clonase II (ThermoFisher Scientific), following manufacturer’s 
instructions. Following a 1 hour incubation with the LR clonase II enzyme, 1µl of each of the 
reactions was transformed into 50µl of NEB 5-alpha high efficiency competent E.coli (NEB) by 
heat-shock (incubating at 42°C for 30 seconds). After 1 hour of incubation with shaking at 37°C 
in SOC medium, 100µl of the transformation was plated onto LB agar plates containing 
100µg/ml Ampicillin. The following day, colonies were picked from the agar plate and 3ml of 
LB broth medium (containing 100µg/ml Ampicillin) was inoculated. Cultures were incubated at 
37°C for 16 hours with vigorous shaking, following which plasmid DNA was purified from 
pelleted cultures using the Zyppy plasmid miniprep kit (Zymo Research), following 
manufacturer’s instructions.  
 
2.9.3 Generation of lentiviral particles 
To generate lentiviral particles, HEK293T cells at 70% confluency were transfected with 3µg of 
the expression vector for a target gene, 2µg of the packaging construct pCMV Δ8.91, and 1µg 
of the vesicular stomatitis virus glycoprotein (VSV-G) containing envelope expressing plasmid 
pMD2.G, using jetPrime (Polyplus) at a ratio of 1:2. 48 hours later, media containing viral 
particles was collected and filtered through a 0.22µm filter. 
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2.9.4 Transduction of hESCs and generation of stable overexpression cell lines 
Primed hESCs were treated with 6µg/ml polybrene (Sigma Aldrich) for 15minutes, followed 
by transduction with filtered lentiviral particles. Stable hESC knock down cell lines were 
generated by puromycin selection (1µg/ml) of successful integrants for 48 hours.   
 
Gene Vector Catalogue Number Source 
TET1 TET1 in pENTR223 HsCD00399189 Harvard PlasmID 
repository 
MECP2 MECP2 in pENTR223 HsCD00373134  Harvard PlasmID 
repository 
Table 2.6. Entry clones used for overexpression of genes 
 
2.10 Chromatin Immunoprecipitation and qPCR (ChIP-qPCR) 
 
2.10.1 Chromatin extraction 
Cells were cross-linked with 1% formaldehyde for 10 minutes at room temperature with gentle 
rocking, after which the formaldehyde was quenched with 1.25M glycine. Chromatin was then 
extracted from the cross-linked cells using the chromatin extraction kit (Abcam), as per the 
manufacturer’s instructions. The extracted chromatin was then fractionated by sonication at 
4 (12 cycles of 15s on, 60s off; Diagenode Bioruptor® Plus). The size profile of the sonicated 
chromatin was checked by agarose gel electrophoresis.  
 
2.10.2 Chromatin Immunoprecipitation 
Chromatin immunoprecipitation was carried out using the ChIP – One Step kit (Abcam) with a 
starting total of 5µg of chromatin. Immunoprecipitation was carried out as per the 
manufacturer’s instructions and the following quantities of antibody were used for 
immunoprecipitation: H3K4me3 0.5g (Abcam; ab8580), H3K27me3 2g (Abcam; ab195477). 
As a loading control for assessing immunoprecipitation, input DNA was isolated from 10µl of 
chromatin for each sample by incubation with 88l of DNA release buffer and 2.5l of 
proteinase K at 65°C for 15 minutes followed by 95°C for 10 minutes. The input DNA is 
representative of the starting quantity of chromatin prior to immunoprecipitation. Input and 
immunoprecipitated DNA were quantified by real-time PCR, and data was quantified as the % 
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enrichment of immunoprecipitated DNA relative to the input for each sample. Primers used for 
PCR reactions are listed in Table 2.7. 
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2.11 Targeted Bisulphite Sequencing 
 
2.11.1 Primer design 
Bisulphite PCR primers were designed against an in silico bisulphite converted reference 
sequence using the Bisulphite Primer Seeker software (Zymo) or Methprimer (Urogene), and 
the following universal Illumina adapter sequences were added to the 5’ end of each primer.  
Forward primer: ACACTCTTTCCCTACACGACGCTCTTCCGATCT 
Reverse primer: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
 
Target genomic region Primer Sequence (5’ – 3’) 
COL11A1 AGAGAACTGCACGTCCAACC 
TGCAACCAAGTGAGAAGCAG 
DLX5 GGCAATCTGGGAGTTCCACA 
CTGAGCGGGGCTGTATCTTG 
TRPC4 TATATGCACCCAGATGCCCC 
TTTAAAGCAGGGGAGAGGGC 
PITX1 CATACACAGGGACGCTGTAAAC 
GGGAGGTCCATCTCAGAACA 
SIM1 GCCTGGGGAGTAAGGAGACT 
AACTTCCTTCCGCTGGTAGC 
SLC17A9 GCTCCTATGGGGCAGCAG 
GGCTTGGGGTGCTCAGAC 
LIN9 ATCTCAGGCACGTTGGTTTC 
CCAGTGACTCACCCAATCCT 
WTIP GGTTGGGACGAGGAAGGT 
AGTGTGCCCATGAACCTGAC 
DPP6 TATTGGTAGCGGCCAAAAAG 
GATCATGGCCTTTTCCTTCA 
Table 2.7 Primers used for ChIP-qPCR 
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2.11.2 DNA isolation and bisulphite conversion 
Cells were dissociated to single cells using Accutase and serially plated for 2 hours to eliminate 
excess iMEFs. DNA was isolated from pelleted cells using the PureLink Genomic DNA mini kit 
(ThermoFisher Scientific) and quantified using the Nanodrop 2000 spectrophotometer 
(ThermoFisher Scientific). Bisulphite conversion of DNA was carried out using the Imprint® 
DNA Modification kit (Sigma Aldrich), following the manufacturer’s instructions. This process 
involves a chemical reaction of the DNA with a sodium bisulphite reagent with which results in 
unmethylated cytosine bases being converted to uracils (which will be sequenced as thymine), 
whereas methylated cytosine bases are not converted. 
 
2.11.3 PCR amplification of target regions 
The modified DNA was amplified using the loci specific bisulphite PCR primers with HotStar Taq 
DNA Polymerase (Qiagen). The PCR conditions were as follows: 95 °C for 15 min; 94 °C for 30 
seconds; 56 °C for 30 seconds; 72 °C for 1 min; Repeat steps 2-4 29X; 72 °C for 10 min; Hold 
12°C. PCR products were purified using solid phase reverse immobilisation (SPRI) magnetic 
beads at a 1:1 ratio (Agencourt AMPure XP, Beckman Coulter). Purified PCR amplicons were 
PCR amplified with a further 8 cycles using a universal Illumina forward (P5) primer and an 
indexed reverse (P7) primer. PCR products were purified using SPRI beads at a 1:1 ratio. 
Purified amplicons were quantified using the Qubit™ dsDNA high sensitivity assay, measured 
on the Qubit 4 Fluorometer (ThermoFisher Scientific). Amplicons for each sample were pooled 
at equal concentrations, based on quantification on the Nanodrop 2000 spectrophotometer 
(ThermoFisher Scientific). Quantification of each sample was performed using the Kapa Library 
quantification kit for Illumina (Roche), and samples were pooled at equal concentrations to 
enable multiplexing. Bisulphite primer sequences for target loci are listed in table 2.8 and 
Illumina P5 and P7 index primers are listed in table 2.9. 
 
2.11.4 Fluidigm targeted amplicon sequencing 
For larger experiments, multiplex targeted bisulphite sequencing was performed on 
bisulphite converted DNA using the 48x48 layout on the Fluidigm C1 system (Fluidigm). This 
system allows amplification of 48 genomic regions (based on 48 primer pairs) for 48 
samples of bisulphite converted genomic DNA. Bisulphite primer sequences for target loci 
analysed on the Fluidigm platform are listed in table 2.10. 
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2.11.5 Amplicon library Sequencing 
Sequencing was performed on an Illumina MiSeq with 150bp paired-end reads, using v3 
chemistry, at Barts and the London Genome Centre (London, UK).  
 
2.11.6 Data Analysis 
Sequencing reads were obtained in the form of FASTQ files and quality of reads was assessed 
using FastQC (Babraham Bioinformatics). Sequencing reads were trimmed to remove adapters 
and low-quality ends using Seqtk. The remaining sequences were mapped to a customised 
human genome composed of amplicon sequences or the human genome GRCh38 using 
Bowtie2-2.2.9 and Bismark v0.19.0 (Krueger and Andrews 2011) with default parameters, and 
methylation calls were extracted as a percentage for each individual CpG site using Bismark 
methylation extractor. 
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  Table 2.8. Bisulphite primer sequences for targeted bisulphite sequencing 
Gene/region Primer Sequence (5’ – 3’) 
DLX5 TGTTTAGTATTAGTTTAGTTTTATTTGGAGTGTGG 
AATCCAAACCRCAAAAACAAAAAATTAATACAC 
PITX1 GGGGTTGTTYGTTTAGATAGAGGGTTATTTTTTAG 
TTAAAAAAACRATACCCCCAACCCAAAATC 
FGF17 GGTAYGAGGGTTGGTTTATGG 
AATAAAAAAACRACCCAAAAACTACTACCCCCTAC 
SLC17A9 TTGGTTTYGTTTTTATGGGGTAGTAGGG 
TATATCCCRAAACTACCTCCCAACCCAAACTAACC 
Col11A1 GTTTTTYGTGTTTTTAGTTTTTTTTTTTTTTTTTGAG 
ACCCACTAACRACATAAAACCTTTAAAAACACAC 
HOXA3 GAYGTTAGTATGTTTTTGTTTTTTTGATTTTTTTTG 
CRAATAAAAATAACCAATCTACTAAACCTCACTAAAC 
VAV3 TTGAATTGTGATTTTTGAGTTGATTTTAGGGTG 
AAAAACRAATCCAACCTCTCTCAACAAC 
TRPC4 GAAGAGAGTYGGTTTTTTAGGTAGTTTAGG 
TCAATCCTCRAATCCCATCACTTCAACC 
MEIS2 AATAGTTAGTTTTTTTTGTTTAGGTTGGAAATGG 
AAATCCCCACRCAACTAAACAACTCCTCTC 
Hypomethylated_region_1 GTTTGGGTYGAGTTTAGTGTTTTATTTATATTTG 
ATATTTCAATTATCCAAACTTCCTCTCTCTTCC 
Hypomethylated_region_2 GYGAATGTTAGTGGGTTAGAATTGGGAG 
AACRAAAAAAATTAAAAAACTCTAACCCCATAC 
Hypomethylated_region_3 GTTYGGAGGATTTAGGGTTTGGG 
ACRAAACCAAAAAAAAACACAACAACTACTACC 
Hypomethylated_region_4 GGTYGATTTGTTTTTTAGTTTTGAGGTTTTG 
ACRTTAACCACCAAACCCAAAATATC 
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Primer Primer Sequence (5’ – 3’) - unique index underlined 
P5 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT 
 
P7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CAAGCAGAAGACGGCATACGAGATTACAAGTTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
CAAGCAGAAGACGGCATACGAGATATCACTGGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
CAAGCAGAAGACGGCATACGAGATCGCATCAAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
CAAGCAGAAGACGGCATACGAGATGCACGACCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
CAAGCAGAAGACGGCATACGAGATTACACTCCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
CAAGCAGAAGACGGCATACGAGATCGGTCTAAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
CAAGCAGAAGACGGCATACGAGATATGTTCGGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
CAAGCAGAAGACGGCATACGAGATCGTGGACCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
CAAGCAGAAGACGGCATACGAGATATTGAGCCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
CAAGCAGAAGACGGCATACGAGATTAGTTCGGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
CAAGCAGAAGACGGCATACGAGATCGGTGAGGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
CAAGCAGAAGACGGCATACGAGATCGTGAGTTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
Table 2.9. Illumina P5 and P7 indexed adapters used for targeted bisulphite sequencing 
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2.12 Mass Spectrometry based Proteomics 
 
2.12.1 Cell lysis and trypsin digestion 
For proteomics experiments, 3 independent biological replicates per condition were used. Cells 
were washed twice with ice cold PBS supplemented with 1 mM Na3VO4 and 1 mM NaF, lysed in 
urea buffer (8M urea in 20 mM in HEPES pH 8.0, 1 mM Na3VO4, 1 mM NaF, 1mM Na4P2O7 and 
1 mM sodium β-glycerophosphate) for 30 min and homogenized by sonication (15 cycles of 
Gene/region Primer Sequence (5’ – 3’) 
DLX5 TGTTTAGTATTAGTTTAGTTTTATTTGGAGTGTGG 
AATCCAAACCRCAAAAACAAAAAATTAATACAC 
ZFHX3 GAGATGTTGATTTAGAGTTTTTTTT 
ACCACCTAAAATCCCTCTACTTCTT 
FBXL13 GTAATTGGGGTTAGTTGGATGTTAG 
AAACAACACATAAACTAATTTTCTTTCTTA 
RAB34 AGGTTTGGGAGGTGATTTATAGAGT 
ACAATAAACACCCATACCAAAAAAA 
ACHE GAAGGAAGGGAAGGTTTAGTTTAGA 
TTTAAAAAAATCTCAAAACATCCTAAC 
SIM1 TTTTTTGAGAGAGTGTAGGAGAGTTT 
ACTAATTACACCAATTTCCCTCTCTT 
TBX4 GGGTTTTAGATATAGTTGGATTTAG 
ACCCATAAAAATAAAATTAACAAAC 
NFIX TAGTAAATTGAAAGGATTAGTGAAT 
TCTAACCCCTACAAAAAATAACACC 
NR2F2 TTATTAATTGTGGAGTGTTTTTTTT 
ATACCCATAATATTATTAAACTACATACAT 
SHH ATAGTAGGTTTGATAGAGATTTGGG 
ACTACAAATAACAACTCACCTAACC 
TBX5 AAAGTAAAGATTTTTAAGGTTGGTT 
TTCCTATTCCCCCAAAAAAAA 
FGF17 GGTAYGAGGGTTGGTTTATGG 
AATAAAAAAACRACCCAAAAACTACTACCCCCTAC 
NKX6-1 TTGATTTGTGAGAATTAATAAATAA 
ACAATAAACTCCCTAACTATTTAAC 
PITX1 GGGGTTGTTYGTTTAGATAGAGGGTTATTTTTTAG 
TTAAAAAAACRATACCCCCAACCCAAAATC 
ITGAM TGGGGAATTTTTAGAAATTTAGAGT 
CCCCAATCACACAACTAACAAC 
PAX8 TTAATTTTTGGGTGATATATTTGGT 
ATTTCTAACTCCTAAATCCACTCAAC 
SLC17A9 TTGGTTTYGTTTTTATGGGGTAGTAGGG 
TATATCCCRAAACTACCTCCCAACCCAAACTAACC 
Table 2.10. Primer sequences for Fluidigm targeted bisulphite sequencing 
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30s on 30s off; Diagenode Bioruptor® Plus, Liege, Belgium). Insoluble material was removed by 
centrifugation at 20,000 xg for 10min at 5C and protein levels in the cell extracts were 
quantified by bicinchoninic acid (BCA) analysis. 
For trypsin digestion, 100 µg of protein were reduced and alkylated by sequential incubation 
with 10 mM DTT and 16.6 mM iodoacetamyde for 1h and 30min, respectively. Urea 
concentration was diluted to 2 M with 20 mM HEPES (pH 8.0), 80 µL of preconditioned trypsin 
beads [(50% slurry of TLCK-trypsin (Thermo-Fisher Scientific; Cat. #20230)] were added and 
samples were incubated for 16h at 37C with agitation. Trypsin beads were preconditioned with 
3 washes of 20 mM HEPES (pH 8.0)). Finally, samples were centrifuged for 2,000 xg for 5min at 
5C and supernatants were transferred to fresh tubes.  
 
2.12.2 Desalting 
Peptide solutions were desalted using 10 mg OASIS-HLB cartridges (Waters, Manchester, UK). 
Briefly, OASIS cartridges were accommodated in a vacuum manifold (-5 mmHg), activated with 
1 mL ACN and equilibrated with 1.5 mL washing solution (1% ACN, 0.1% TFA). Peptides were 
loaded into the cartridges, washed with 1 mL of washing solution, eluted with 500 µL of ACN 
solution (30% ACN, 0.1% TFA), dried in a speed vac (RVC 2-25, Martin Christ 
Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany) and stored at -80C. 
 
2.12.3 Mass spectrometry data acquisition  
Dried peptides were dissolved in 0.1% TFA and analysed by nanoflow ultimate 3,000 RSL nano 
instrument was coupled on-line to a Q Exactive plus mass spectrometer (Thermo Fisher 
Scientific). Gradient elution was from 3% to 35% solvent B in 120 min at a flow rate 300 nL/min 
with solvent A being used to balance the mobile phase (buffer A was 0.1% formic acid in water 
and B was 0.1% formic acid in acetonitrile) . The spray voltage was 1.95 kV and the capillary 
temperature was set to 255C. The Q-Exactive plus was operated in data dependent mode with 
one survey MS scan followed by 15 MS/MS scans. The full scans were acquired in the mass 
analyser at 375-1500 m/z with the resolution of 70,000 and the MS/MS scans were obtained 
with a resolution of 17,500. Overall duty cycle generated chromatographic peaks of 
approximately 30s at the base, which allowed the construction of extracted ion 
chromatograms (XICs) with at least 10 data points.  
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2.12.4 Peptide identification and quantification 
Mascot Daemon 2.5.0 was used to automate peptide identification from MS data. Peak list 
files (MGFs) from RAW data were generated with Mascot Distiller v2.5.1 and loaded into the 
Mascot search engine (v2.5) in order to match MS/MS data to peptides. Searches were 
performed against the SwissProt Database (release December 2015) with a FDR of ~1% and 
restricted to the human entries. Mass tolerance of ±10 ppm for the MS scans and ±25 mmu for 
the MS/MS scans, 2 trypsin missed cleavages, carbamidomethyl Cys as a fixed modification and 
PyroGlu on N-terminal Gln and oxidation of Met as variable modifications were allowed. The 
in-house developed Pescal software was used for label-free peptide quantification as 
described before (Alcolea et al. 2012). XICs for all the peptides identified across all samples 
were constructed with ±2 min and ±7 ppm retention time and mass windows, respectively. 
Peak areas from all XICs were calculated. The maximum intensity value for the 2 technical 
replicates was selected and used for further analysis. Intensity values for each peptide were 
normalized to total sample intensity. Statistical significance was calculated using two tail 
unpaired Student’s t-test. Multiplicity correction was performed by applying the Benjamini-
Hochberg method on the p-values, to control the false discovery rate (FDR). Differences were 
considered significant when FDR < 0.05. Proteins with a Mascot score > 40 were used for 
analysis. 
 
2.13 Mass Spectrometry of Nucleosides 
 
2.13.1 Isolation and digestion of genomic DNA 
DNA was isolated from pelleted cells using the PureLink Genomic DNA mini kit (ThermoFisher 
Scientific). 500ng of genomic DNA (3 biological replicates per sample) was digested using DNA 
Degradase Plus (Zymo Research) by incubating genomic DNA with 1µl DNA Degradase Plus 
enzyme in a total volume of 25µl at 37° for 12 hours.  
 
2.13.2 Mass Spectrometry quantification of nucleosides 
Nucleosides were analysed by LC-MS/MS on a Q-Exactive mass spectrometer (Thermo 
Scientific) fitted with a nanoelectrospray ion-source (Proxeon). All samples and standards had 
a heavy isotope-labelled nucleoside mix added prior to mass spectral analysis (2'-
deoxycytidine-13C1, 15N2 (Santa Cruz), 5-(methyl-2H3)-2'-deoxycytidine (Santa Cruz), 5-
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(hydroxymethyl)-2'-deoxycytidine-2H3 (Toronto Research Chemicals). MS2 data for 5hmC, 5fC, 
5mC and C were acquired with both the endogenous and corresponding heavy-labelled 
nucleoside parent ions simultaneously selected for fragmentation using a 5 Th isolation 
window with a 1.5 Th offset. Parent ions were fragmented by Higher-energy Collisional 
Dissociation (HCD) with a relative collision energy of 10%, and a resolution setting of 70,000 
for MS2 spectra. Peak areas from extracted ion chromatograms of the relevant fragment ions, 
relative to their corresponding heavy isotope labelled internal standards, were quantified 
against a six-point serial 2-fold dilution calibration curve, with triplicate runs for all samples 
and standards. 
 
2.14 Infinium MethylationEPIC BeadChip assay 
Genomic DNA was extracted using the PureLink Genomic DNA mini kit (ThermoFisher 
Scientific) and quantified using the Nanodrop 2000 spectrophotometer (ThermoFisher 
Scientific). Bisulphite conversion of DNA was carried out using the Imprint® DNA Modification 
kit (Sigma Aldrich), following the manufacturer’s instructions. Infinium MethylationEPIC 
BeadChip assay (Illumina) was performed according to manufacturer instructions by Barts 
and the London Genome Centre (London, UK). The Illumina Infinium MethylationEPIC 
BeadChip assays DNA methylation levels at approximately 850,000 different CpG sites. For 
each CpG site, methylation levels are measured by probes attached to beads, one each for 
unmethylated and methylated DNA, followed by allele-specific base extension that includes a 
fluorescent label. Different labels are used for the T (unmethylated) or C (methylated) alleles. 
Methylation scores for each CpG site are classified as “Beta” values that range from 0 
(unmethylated) to 1 (fully methylated) on a continuous scale, and are based on the ratio of 
methylated to unmethylated signal outputs. The Bioconductor package ChAMP (version 
2.11.3: https://bioconductor.org/packages/release/bioc/html/ChAMP.html) (Tian et al. 
2017) was used to process raw Infinium idat files using the GRCh37 human genome 
manifest file, and generate beta values. Data was normalised using the “SWAN” method of 
normalisation. 
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2.15 RNA sequencing 
 
2.15.1 Library Preparation 
Total RNA was extracted using Direct-zol RNA mini kit (Zymo) and DNase treated 
(ThermoFisher Scientific), before being quantified using the Nanodrop 2000 
spctrophotometer (ThermoFisher Scientific). Messenger RNA (mRNA) was isolated from 
500ng of total RNA using Dynabeads mRNA DIRECT purification kit (ThermoFisher Scientific) 
and fragmented with RNA fragmentation reagent (ThermoFisher Scientific). First strand 
cDNA synthesis was performed with SuperScript III First-Strand Synthesis System and 3 μg 
μl−1 random hexamers (ThermoFisher Scientific) followed by second strand synthesis with 
DNA polymerase I and RNase H. After purification using SPRI beads, the double stranded 
cDNA was ligated to in house designed adapters (based on TruSeq Indexed adapters 
(Illumina); listed in Table 2.11) using NEBNext Ultra II (NEB) followed by 15 cycles of 
amplification with universal P5 (AATGATACGGCGACCACCGAGATCTAC) and P7 
(CAAGCAGAAGACGGCATACGAGAT) PCR primers and library purification.  
 
2.15.2 Library Quantification and Quality Control 
Library size distribution and molarity was assessed by the DNA 1000 assay on the 4200 
Bioanalyzer (Agilent), and quantification was performed using the Qubit™ dsDNA high 
sensitivity assay, measured on the Qubit 4 Fluorometer (ThermoFisher Scientific). Libraries 
were also quantified using the Kapa Library quantification kit for Illumina (Roche), and final 
multiplexing of samples was based on concentrations calculated from the Kapa library 
quantification.  
 
2.15.3 Library Sequencing 
Sequencing was performed on an Illumina NextSeq500 with 75bp paired-end sequencing at 
Barts and the London Genome Centre (London, UK). Raw data was received in FASTQ 
format.  
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Primer Primer Sequence (5’ – 3’) - unique index underlined 
P5 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC*T 
P7 GATCGGAAGAGCACACGTCTGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG 
GATCGGAAGAGCACACGTCTGAACTCCAGTCAC CGATGT ATCTCGTATGCCGTCTTCTGCTTG 
1. GATCGGAAGAGCACACGTCTGAACTCCAGTCAC TTAGGC ATCTCGTATGCCGTCTTCTGCTTG 
1. GATCGGAAGAGCACACGTCTGAACTCCAGTCAC TGACCA ATCTCGTATGCCGTCTTCTGCTTG 
1. GATCGGAAGAGCACACGTCTGAACTCCAGTCAC ACAGTG ATCTCGTATGCCGTCTTCTGCTTG 
1. GATCGGAAGAGCACACGTCTGAACTCCAGTCAC GCCAAT ATCTCGTATGCCGTCTTCTGCTTG 
1. GATCGGAAGAGCACACGTCTGAACTCCAGTCAC CAGATC ATCTCGTATGCCGTCTTCTGCTTG 
1. GATCGGAAGAGCACACGTCTGAACTCCAGTCAC ACTTGA ATCTCGTATGCCGTCTTCTGCTTG 
GATCGGAAGAGCACACGTCTGAACTCCAGTCAC CTTGTA ATCTCGTATGCCGTCTTCTGCTTG 
Table 2.11. Illumina P5 and P7 indexed adapters used for RNA-seq and WGS 
 
2.15.4 Data analysis 
Read quality of FASTQ files was determined using FASTQC. Genomic mapping of short reads 
was performed using hisat2 (v. 2.1.0) to the human genome (GRCh38). Mapped reads were 
counted for each sample using FeatureCounts (Subread, v. 1.6.3) (Liao, Smyth, and Shi 
2014), with counting performed over all exons. Downstream RNA-sequencing analysis was 
performed using the R package EdgeR (v3.18.1) (Robinson, McCarthy, and Smyth 2010). 
Upregulated and downregulated genes were called as those with Benjamini-Hochberg 
corrected FDR < 0.05 and a log2 fold change > 1. Pathway enrichment analysis was 
performed using DAVID Bioinformatics Resources (Huang, Sherman, and Lempicki 2009; 
Huang, Sherman, and Lempicki 2008) 
 
2.16 Targeted sequencing for mutational analysis 
 
2.16.1 DNA isolation  
Cells were dissociated to single cells using Accutase and serially plated for 2 hours to eliminate 
excess iMEFs. DNA was isolated from pelleted cells using the PureLink Genomic DNA mini kit 
(ThermoFisher Scientific) and quantified using the Nanodrop 2000 spectrophotometer 
(ThermoFisher Scientific).  
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2.16.2 PCR amplification of target regions 
The modified DNA was amplified using loci specific PCR primers with HotStar Taq DNA 
Polymerase (Qiagen). The following universal Illumina adapter sequences were added to the 5’ 
end of each primer.  
Forward primer: ACACTCTTTCCCTACACGACGCTCTTCCGATCT 
Reverse primer: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
The PCR conditions were as follows: 95 °C for 15 min; 94 °C for 30 seconds; 56 °C for 30 
seconds; 72 °C for 1 min; Repeat steps 2-4 29X; 72 °C for 10 min; Hold 12°C. PCR products 
were purified using SPRI magnetic beads at a 1:1 ratio (Agencourt AMPure XP, Beckman 
Coulter). Purified PCR amplicons were PCR amplified with a further 8 cycles using a 
universal Illumina forward (P5) primer and an indexed reverse (P7) primer (Table 2.9). PCR 
products were purified using SPRI beads at a 1:1 ratio. Primer sequences are listed in Table 
2.12.  
 
2.16.3 Library quantification 
Purified amplicons were quantified using the Nanodrop 2000 and the Qubit™ dsDNA high 
sensitivity assay, measured on the Qubit 4 Fluorometer (ThermoFisher Scientific). Amplicons 
for each sample were pooled at equal concentrations, based on quantification on the 
Nanodrop 2000 spectrophotometer (ThermoFisher Scientific). Quantification of each sample 
was performed using the Kapa Library quantification kit for Illumina (Roche), and samples 
were pooled at equal concentrations to enable multiplexing.  
 
2.16.4 Amplicon library Sequencing 
Sequencing was performed on an Illumina MiSeq with 150bp paired-end reads, using v3 
chemistry, at Barts and the London Genome Centre (London, UK).  
 
2.16.5 Data Analysis 
Data analysis was performed on the bioinformatics platform Galaxy (https://usegalaxy.org/). 
Sequencing reads were obtained in the form of FASTQ files and quality of reads was assessed 
using FastQC (Babraham Bioinformatics). Sequencing reads were aligned to the human 
GRCh38 genome using Bowtie2 with standard parameters. The function samtools mpileup 
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was used to generate a multi-way pileup file with a maximum read depth of 1,000,000 reads. 
Varscan (v2.4.2) was used for variant calling from the mpileup file, with a minimum variant 
allele frequency (VAF) threshold of 0.001 (0.1%). The resulting VCF file was used for 
downstream analysis which was performed using Microsoft excel. Variants with less than 
10,000 reads were eliminated from the analysis.   
DNA methylation status during 
reprogramming 
Gene/region Primer Sequence (5’ – 3’) 
Hypermethylated DLX5 TAGGGTTATCTGGCCTCCCC 
GCTGTGTTTTTCTGGTGCAGT 
Hypermethylated PITX1 GGGGTGTTCTGAGATGGACC 
GATTTCCCGACCCCGTACAA 
Hypermethylated FGF17 TCCCTCCTCAGTCGTCCAAA 
CCTTGGTAGAGGCGCTTGAT 
Non-hypermethylated WTIP GGTTGGGACGAGGAAGGT 
AGTGTGCCCATGAACCTGAC 
Non-hypermethylated CAMK2D TAGGTCTCCTGCCTCCTTCC 
ACGTGTGCATCTTTGCGTTC 
Table 2.12. Primers sequences used for targeted sequencing for mutation analysis 
 
2.17 Whole genome sequencing 
 
2.17.1 Library Preparation 
DNA was isolated from pelleted cells using the PureLink Genomic DNA mini kit (ThermoFisher 
Scientific) and quantified using the Nanodrop 2000 spectrophotometer (ThermoFisher 
Scientific). 3 independent biological replicates per condition were used. 200ng of genomic DNA 
was fragmented using 2µl of NEBnext® dsDNA fragmentase® (NEB) for 15 minutes at 37°C in a 
total volume of 20µl. The reaction was stopped with 5μl of 0.5M EDTA pH8.0. Fragmented DNA 
was cleaned up using SPRI beads at a 1:1 ratio (Agencourt AMPure XP, Beckman Coulter). 
Sequencing libraries were prepared using the NEBNext Ultra II library preparation kit for 
Illumina (NEB). Fragmented DNA was subjected to end repair which results in 5’ 
phosphorylation and dA tailing, followed by ligation with 1.5µM of TruSeq adaptors 
containing unique indexes for each sample (Table 2.11). Size selection of adaptor-ligated 
DNA was performed by using a 0.9X ratio of SPRI beads to sample, followed by 6 cycles of 
library amplification with Illumina universal P5 (AATGATACGGCGACCACCGAGATCTAC) and P7 
(CAAGCAGAAGACGGCATACGAGAT) PCR primers and a final library purification with 1:1 SPRI 
beads. 
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2.17.2 Library Quantification and Quality Control 
Library size distribution and molarity was assessed by the DNA 1000 assay on the 4200 
Bioanalyzer (Agilent), and quantification was performed using the Qubit™ dsDNA high 
sensitivity assay, measured on the Qubit 4 Fluorometer (ThermoFisher Scientific). Libraries 
were also quantified using the Kapa Library quantification kit for Illumina (Roche), and final 
multiplexing of samples was based on concentrations calculated from the Kapa library 
quantification.  
 
2.17.3 Library Sequencing 
Sequencing was performed on an Illumina HiSeq X-ten with 150bp paired-end sequencing at 
BGI Tech Solutions, Hong Kong. Raw data was received in FASTQ format.  
 
2.17.4 Data Analysis 
Sequencing reads were obtained in the form of FASTQ files and quality of reads was assessed 
using FastQC (Babraham Bioinformatics). Sequencing reads were aligned to the human 
GRCh38 genome using the BWA-MEM algorithm used in Burrows-Wheeler Aligner with 
standard parameters. The resulting SAM file was processed into a sorted and indexed BAM 
file using Samtools v1.3, and PCR duplicates were marked using Picard v2.6. BAM files were 
imported onto the Galaxy Bioinformatics platform and the FreeBayes tool was used to detect 
genetic variants and produce a Variant Call Format (VCF) file, with a minimum coverage of 1 to 
call a variant, due to low sample coverage (5x). BCF tools was used to filter out common 
variants between samples and retain only unique ones. The total number of single nucleotide 
variants for each sample was counted and normalised to the total read count, and the number 
of C to T mutations was also counted and normalised to the total read count for each sample. 
Additionally, the total number of C to T mutations and the number of A to G mutations was 
counted and a C to T/ G to A ratio was calculated.  
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2.18 Bioinformatics Analysis 
 
2.18.1 Bisulfite Sequencing Analysis 
Bismark coverage files downloaded from GEO were uploaded into SeqMonk (v1.41.0), 
where the genomes were binned into 300bp probe windows. Methylation quantitation was 
carried out using the ‘Bisulphite methylation over features’ pipeline in SeqMonk (v1.41.0), 
with a 300bp probe carried forward if it contained at least 5 CpGs each with at least 3 
counts. Motif enrichment analysis was performed using the analysis of motif enrichment 
(AME) tool on the MEME suite (v5.0.4) (Bailey et al. 2009), searching against the human 
HOCOMOCO (v11 FULL) database. Sequences were scored using the average odds score and 
motif enrichment calculated using Fisher’s exact test. 
2.18.2 Overlap analysis 
Overlap analysis was performed in R using the package regioneR (Version 3.8: 
https://bioconductor.org/packages/release/bioc/html/regioneR.html). Overlap was 
performed using the ‘overlapPermTest’ function with 1000 permutations. Random regions 
were generated for the hg19 genome using the ‘circularRandomizeRegions’ function. 
Random loci generation was restricted to loci present in the Illumina EPIC array (for 
overlaps performed with Illumina EPIC array probes) or to regions with a (G+C) fraction 
>0.55 and a CpG observed-to-expected ratio >0.6 (for overlaps performed with bisulfite 
sequencing data). ENCODE and ChromHMM data for the H1 hESC cell line were downloaded 
from the UCSC genome browser. For ENCODE data, StdPk files were downloaded for each 
histone modification and genomic coordinates extracted (as BED files) for use in the overlap 
analysis. 
2.18.3 TCGA Analysis 
Illumina 450K DNA Methylation data spanning 396965 CpGs and 9664 samples was 
downloaded from the Pan Cancer Atlas (https://gdc.cancer.gov/about-
data/publications/pancanatlas). All samples from individuals without both a tumour and 
normal tissue sample were removed. Samples from tumour types with less than 30 individuals 
were removed. In order to assess only CpGs deemed “bivalent”, CpGs outside of regions that 
showed a peak of H3K27me3 and H3K4me3 in ENCODE H1 hESCs were removed. For this 
analysis, raw infinium IDAT files from the hESC reprogramming experiment were processed 
using minfi and normalised via the singlesample Noob method. CpGs used for analysis were 
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filtered for those that are unmethylated in primed hESCs (mean beta < 0.3). Unmethylated 
probes were restricted to those CpGs with mean Beta < 0.3 during the primed to naïve 
transition. Hypermethylated probes were defined using ChAMP, and restricted to those CpGs 
with ΔBeta > 0.1 in the early transition, late transition or naïve state. For the creation of 
heatmaps, data was first ordered by sample based on mean methylation of all CpGs, and then 
by CpG based on mean methylation across all samples of every cancer type. Statistical 
significance was calculated using a paired Wilcoxon test.  
 
2.19 Statistical Analysis 
Significance testing was performed using Prism (v.7.04) and Student’s T-test, one-way 
ANOVA or two-way ANOVA with Bonferroni post-hoc tests as specified in the Figure 
legends. Where applicable, data are plotted as mean  ± SEM. Representative data are shown 
where experiments were repeated at least twice with similar results.  
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Chapter 3. Results 1: The DNA methylation landscape during 
primed to naïve hESC reprogramming 
 
3.1 Introduction 
Human embryonic stem cells are derived from the ICM of pre-implantation human blastocysts 
(Thomson et al. 1998). However paradoxically, their in vitro morphology and transcriptional 
and epigenetic profiles exhibit closer resemblance to murine EpiSCs rather than the more 
primitive mESCs (Nichols and Smith 2009). Notably, the genomes of conventional hESCs are 
globally hypermethylated at levels comparable to somatic cells (Hackett and Surani 2014). In 
vitro, two pluripotent states with distinct culture conditions have been defined: primed and 
naïve pluripotency (Nichols and Smith 2009). In conventional culture conditions, hESCs are 
dependent on FGF signalling (Xu et al. 2005) and exist as a population of cells heterogeneous 
for pluripotency markers that are primed for differentiation, with low clonogenicity (Hackett 
and Surani 2014). Manipulation of in vitro culture conditions by a variety of published methods 
(summarised in Chapter 1) enables the maintenance and survival of more naïve hESCs through 
reprogramming of primed hESCs. While each method uses a different combination of 
inhibitors, growth factors or transgenes to reprogram primed hESCs, a feature common to 
them all is the presence of hLIF and the use of two small molecule inhibitors (2i) which include 
a MEK inhibitor and a GSK3β inhibitor. Naïve hESCs are characterised by a transcriptional 
profile more representative of the human ICM and a globally hypomethylated genome, as in 
the ICM (Takashima et al. 2014; Pastor et al. 2016). Each variety of naïve hESCs has been 
thoroughly characterised at a molecular level, but the transition from the primed to naïve 
state, which is likely when molecular processes that mediate the changing cellular state occur, 
has not been studied. In particular, the dynamics of the large-scale remodelling of DNA 
methylation that occurs between primed and naïve pluripotent states has not been 
comprehensively characterised, and the biological context of the DNA methylation changes 
has not been investigated. Additionally, while there have been brief references to discrete loci 
in some naïve hESCs that exhibit higher levels of DNA methylation than their primed 
counterparts (Guo et al. 2017; Guo et al. 2016), this phenomenon has not been explored 
comprehensively. 
This chapter will explore the changing DNA methylation landscape during primed to naïve hESC 
reprogramming using the NANOG/KLF2 + 2iLGö method of reprogramming (Takashima et al. 
2014). The timing and dynamics of these changes during the transition to naïve pluripotency 
will be discussed, as well as the genomic context of the methylation changes. Additionally, the 
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biological significance of the naïve hESC methylation patterns will be described. Finally, 
parallels between DNA methylation patterns upon reprogramming and methylation patterns 
frequently observed in cancer will be highlighted, and the possible utility of the primed to 
naïve reprogramming system as a mechanistic model for aberrant DNA methylation in cancer 
will be presented.  
 
3.2 Naïve hESCs are morphologically and transcriptionally distinct from primed 
hESCs 
To validate that reprogramming of primed H9-NK2 hESCs to the naïve state was successful in 
our hands, we began with primed hESCs cultured in KSR/FGF. We induced overexpression of 
the NANOG and KLF2 transgenes using doxycycline, alongside the use of the 2i inhibitors in the 
presence of hLIF (collectively referred to as 2iL+dox). After two weeks, upon removal of 
doxycycline, we propagated the naïve hESCs in the presence of a PKC inhibitor, Gö, along with 
the 2i inhibitors (collectively referred to as 2iL+Gö; Figure 3.1a) (Takashima et al. 2014). The 
primed and naïve hESCs exhibit distinct morphologies as expected, with the primed hESCs 
growing in large, flattened colonies and the naïve hESCs growing in smaller dome-shaped 
colonies (Figure 3.1b). We measured the expression of a number of genes that are known to 
be upregulated upon primed to naïve hESC reprogramming based on previous studies 
(Takashima et al. 2014; Guo et al. 2017; Guo et al. 2016). The expression of KLF4, NANOG, 
TFCP2L1 and DNMT3L was markedly higher in naïve hESCs compared to primed hESCs, 
characteristic of successful conversion to the naïve state (Figure 3.1c). Additionally, we could 
detect increased protein expression of KLF4 in naïve hESCs by immunostaining, as well as 
reduced expression of the cell surface marker Thy1/CD90 which is a marker of primed hESCs 
(Collier et al. 2017) (Figure 3.1d).  
 
 
 
 
 
 
 
90 
 
 
Figure 3.1. Naïve hESCs are morphologically and transcriptionally distinct from primed hESCs. a) The timeline of 
reprogramming from primed to naïve hESCs. b) Brightfield images of primed and naïve hESCs showing their 
different morphologies. Scale bars represent 125µm. c) qRT-PCR for naïve hESC markers in primed and naïve hESCs. 
Bars are representative of the mean of three technical replicates and three independent biological replicates. Error 
bars represent the standard error of the mean. Statistical difference between samples was analysed by a two-tailed 
Student’s t-test. **P<0.01 and ***P<0.001. Human GAPDH was used to normalise expression. d) Immunostaining 
for KLF4, a naïve pluripotency marker, and THY1, a primed pluripotency marker. Scale bars represent 50μm. 
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It has been previously demonstrated that naïve hESCs retain their differentiation potential 
(Takashima et al. 2014). To validate that this was also the case in our hands, we generated 
embryoid bodies directly from naïve hESCs. A representative embryoid body is displayed in 
Figure 3.2a. Embryoid bodies were harvested after 5 days and expression of transcripts 
representative of the three germ layers was measured. In line with published data, we saw 
upregulation of transcripts associated with the three germ layers (Figure 3.2b), indicative of 
retained differentiation capacity. 
 
Figure 3.2. Naïve hESCs can differentiate into all three germ layers. a) Representative brightfield image of an 
embryoid body at day 5, taken at 40X magnification. b) qRT-PCR for markers of the endoderm, mesoderm and 
ectoderm in naïve hESCs (day 0) and embryoid bodies generated from naïve hESCs, harvested after 5 days. Data 
points are representative of the mean of three technical replicates (with RNA pooled from multiple embryoid 
bodies). Human GAPDH was used to normalise expression. 
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3.3 Naïve hESCs are characterised by global DNA hypomethylation and regional 
hypermethylation 
It is well established that the primed to naïve hESC reprogramming is characterized by global 
demethylation of the genome (Takashima et al. 2014; Pastor et al. 2016), more closely 
resembling the hypomethylated ICM of human pre-implantation blastocysts (Guo et al. 2014; 
Smith et al. 2014), albeit with the additional loss of methylation at imprinted regions (Pastor et 
al. 2016). To confirm that this was also true in our hands, we performed immunostaining of 
5mC in primed and naïve hESCs and observed a marked reduction in signal in naïve hESCs 
(Figure 3.3a). We also re-analysed published whole genome bisulfite-sequencing (WGBS) data 
for primed and naïve hESCs (Takashima et al. 2014). We divided the genome into 300 base pair 
(bp) regions and performed a comparison between the mean methylation of the three 
replicates of primed and naïve samples. We observed that while the majority of the genome is 
hypomethylated in naïve hESCs, this is accompanied by distinct regions that are 
hypermethylated in naïve hESCs compared to primed hESCs (Figure 3.3b). We identified 26,625 
regions (300bp each) that are hypermethylated (>5% increase in methylation) in naïve hESCs. 
Interestingly, this pattern of global hypomethylation along with regional hypermethylation is 
characteristic of cancer cells, with respect to their normal counterparts (Ehrlich 2002). 
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Figure 3.3. Naïve hESCs are characterised by global DNA hypomethylation and regional hypermethylation.  
a) Immunostaining with an antibody against 5mC shows markedly reduced staining in the naïve cells compared to the 
primed cells. iMEF feeder cells are used as a positive control as they display a characteristic pattern of 5mC staining. 
Scale bars represent 10μm. b) Scatter plot showing re-analysed published whole genome bisulfite sequencing (WGBS) 
data (Takashima et al. 2014). Naïve hESCs display global hypomethylation compared to primed hESCs, along with 
regional hypermethylation. Each dot represents a 300 base pair genomic region and depicts the % methylation of the 
region in primed hESCs (y-axis) and naïve hESCs (x-axis). Red line represents the 5% threshold selected to identify 
hypermethylated regions in naïve hESCs.  
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3.4 Global demethylation occurs gradually during the primed to naïve transition 
While primed and naïve hESCs have been studied thoroughly, the transitional period between 
the two states is not well characterised. As this intermediate period is likely when the changes 
in DNA methylation occur, it was in our interest to characterise the dynamics of these changes.  
We designed a time-course experiment to study this transition, capturing primed and naïve 
hESCs as well as the transition between the two states, termed ‘early transition’ and ‘late 
transition’ as the cells are in 2iL+dox or 2iL+Gö, respectively (Figure 3.4a). We employed a 
number of approaches to measure DNA methylation upon reprogramming of primed hESCs to 
the naïve state. We first used a targeted approach to measure DNA methylation at a number 
of regions that we had identified as being hypomethylated (>5% decrease in methylation) in 
naïve hESCs from the WGBS data (Figure 3.3b) and in line with previous studies, we were able 
to validate loss of methylation at these regions during primed to naïve reprogramming (Figure 
3.4b). We next used mass spectrometric measurement of nucleosides as a more global 
measure of DNA methylation during the primed to naïve transition. We detected progressive 
global DNA demethylation of the genome in naïve cells, as measured by mass spectrometry of 
the 5mC nucleoside (Figure 3.4c). 5mC in the genome can undergo active demethylation; a 
process that begins with oxidation of 5mC by the TET proteins into 5hmC (Tahiliani et al. 2009; 
Kriaucionis and Heintz 2009), which can be further oxidised to 5fC (Ito et al. 2011). Alongside 
the reduction in 5mC, we detected globally reduced levels of 5hmC upon reprogramming, 
which is also a common phenomenon in the genomes of cancer cells (Ficz and Gribben 2014). 
Intriguingly, we were also able to detect a significant increase in the global level of 5fC during 
the early transition of reprogramming. This may be indicative of ongoing TET activity, and a 
lack of base excision by TDG DNA glycosylase, suggesting that the accumulated 5fC may play a 
functional role during reprogramming. 
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Figure 3.4. Global demethylation occurs gradually during the primed to naïve transition. a) Schematic detailing the 
model system and time points used in the study. hESCs; human embryonic stem cells, KSR/FGF; knockout serum 
replacement/fibroblast growth factor, dox; doxycycline. b) Targeted bisulfite-sequencing of four genomic regions. 
Each square represents the methylation % indicated by the colour key of a single CpG. c) Mass spectrometry analysis 
of 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) at the time points analysed, displayed as a % of total 
genomic cytosine (C) content.  Data shown is representative of two biological replicates, each with three technical 
replicates. Statistical difference between samples was analysed by a one way ANOVA test with a Bonferroni post-hoc 
test of each sample compared to primed hESC. *P<0.05 and ****P<0.0001.  
 
To further investigate global DNA methylation patterns during primed to naïve reprogramming 
at higher resolution, we carried out two independent reprogramming experiments and 
analysed DNA methylation using the Illumina Infinium MethylationEPIC BeadChip (each 
experiment with 2 or 3 replicates – independent populations of cells -  per time point). The 
Illumina Infinium MethylationEPIC BeadChip allows determination of DNA methylation levels 
at single-CpG resolution of approximately 850,000 different CpG sites in the human genome, 
with the methylation score for each CpG classified as a β-value, which can range from 0 to 1, 
corresponding to 0 to 100% methylation per CpG. Our samples clustered together by time 
point, indicative of reproducible changes in DNA methylation upon hESC reprogramming 
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(Figure 3.5a). We used differential methylated probe (DMP) analysis to compare the 
methylation β-value of individual CpG probes at each stage of the transition and in naïve hESCs 
compared to primed hESCs. We identified CpGs that are hypomethylated at each time point 
compared to primed hESCs. Over 500,000 CpGs exhibit reduced levels of methylation upon 
reprogramming (Figure 3.5b), of which the top 20,000 variably methylation CpGs are displayed 
in Figure 3.5c. Collectively, these data show that global demethylation upon reprogramming 
occurs gradually across the transition to naïve pluripotency. 
 
Figure 3.5. Global DNA demethylation can be detected at an individual CpG level during primed to naïve 
reprogramming. a) Dendogram of Infinium MethylationEPIC BeadChip samples for pre-normalised data. b) Bar plot 
showing the number of CpGs hypomethylated (Δβ vs Primed < -0.1, adjPval < 0.05) at each stage of reprogramming 
compared to primed hESCs c) Heatmap showing methylation levels of the top 20,000 variably methylated CpG 
probes across all samples. Methylation β-value is indicated by the colour key. 
 
97 
 
3.5 Reprogramming-associated hypermethylation is non-random and reproducible 
To investigate the dynamics of hypermethylation during primed to naïve reprogramming, we 
first used a targeted bisulfite-sequencing approach to measure DNA methylation at a number 
of regions that we had identified as being hypermethylated in naïve hESC from the WGBS data 
(Takashima et al. 2014) (Figure 3.3b). We measured DNA methylation at these regions across 
the transition to naïve pluripotency to determine at what stage hypermethylation occurs. We 
found that hypermethylation was detectable at some regions during the early transition, with 
a peak in the level and extent of hypermethylation during the late transition, following which 
hypermethylation was maintained at some regions and lost at others, indicative of a transitory 
nature of methylation at some genomic loci (Figure 3.6a). Using the Infinium MethylationEPIC 
BeadChip data and performing individual probe based analysis, we were able to confirm this 
pattern of hypermethylation at a genome-wide level and identify DMPs that were 
hypermethylated at each stage of reprogramming compared to primed hESCs. Of these, the 
top 10,000 hypermethylated DMPs at each time point are displayed in Figure 3.6b and a 
genome browser screen shot of the HOXA cluster is displayed in Figure 3.6c, exemplifying the 
phenomenon of hypermethylation upon reprogramming. A large proportion of the 
hypermethylated DMPs at each time point compared to primed hESC are shared (Figure 3.6d), 
though many are also uniquely hypermethylated at the late transition. This peak of 
hypermethylation that occurs during the late transition is measured after 4 days of removing 
dox and being in 2iL+Gö (18 days after the induction of reprogramming). This raised the 
possibility that the addition of the PKC inhibitor, Gö, may intensify or accelerate the process of 
hypermethylation. To verify whether this was the case, we cultured cells until the late 
transition of reprogramming in the presence and absence of the PKCi. We found that when 
compared to primed hESCs, hypermethylation of the same sites occurs in both conditions 
(Figure 3.6e), implying that the addition of the PKCi does not impact hypermethylation and 
that there is a time dependent accrual of DNA methylation instead. The reproducibility of the 
hypermethylation during the reprogramming process is apparent from the strong overlap 
between hypermethylated DMPs across biologically independent MethylationEPIC arrays (with 
2 or 3 cell populations assayed within each array), suggesting that the site-specific gain in 
methylation is unlikely to be the result of a stochastic process (Figure 3.6f). This points towards 
a defined cellular mechanism controlling hypermethylation, which may have a biological 
function. 
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Figure 3.6. Reprogramming-associated hypermethylation is non-random and reproducible. a) Targeted bisulfite-
sequencing of six genomic regions. Each square represents the methylation % indicated by the colour key of a single 
CpG. b) Heatmap showing methylation levels of the top 10,000 hypermethylated CpG probes at each time point 
compared to primed hESC. Methylation β-value is indicated by the colour key. c) Genome browser tracks for Infinium 
MethylationEPIC BeadChip data capturing a representative hypermethylated locus. The heatmap shows the raw 
methylation β-values per CpG for each sample, while the subsequent rows show the per-probe difference in 
methylation for each time point of reprogramming compared to primed hESCs. CpG islands (CGIs) are highlighted in 
green. d) Venn diagram showing the overlap of hypermethylated DMP at each stage of reprogramming compared to 
Primed hESC. e) Venn diagram showing the overlap of late transition hypermethylated DMP in the presence or 
absence of PKCi (Gö). f) Venn diagram showing the overlap of hypermethylated DMP between the late transition and 
primed hESCs between two biologically independent Infinium Methylation EPIC BeadChip arrays.  
DMP, differentially methylated probe. Hypermethylated CpG/DMP: (Δβ vs Primed > 0.1, adjPval < 0.05). AdjPval is 
based on Benjamini-Hochberg adjustment. 
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3.6 Hypermethylation is a feature of the naïve human pluripotent state 
As we were using an in vitro system of reprogramming, it was important to ensure that the 
hypermethylation we had observed was not simply an artefact of the NANOG/KLF2 + 2iLGö in 
vitro system. To address this, we compared our naïve hypermethylated and hypomethylated 
regions identified from the published WGBS data (Takashima et al. 2014) to hypermethylated 
and hypomethylated regions identified in naïve cells generated using alternative methods of 
primed to naïve hESC reprogramming. The first of these methods involves the generation of 
naïve cells by transferring primed hESCs to a media containing a cocktail of five inhibitors 
alongside LIF, Activin, and/or Fibroblast Growth Factor 2 (5iLAF) (Theunissen et al. 2014; Pastor 
et al. 2016). The second method involves the generation of naïve cells by chemical resetting 
(cR) (Guo et al. 2017), whereby primed hESCs are transiently exposed to histone deacetylase 
inhibitors before being propagated in 2iL+Gö. We saw a significant overlap between the 
hypermethylated regions in each of these data sets compared to the 2iLGö naïve cells (Figure 
3.7a). The parallels between the three in vitro reprogramming systems suggest that 
hypermethylation is not simply an artefact of the NANOG/KLF2 + 2iLGö reprogramming 
method. We next compared our naïve hypermethylated regions to regions that are 
hypermethylated in the human ICM compared to the post-implantation embryo (Guo et al. 
2014). Once again, we saw a significant overlap between the two data sets (Figure 3.7b) 
indicating that the hypermethylation we observed in vitro recapitulates the in vivo relationship 
between the ICM and the post-implantation embryo. Mouse embryonic stem cells (ESC) can 
also be cultured in naïve conditions with media containing the 2i inhibitors, but interestingly, 
when we performed a similar analysis of WGBS data for 2i ESCs and conventional ESCs 
cultured in serum (Ficz et al. 2013), we did not detect any hypermethylation in the mouse 2i 
ESCs (Figure 3.7c). Additionally, analysis of in vivo mouse developmental WGBS data also 
indicated that while there is a small amount of hypermethylation present in the mouse ICM 
compared to the mouse post-implantation epiblast (Figure 3.7d), it is far less extensive than 
the hypermethylation we see upon NANOG/KLF2 + 2iLGö hESC reprogramming (Figure 3.3b). 
Overall from these results, we can conclude that this hypermethylation pattern is a feature 
unique to human cells and is characteristic of in vitro naïve human pluripotency and the in vivo 
human ICM, suggesting that it may play a critical role in the biology of naïve human pluripotent 
stem cells.  
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Figure 3.7. Hypermethylation is a feature of the naïve human pluripotent state. a) Overlap of hypomethylated and 
hypermethylated (26,625) 300bp regions identified from published WGBS data (Takashima et al. 2014) with naïve 
hypomethylated and hypermethylated (13,945) 300bp regions identified from published data for the 5iLAF resetting 
method (Pastor et al. 2016) and with naïve hypomethylated and hypermethylated (34,859) 300bp regions identified 
from published data for the chemical resetting method (Guo et al. 2017). b) Overlap of naïve hypomethylated and 
hypermethylated (26,625) 300bp regions from published WGBS data (Takashima et al. 2014) with hypomethylated 
and hypermethylated (13,400) 300bp regions identified in human ICM compared to post-implantation embryo from 
published data (Guo et al. 2014). Data is presented as the log2 corrected fold increase in the observed overlap 
compared to the mean overlap of 1000 randomly generated regions. * indicates p < 0.05 c) Scatter plot showing 
methylation % for 300bp genomic regions in mouse ESCs cultured in serum or 2i (Ficz et al. 2013). d) Scatter plot 
showing methylation % for 300bp genomic regions in mouse ICM vs mouse post-implantation blastocyst (Smith et al. 
2012).  
 
 
3.7 Reprogramming-associated hypermethylation occurs primarily at bivalent CGIs 
Using hypermethylated probes identified from the Infinium MethylationEPIC array, we sought 
to characterize the genomic features and locations of CpG loci that gain DNA methylation 
during primed to naïve hESC reprogramming. To gain a deeper insight into the underlying 
genomic and chromatin context of CpG hypermethylation, we performed a regional overlap 
analysis of reprogramming-associated hypermethylated DMPs with datasets from the 
Encyclopaedia of DNA elements (ENCODE), which contains ChIP-seq data for various histone 
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modifications in the primed H1 hESC cell line. We utilized pre-defined ChIP-seq peaks from 
ENCODE for each histone modification. We observed that hypermethylated probes at each 
stage of reprogramming are enriched within regions marked by H3K4me1/2/3 and H3K27me3 
in primed hESCs, whereas no significant enrichment was observed for other histone 
modifications (Figure 3.8a). The majority of the hypermethyated probes fall within regions 
marked by bivalent histone modifications, defined by co-occurrence of H3K4me3 and 
H3K27me3 in the H1 hESC cell line (Figure 3.8b), and the remainder are marked by H3K4me3 
alone. Bivalent regions typically mark regulatory regions (Bernstein et al. 2006) and to this end, 
we saw a striking overlap of hypermethylated DMPs with CGIs and regulatory regions of the 
genome, which encompass promoters and enhancers (Bernstein et al. 2006) (Figures 3.8c and 
3.8d). We further compared our hypermethylated probes to the ChromHMM model, which 
uses genome-wide data to annotate the genome and enables functional interpretation of 
chromatin states (Ernst and Kellis 2017). This analysis showed that the majority of the 
hypermethylated probes reside within ChromHMM predicted poised promoters (Figure 3.8e) – 
again pointing to a relationship between hypermethylation with an existing bivalent histone 
signature; an association that has been observed previously in relation to hypermethylation in 
cancer (Ohm et al. 2007; Ohm et al. 2010; Easwaran et al. 2012). We next used the 300bp 
naïve hypermethylated regions identified from the WGBS data to validate our observations. 
Here too, we observed enrichment of the naïve hypermethylated regions within loci marked 
by bivalent histone modifications in primed hESCs (Figure 3.8f). Additionally, we observed that 
these hypermethylated regions were highly enriched within regulatory regions and CGIs 
(Figures 3.8g and 3.8h), as we saw with the Illumina MethylationEPIC array data, thus strongly 
reinforcing the highly reproducible nature of the DNA hypermethylation that occurs upon 
reprogramming to naïve human pluripotency. 
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Figure 3.8. Reprogramming-associated hypermethylation occurs primarily at bivalent CGIs. a) Overlap of 
hypermethylated probes at each stage of reprogramming with regions of histone modification enrichment (obtained 
from the ENCODE ChIP-seq data for hESC cell line H1). b) The proportion of hypermethylated probes that overlap 
H3K4me1/2/3, divided further into those that are enriched for H3K4me1/2/3 alone or bivalent regions (marked by 
H3K4me 3 and H3K27me3). c) Overlap of late transition hypermethylated probes with CpG islands. d) The proportion 
of hypermethylated probes that overlap with ChromHMM regulatory regions (promoters or enhancers as defined in 
the hESC cell line H1). e) Overlap of late transition hypermethylated probes with ChromHMM predicted promoter 
and enhancer sub-categories. f) The proportion of hypermethylated regions (>5% methylation in naïve vs primed 
hESC) identified from published WGBS data (Takashima et al. 2014) that overlap H3K4me1/2/3, divided further into 
those that are enriched for H3K4me1/2/3 alone or bivalent regions (marked by H3K4me 3 and H3K27me3). g) Overlap 
of Takashima hypermethylated regions with CpG islands. h) The proportion of Takashima hypermethylated regions 
that overlap with ChromHMM regulatory regions (promoters or enhancers as defined in the hESC cell line H1). 
DMP, differentially methylated probes. Where appropriate, data is presented as the log2 corrected fold increase in 
the observed overlap compared to the mean overlap of 1000 randomly generated loci.  
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3.8 Reprogramming-associated hypermethylation is associated with 
developmental genes 
In order to understand the genomic context of the hypermethylation observed upon 
reprogramming, we next used DAVID bioinformatics software to perform gene ontology (GO) 
analysis of the genes that exhibit reprogramming-associated hypermethylation (Huang, 
Sherman, and Lempicki 2008). We classified a gene as hypermethylated if it possessed a 
hypermethylated DMP within 1500bp upstream of its transcription start site (i.e. classical 
promoter). GO analysis revealed an extensive enrichment of hypermethylated genes in 
developmental pathways, particularly pathways involved in neuronal development, compared 
to hypomethylated genes which showed much weaker enrichment in pathways involved in ion 
transport and metabolism (Figure 3.9a). We validated this observation using the 300bp regions 
identified from the WGBS data. Here, we took the nearest overlapping gene to each 
hypermethylated or hypomethylated region and performed GO analysis. Once again, GO 
analysis revealed an extensive enrichment of hypermethylated genes in developmental 
pathways, compared to hypomethylated genes which show much weaker enrichment in 
pathways involved in ion transport and metabolism (Figure 3.9b). Interestingly, this 
observation draws parallels to the cancer methylome, where it has been observed that DNA 
hypermethylation is enriched in developmental genes, notably neuronal development 
(Easwaran et al. 2012).  
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Figure 3.9. Reprogramming-associated hypermethylation is associated with developmental genes. a) GO term 
analysis of hypermethylated and hypomethylated genes at the late transition of reprogramming compared to primed 
hESCs. A gene was classified as hypermethylated if a hypermethylated probe was present within 1500bp upstream of 
the transcriptional start site. b) GO term analysis of hypermethylated and hypomethylated genes in naïve hESCs 
compared to primed hESCs. A gene was classified as hypermethylated or hypomethylated based on the closest 
overlapping gene to the 300bp regions identified as hypermethylated or hypomethylated from WGBS published data 
(Takashima et al. 2014). GO terms plotted are the most highly enriched biological processes with FDR < 0.05. 
 
 
3.9 Genes from developmental pathways are hypermethylated and downregulated 
during reprogramming 
Typically, DNA hypermethylation of gene promoters is associated with gene repression (Weber 
et al. 2007). To investigate whether this is true during reprogramming, we performed temporal 
transcriptome analysis of cells during the transition from primed to naïve pluripotency. Our 
RNA-seq samples clustered together by time point, once again indicative of reproducible 
processes occurring during hESC reprogramming (Figure 3.10a). We observed large numbers of 
genes differentially expressed at each stage of the transition compared to primed hESCs 
(Figure 3.10a).  To determine if DNA methylation changes upon reprogramming had any 
impact upon gene expression, we used the Infinium MethylationEPIC data to compare the 
average promoter methylation (average β-value for probes within 1500bp upstream of the 
transcriptional start site (TSS)) for each gene to the gene expression. We observed a 
statistically significant reduction in the average expression of genes that are hypermethylated 
at each stage of reprogramming compared to primed hESCs, while hypomethylated genes 
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showed either no change or an increase in average expression compared to primed hESCs 
(Figure 3.10b). Moreover, we observed that when comparing primed to naïve hESCs, genes 
which undergo hypermethylation are characterised by low average expression in primed hESCs 
compared to hypomethylated genes. These lowly expressed genes are then further attenuated 
upon reprogramming, as is often observed in cancer (Figure 3.10b) (Sproul et al. 2012; 
Easwaran et al. 2012). GO analysis of genes downregulated during the early transition showed 
an enrichment of genes involved in cell adhesion and motility as well as DNA replication and 
metabolism. However, at both the late transition and in naïve hESCs compared to primed 
hESCs, GO analysis showed an enrichment of genes in developmental pathways (Figure 3.10c). 
As hypermethylation is also enriched in developmental genes, this finding suggests that the 
hypermethylation may play a functional role in these cells by contributing to downregulation 
of developmental and differentiation-related pathways, perhaps enhancing the pluripotent 
state by providing a more stable gene repression mechanism and associated differentiation 
block.  
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Figure 3.10 Genes from developmental pathways are hypermethylated and downregulated during 
reprogramming. a) MDS plot showing the top 500 most variably expressed genes from RNA-seq data. Replicates for 
each time point cluster together. b) Average gene expression displayed as logCPM for genes with promoter 
hypermethylation (average β-value of CpG probes within 1500bp of TSS > 0.1) or hypomethylation (average β-value 
of CpG probes within 1500bp of TSS < 0.1) during reprogramming. CPM, Counts per Million. Statistical significance 
between time points determined via paired Wilcoxon test. ***P<0.001 and ***P<0.0001. Statistical difference of 
average gene expression of hypermethylated and hypomethylated genes in primed hESCs (which go on to change in 
naïve hESCs) determined via two-tailed Mann-Whitney U test. c) GO analysis of genes that are downregulated at 
each stage of reprogramming compared to primed hESCs. GO terms plotted are the most highly enriched biological 
processes with FDR < 0.05. 
 
Intriguingly, whilst we observe the expected anti-correlation between hypermethylation and 
gene expression at a pathway level, there are subsets of genes, notably the HOX gene family, 
that become hypermethylated and are upregulated upon hESC reprogramming (Figure 3.11). 
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Such a phenomenon has been previously described in the context of cancer, where HOX genes 
are often found to be dysregulated (Bernhart et al. 2016; Su et al. 2018). Additionally, 
hypermethylation and upregulation of HOX genes has been observed in the context of a 
mutant form of DNMT3A with a point mutation in the PWWP domain (Sendzikaite et al. 2019).  
 
 
Figure 3.11 HOX genes are hypermethylated and upregulated. Scatter plot showing the average promoter 
methylation of 21 HOX genes (average β-value of CpG probes within 1500bp of TSS) versus the log2 CPM (counts 
per million) for each gene from RNA-seq data. Data for each individual time point is indicated by the colour key. 
 
 
3.10 A subset of functionally distinct bivalent loci are hypermethylated upon 
reprogramming 
The significant overlap of hypermethylated regions with loci marked by bivalent histone 
modifications in primed hESCs led us to hypothesise that the hypermethylation that we 
observe upon reprogramming may simply be a consequence of bivalency, or that a pre-existing 
bivalent chromatin state is predictive of hypermethylation upon reprogramming. Utilising the 
ENCODE ChIP-seq data-set, we classified bivalent regions as those possessing significant peaks 
of both H3K4me3 and H3K27me3. Having defined bivalent regions in primed hESCs, we 
observed that only 41% of these loci gain DNA methylation upon reprogramming (Figure 
3.12a), indicating that a bivalent chromatin state is not an adequate prerequisite for a genomic 
region to undergo DNA hypermethylation. We therefore divided all bivalent regions in primed 
hESCs into two groups: those that become hypermethylated during reprogramming (bivalent 
hypermethylated) and those that do not become hypermethylated (bivalent non-
hypermethylated) (Figure 3.12a). Taking the nearest gene to each region (within 1500bp 
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upstream of the transcriptional start site), we performed GO analysis of the two groups and 
observed a striking differential enrichment of pathways. The bivalent hypermethylated group 
showed a strong enrichment for developmental pathways, as was seen for hypermethylated 
regions overall, while the bivalent non-hypermethylated group showed lower enrichment of 
other biological processes (Figure 3.12b). This functional separation of bivalent 
hypermethylated and non-hypermethylated regions suggests that a shared mechanism 
coordinates hypermethylation of bivalent CGIs associated with developmental genes.  
 
 
Figure 3.12. A subset of functionally distinct bivalent loci are hypermethylated upon reprogramming. a) Pie chart 
showing the proportion of loci marked by bivalent histone modifications in primed cells that do and do not gain 
DNA methylation upon reprogramming. b) Gene ontology analysis of bivalent hypermethylated and non-
hypermethylated genes respectively (based on the nearest gene to each bivalent region, within 1500bp of the gene 
transcriptional start site). GO terms plotted are the most highly enriched biological processes with FDR < 0.05. 
 
3.11 Reprogramming-associated hypermethylation mirrors cancer 
hypermethylation  
Our data indicate that reprogramming of hESCs result in de novo methylation of DNA at loci 
marked by bivalent chromatin regions, associated with developmental genes. De novo DNA 
methylation of bivalent chromatin in the context of a hypomethylated genome has been 
reported in cancer cell lines and primary tumours (Bernhart et al. 2016; Easwaran et al. 2012). 
We set out to investigate a potential link between the hypermethylation patterns associated 
with hESC reprogramming and the re-emergence of such patterns in cancer. Specifically, we 
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were interested to see whether the specific subset of bivalent regions that are 
hypermethylated upon reprogramming were also hypermethylated in cancer. We compared 
our reprogramming-associated bivalent hypermethylated and bivalent non-hypermethylated 
CpGs with data from the cancer genome atlas (TCGA) pan-cancer atlas.  
 
Figure 3.13. Naïve bivalent hypermethylated CpGs exhibit increased methylated in tumour vs. normal tissues. 
Differences in mean methylation level between normal tissue and tumour samples (from TCGA pan-cancer atlas) of 
bivalent CpGs identified as hypermethylated or not hypermethylated during the transition to the naïve state in 
hESCs. Data is presented for 592 individuals, separated by tumour location. P-values determined via paired 
Wilcoxon test. CpGs used for analysis were filtered for those that are unmethylated in primed hESCs (β < 0.3).  
 
 
We saw a significantly higher gain in methylation between normal and cancer tissue for 
bivalent CpGs identified as hypermethylated during the reprogramming process compared to 
those that remain unmethylated (Figure 3.13). Strikingly, this was consistent across all cancer 
types analysed and indicates that reprogramming-associated hypermethylation parallels pan-
cancer hypermethylation. Notably, normal control tissues are also generally more susceptible 
to methylation within these regions (Figure 3.14), suggesting some pre-existing heterogeneity 
at these sites, perhaps as a result of the ageing process (Rakyan et al. 2010), given that many 
of the datasets on TCGA are from elderly individuals. Additionally, as the normal controls are 
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typically tumour-adjacent tissue samples derived from diseased patients, it is plausible that 
these tissues are already different to tissues obtained from a completely healthy individual.  
 
 
Figure 3.14. Reprogramming-associated hypermethylation mirrors cancer hypermethylation. Heatmaps showing 
the mean methylation level of CpGs identified as hypermethylated or not hypermethylated in hESCs (as in Fig 3.12) 
during the transition from primed to naïve state, in tumour and corresponding normal tissue samples (from TCGA 
pan-cancer atlas) for a variety of cancer types. Data is ordered by mean methylation level, for each cancer type. 
Data was restricted to those cancer types that had at least 30 matched normal and cancer tissue datasets available.  
 
 
In addition to the overall cancer-like hypermethylation pattern during reprogramming, we 
were also specifically able to detect hypermethylation of a number of tumour suppressor 
genes (using a list manually curated from the literature) (Llinas-Arias and Esteller 2017) that 
are commonly hypermethylated and inactivated in various cancer types (Figure 3.15), 
reinforcing the similarity between hypermethylation during reprogramming and in cancer.  
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Figure 3.15. Common tumour suppressor genes are hypermethylated upon primed to naïve reprogramming. 
Heatmap showing the average promoter methylation level (average β-value of CpG probes within 1500bp of the 
transcriptional start site) of common tumour suppressor genes (manually curated list from the literature) at each 
time point. Methylation β-value is indicated by the colour key. 
 
We further compared hypermethylated CpGs at each stage of reprogramming with regions 
previously identified as hypermethylated in B-cell chronic lymphocytic leukaemia (B-CLL) 
(Kushwaha et al. 2016). The most substantial overlap is observed between hypermethylated 
CpGs associated with the late transition of reprogramming and B-CLL hypermethylated 
regions, which corresponds to the peak of hypermethylation we observe during 
reprogramming (Figure 3.16a). Interestingly, we also see a more significant overlap between 
hypermethylated regions identified in B-CLL and colon cancer (Hansen et al. 2011) and 
reprogramming-associated hypermethylated CpGs with a low basal methylation level (<5%) in 
primed hESCs (Figures 3.16b, 3.16c). We see no further enrichment of reprogramming-
associated hypermethylated CpGs when we overlap this dataset with more advanced stages of 
cancer (Figure 3.16d), suggesting that DNA hypermethylation occurs earlier in cancer 
112 
 
development and that this pattern might be maintained as the cancer progresses and evolves. 
These data support the idea that common underlying mechanisms of hypermethylation may 
be at play during hESC reprogramming and tumourigenesis and that further exploitation of this 
model system may shed further light on the cellular networks regulating this.  
 
 
Figure 3.16. Cancer hypermethylation shows the strongest overlap with late transition hypermethylation. a) 
Proportion of hypermethylated and hypomethylated regions in B-CLL (from published data) that overlap 
hypermethylated probes identified during each stage of hESC reprogramming. Data shows an enrichment for late 
transition hypermethylated probes within B-CLL hypermethylated regions (and to a lesser extent naïve 
hypermethylated probes). b) Bar plot showing the basal level of methylation in primed hESCs of probes that are 
hypermethylated during the late transition of reprogramming. c) Overlap of late transition hypermethylated probes 
(with <5% or >30% starting methylation in primed hESCs) with B-CLL and colon cancer hypermethylated regions 
from published data. d) Overlap of late transition DMPs with cancer hypermethylated probes obtained from TCGA. 
Overlaps were performed for both hyper- and hypomethylated probes compared to either stage I or stage IV 
hypermethylated probes (compared to normal controls) for each cancer type.  
For overlap analysis, data is presented as the log2 corrected fold increase in the observed overlap compared to the 
mean overlap of 1000 randomly generated loci, where random loci generation was restricted to loci present in the 
Illumina EPIC array. ***P<0.001.  
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3.12 Discussion 
The data presented in this chapter demonstrate for the first time the temporal dynamics of 
DNA methylation upon hESC reprogramming to the naïve state. Using both global and targeted 
approaches to measure DNA methylation, we see a high degree of similarity between the 
results using different techniques, highlighting the reproducible nature of reprogramming-
associated DNA methylation changes. We observed that upon the transition from primed to 
naïve pluripotency, the genome is globally demethylated in a time-dependent manner. Whilst 
we do not focus on the genomic context of DNA demethylation in this chapter, other studies 
have shown that the DNA methylation landscape in naïve hESCs is comparable to that of the 
human ICM (Takashima et al. 2014; Pastor et al. 2016). Notably, however, DNA methylation is 
also lost from imprinted regions in naïve hESCs (Pastor et al. 2016). The loss of stable imprints 
is not reflective of the human ICM, but is often implicated in cancer (Cui et al. 2003; Holm et al. 
2005; Jelinic and Shaw 2007). 
In parallel with global DNA demethylation, we also observe a decrease in the level of 5hmC in 
the genome. This has been reported previously in naïve hESCs (Takashima et al. 2014), 
however our temporal analysis shows that the kinetic profile of 5hmC loss is distinct to the loss 
of 5mC. It appears that the level of 5hmC drops to its lowest level during the early transition of 
reprogramming, and subsequently recovers to some degree, though still at a significantly 
lower level than that in primed hESCs. This may indicate that the global loss of DNA 
methylation in the early stages of reprogramming can be attributed to a passive mechanism of 
demethylation, but that this may be accompanied by active oxidation of 5mC into 5hmC in the 
later stages of reprogramming. Interestingly, one week following induction of the naïve state, 
when 5hmC levels are at their lowest, we detected a significant spike in the level of 5fC in the 
genome. Such an increase in 5fC, which is usually present at very low levels in the genome, 
suggests that the modified base may be playing a role in the reprogramming process. 5fC has 
been shown to be bound by a number of transcriptional and chromatin regulatory proteins 
(Spruijt et al. 2013; Iurlaro et al. 2013) and it has been suggested that it may exhibit regulatory 
functions in cells (Song and He 2013; Song et al. 2013). However, additional replicates are 
required to draw any firm conclusions from this data as the two biological replicates measured 
display a high degree of variability.  
We observed that upon hESC reprogramming, DNA methylation is acquired at specific loci, 
primarily CGI promoters, which are typically unmethylated in mammalian cells (Bird et al. 
1985). Notably, we observe that the gain in DNA methylation is gradual, with a peak of 
hypermethylation during the late transition of reprogramming, after which hypermethylation 
114 
 
is maintained at some genomic regions but lost at others. The transient nature of 
hypermethylation at some genomic regions may be a result of improper maintenance of DNA 
methylation, particularly as the majority of the genome is undergoing demethylation during 
the reprogramming process. It may also be an indication that cells in the late transition of 
reprogramming have a unique cellular identity, which is not maintained upon complete 
generation of naïve hESCs. It is plausible that there may be some in vitro selective pressure on 
the cells as they transition to the naïve state, particularly during the later stages of 
reprogramming, which may select for hESCs with a specific DNA methylation signature, 
however further experimentation is required to test this hypothesis.  
For Infinium MethylationEPIC BeadChip data, we classify hypermethylation as a >10% increase 
in methylation per CpG at any time point of reprogramming compared to primed hESCs. For 
re-analysis of published bisulphite sequencing data, we classify a hypermethylated region as a 
300bp region containing 5 or more CpGs, with >5% increase in methylation in naïve compared 
to primed hESCs. These cut-off values were selected based on other publications, however it is 
difficult to determine the change in DNA methylation required to have a biological impact and 
there is no unified consensus on a biologically relevant cut-off for calling methylation changes 
in the literature. Additionally, when using data from a methylation array and performing DMP 
analysis, each CpG probe is treated individually. This makes it difficult to determine whether 
multiple CpGs on the same DNA, from the same cell are hypermethylated or whether the true 
pattern of hypermethylation in the population of cells is more stochastic. However, the 
reproducibility of results between multiple methylationEPIC arrays and also across multiple 
methods of measuring DNA methylation suggests that the site-specific gain in methylation we 
observe is the result of a non-random process.  
While the hypermethylated sites are enriched in regulatory regions, there are 
hypermethylated CGIs present in promoters, enhancers and gene bodies, with individual 
hypermethylated CpGs residing within CGIs but also within their shores, shelves and outside of 
CGIs altogether. It is becoming increasingly evident that DNA methylation in each of these 
contexts can have a unique biological consequence (Jones 2012), implying that the long-
standing anti-correlation between gene promoter hypermethylation and gene expression is 
not the only possible outcome of DNA hypermethylation. Nevertheless, with a focus on 
promoter methylation, we observed a reduction in the average expression of genes that are 
hypermethylated at each stage of reprogramming compared to primed hESCs. The exception 
to this was a subset of genes including several of the HOX genes, which appear to be 
simultaneously hypermethylated and upregulated. Such a phenomenon has been previously 
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described in the context of cancer, where HOX genes are often found to be dysregulated 
(Bernhart et al. 2016; Su et al. 2018) and more recently in the context of a DNMT3A PWWP 
domain mutation, where HOXA7 and HOXD8 were found to be hypermethylated and 
upregulated (Sendzikaite et al. 2019). However, we cannot currently exclude the possibility of 
5-hydroxymethylcytosine being present at the promoters of these genes, or population 
heterogeneity whereby HOX gene overexpression bias is caused by a subpopulation of cells 
which do not undergo HOX promoter hypermethylation.  
The hypermethylation pattern observed upon hESC reprogramming mirrors the frequently 
observed aberrant hypermethylation in human cancers, in both cases occurring in the context 
of a globally hypomethylated genome. Notably, along with the overall similar pattern of 
bivalent CGI hypermethylation of developmental genes, we also see hypermethylation of a 
number of common tumour suppressor genes, emphasising the commonality between the two 
phenomena. Such parallels with cancer hypermethylation have been drawn previously in other 
mammalian species and developmental contexts (Smith et al. 2017), however the data we 
present here demonstrates a hypermethylation phenomenon conserved across in vitro and in 
vivo human pluripotency (Guo et al. 2014), strengthened by its reproducibility across multiple 
in vitro reprogramming methods (Theunissen et al. 2014; Guo et al. 2017). Moreover, it is 
notable that we do not observe comparable hypermethylation in the mouse ICM or in in vitro 
mouse ESCs cultured in the presence of 2i inhibitors, though this may reflect the fact that 
hESCs and mESCs in vitro represent different pluripotent states (Ficz et al. 2013; Smith et al. 
2012; Davidson, Mason, and Pera 2015). This observation has potential implications for making 
inferences with regards to epigenetic processes between species, both in development and in 
the study of cancer, as has been noted previously (Diede et al. 2013). 
We show that the reprogramming-associated hypermethylated loci overlap with loci marked 
by H3K4me1/2/3 and H3K27me3 in primed hESCs. For this analysis, we use ENCODE ChIP-seq 
data from the H1 hESC line as this cell line, despite the experimental cell line in our study being 
H9. This is because the H1 cell line has been extensively characterised on ENCODE, and where 
data is available for both H1 and H9, the data sets are highly similar. Our data indicate that loci 
marked with the bivalent histone modification H3K4me3 and H3K27me3 are almost exclusively 
susceptible to DNA hypermethylation, but that the presence of bivalent chromatin is not a 
sufficient prerequisite for acquiring de novo DNA methylation upon reprogramming. This 
phenomenon parallels what is known about hypermethylation in cancer, where numerous 
studies have reported preferential susceptibility of H3K27me3-marked loci to gain DNA 
methylation (Ohm et al. 2007; Schlesinger et al. 2007; Widschwendter et al. 2007) or shown 
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that bivalent regions in primed embryonic stem cells are frequently hypermethylated in cancer 
(Ohm et al. 2007; Easwaran et al. 2012). It is particularly noteworthy that the bivalent loci that 
undergo hypermethylation both upon reprogramming and across multiple cancer data sets are 
distinguishable from those that do not gain methylation despite having a comparable starting 
chromatin configuration, which adds a further dimension to the current understanding of the 
relationship between bivalent chromatin and hypermethylation in cancer. Aside from the 
difference in GO enrichment between the bivalent hypermethylated and bivalent non-
hypermethylated subsets, it is likely that additional features such as the underlying DNA 
sequence separate these two groups and contribute to the mechanism of hypermethylation.  
The data shows that hypermethylation during primed to naïve reprogramming affects genes 
belonging to developmental pathways. In the context of cancer, the function of 
hypermethylation remains a topic of debate. While several studies have shown clear functional 
roles of hypermethylation and gene repression for individual tumour suppressor genes (Jones 
and Baylin 2002; Saunderson et al. 2017), it remains less well understood what the purpose of 
hypermethylation of a large number of loci, many of which are common between cancer 
types, might be. It has been proposed that aberrant hypermethylation in cancer may act to 
block cellular differentiation, thus enabling cancer cells to continue to propagate in their more 
primitive states (Widschwendter et al. 2007; Easwaran et al. 2012; Pfeifer 2018), and this has 
demonstrated experimentally in a recent study (Tao et al. 2019). It has also been proposed 
that hypermethylation may act to block cancer progression, with CGI hypermethylation 
restricting the epigenetic adaptability of cells during the process of metastasis or upon cancer 
treatment (Sproul and Meehan 2013). The commonality in methylation patterns across cancer 
types, each harbouring different driver mutations, suggests that these methylation changes 
occur early in tumourigenesis, and this has been demonstrated previously (Hanley et al. 2017) 
though models of early cancer development are limited. In line with this, the notion that 
cancer cells follow an evolutionary trajectory towards a stem cell state (Chen and He 2016; 
Ben-Porath et al. 2008) makes the transition from primed to naïve pluripotency an interesting 
model to study biological processes such as DNA methylation that likely occur early during 
cellular transformation or cancer initiation and may be analogous to dedifferentiation.  In 
particular, the following chapter will detail the use of the primed to naïve reprogramming 
system as a model for the mechanism of DNA hypermethylation. 
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Chapter 4. Results 2: The mechanism of DNA hypermethylation 
during primed to naïve reprogramming 
 
4.1 Introduction 
The acquisition of site-specific DNA hypermethylation in the context of a globally 
hypomethylated genome is a hallmark of cancer (Jones and Baylin 2007; Baylin and Jones 
2011; Esteller et al. 2001; Feinberg, Ohlsson, and Henikoff 2006). Despite the frequency with 
which these observations have been made in cancer cell lines or primary cancer cells, how de 
novo DNA methyltransferase activity is preferentially targeted to specific regions of the 
genome in the context of aberrant cancer methylation remains largely a mystery. Two main 
hypotheses prevail in the current literature with regards to the mechanism of 
hypermethylation in cancer (Figure 4.1): site-specific recruitment of DNMTs to target loci 
either as a result of increased DNMT protein expression or loci-specific targeting by 
transcription factors, or loss of passive, protective mechanisms that typically act to maintain 
loci in a hypomethylated state (Sproul et al. 2012). 
 
Figure 4.1. Possible mechanisms of hypermethylation in cancer. Possible mechanisms that result in the 
hypermethylation of CGI promoters in cancer. CGI promoter hypermethylation could result from either the loss of a 
protective mechanism that typically maintains CGIs in a hypomethylated state or a gain of de novo 
methyltransferase activity at the CGI (either targeted by transcription factors or through an increase in levels of the 
DNMTs in the cell). 
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Despite considerable knowledge on the domain composition of the DNMTs, the understanding 
of how these enzymes are targeted and regulated to give rise to specific DNA methylation 
patterns remains limited. The recognition of H3K4 or H3K36me3 by the ADD and PWWP 
domains, respectively, have been proposed as general mechanisms of recruitment for the 
DNMT3 enzymes, implying that the interaction with chromatin is important for the generation 
of DNA methylation patterns (Otani et al. 2009; Ooi et al. 2007; Zhang et al. 2010; Ge et al. 
2004; Dhayalan et al. 2010; Chen, Tsujimoto, and Li 2004). Additionally, the DNMT3 enzymes 
have been shown to be able to directly interact with numerous transcription factors in vitro 
(Hervouet, Vallette, and Cartron 2014), and it has been proposed that such interactions may 
influence localisation and targeting of the DNMTs. It is well established that CGIs in the 
genome are generally unmethylated (Bird et al. 1985; Weber et al. 2007). CpG-rich regions are 
thus thought to have mechanisms at play that protect them from DNA methylation, such as 
the binding of zinc finger CXXC domain-containing proteins which specifically bind to 
unmethylated CpG dinucleotides and attract chromatin environments refractory to DNA 
methylation (Voo et al. 2000; Long, Blackledge, and Klose 2013; Thomson et al. 2010). Both 
active targeting of DNMTs or loss of the inherent protection of CGIs may underlie CGI 
hypermethylation in cancer, or indeed a combination of such mechanisms may be at play. 
It has been hypothesised that cancer cells follow an evolutionary trajectory towards a stem cell 
state, which allows both self-renewal and differentiation (Chen and He 2016). This, along with 
the parallels drawn with the cancer methylome (discussed in chapter 3), makes the transition 
from primed to naïve pluripotency an interesting model to study DNA methylation 
mechanisms that may be analogous to processes occurring during cancer formation. This 
chapter will use knowledge obtained from chapter 3 concerning the targeted 
hypermethylation at bivalent CGI promoters associated with developmental genes, and the 
parallels drawn with pan-cancer hypermethylation. The role of known components of the DNA 
methylation machinery in mediating hypermethylation upon hESC reprogramming will be 
described. Specifically, the DNMT responsible for hypermethylation will be highlighted and 
upstream mechanisms that may coordinate hypermethylation will be discussed. This chapter 
will explore the possibility of both active targeting of DNMTs or loss of protective mechanisms, 
through identification of candidate factors that may mediate each mechanism in the context of 
reprogramming-associated hypermethylation. Additionally, the possible functional relevance 
of hypermethylation in hESCs will be explored. Finally, the relevance of all these findings will 
be discussed in the context of cancer biology. 
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4.2 Downregulation of maintenance methylation machinery coincides with global 
demethylation upon reprogramming 
To investigate the role of epigenetic machinery in regulating the DNA methylation changes 
associated with hESC reprogramming, we measured gene expression changes of known 
mediators of DNA methylation and demethylation by qRT-PCR in a temporal manner. The time 
points used coincide those used to measure DNA methylation changes, with additional 
increased resolution (Figure 4.2a), thus enabling inference of which of the epigenetic 
regulators may be responsible for the changing DNA methylation patterns. We found little 
change in expression levels of the maintenance methylation machinery genes, DNMT1 and 
UHRF1, except for a peak in expression of DNMT1 at the late transition (4 days after addition 
of Gö), coinciding with the peak of hypermethylation alluded to in chapter 3 (Figure 4.2b). We 
also measured the expression of the TET enzymes, which are able to demethylate the DNA by 
oxidation of 5mC (Tahiliani et al. 2009; Ito et al. 2011). We found that all three enzymes are 
upregulated, though the extent and timing of the upregulation varies subtly between the three 
(Figure 4.2b). 
In parallel with transcriptional changes, we measured the level of protein expression of the 
two key proteins typically involved in maintenance of DNA methylation. We initially used 
immunofluorescence to detect expression of DNMT1 and UHRF1 primed hESCs and naïve 
hESCs. We saw little change in the expression of DNMT1 between primed and naïve hESCs 
(Figure 4.2c), while UHRF1 was detectable at high levels in the primed hESCs and markedly 
downregulated in naïve hESCs. We next used Western Blotting to detect the expression of the 
two proteins across the transition from primed to naïve pluripotency. While UHRF1 gene 
expression levels were stable across the transition, UHRF1 protein is downregulated upon 
induction of the naïve state (Figure 4.2d). DNMT1 protein also appears to be downregulated 
during the early transition, but shows a peak in protein expression at the late transition (4 days 
after the addition of Gö), which coincides with the peak observed in expression of the DNMT1 
gene, as well as the peak in hypermethylation (Figure 4.2d). Interestingly, upon multiple 
experimental repeats, two bands can be detected at this stage on the Western blot, suggestive 
of an alternative isoform of DNMT1 protein, a degradation product, or a post-translationally 
modified version of the protein (Figure 4.2d). 
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Figure 4.2. Downregulation of maintenance methylation machinery and upregulation of the TET mRNA coincides 
with global demethylation upon reprogramming. a) Schematic detailing the time points used for expression 
analysis of DNA methylation regulators. b) qRT-PCR for maintenance methylation genes and TET genes across the 
transition of hESC reprogramming. Bars are representative of the mean of three technical replicates and three 
independent biological replicates. Error bars represent the standard error of the mean. Statistical difference 
between samples was analysed by a two-tailed Student’s t-test, with a Bonferroni post-hoc test comparing each 
time point to primed hESCs. *P<0.05, **P<0.01 and ***P<0.001. Human GAPDH was used to normalise expression. 
c) Immunofluorescence of cells stained with DAPI and DNMT1 or UHRF1 in primed and naïve hESCs. Scale bars 
represent 10µm or 50µm as indicated. d) Detection of UHRF1 and DNMT1 protein expression by Western Blotting 
across the transition, with α-tubulin as a loading control. Blots displayed are representative of 3 replicates.   
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Both downregulation of DNA methylation maintenance machinery and upregulation of the TET 
enzymes at the mRNA level coincide temporally with global demethylation of the genome 
upon hESC reprograming. They may both contribute to genome-wide loss of methylation 
through passive or active demethylation, respectively, though the observation that we 
detected a global loss in the levels of 5hmC (detailed in chapter 3) suggest that TET driven 
active oxidation of 5mC is not the primary mechanism of demethylation.  
 
4.3 DNA hypermethylation is carried out by DNMT3A during early hESC 
reprogramming  
To investigate the role of epigenetic machinery in driving hypermethylation, we sought to 
identify the DNMTs that are responsible for the deposition of de novo DNA methylation. We 
measured temporal gene expression changes of the de novo DNMTs, encompassing the 
DNMT3 family. Of the de novo DNMTs, DNMT3A undergoes a transient upregulation during 
the early transition of reprogramming, DNMT3B levels are downregulated across the 
transition, and the catalytically inactive DNMT3L is highly upregulated (Figure 4.3).  
 
 
Figure 4.3. De novo DNMTs are dynamically expressed during primed to naïve hESC reprogramming. qRT-PCR for 
DNMT3 genes across the transition of hESC reprogramming. Bars are representative of the mean of three technical 
replicates and three independent biological replicates. Error bars represent the standard error of the mean. 
Statistical difference between samples was analysed by a two-tailed Student’s t-test, with a Bonferroni post-hoc 
test comparing each time point to primed hESCs. *P<0.05, **P<0.01 and ***P<0.001. Human GAPDH was used to 
normalise expression. 
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To test which of the de novo methyltransferases drives hypermethylation, we generated 
constitutive knockdown primed hESC cell lines using two short hairpin RNAs (shRNAs) targeting 
each of the three DNMT genes. We subjected each of the cell lines to reprogramming until the 
early transition, at which stage reprogramming-associated hypermethylation is already 
detectable. We validated the efficiency of the shRNA knockdowns by measuring expression of 
the target genes in both primed and early transition hESCs (Figure 4.4a). We first used a 
targeted approach to measure DNA methylation at four genomic loci that are hypermethylated 
upon hESC reprogramming. In primed hESCs, we observed no difference in the levels of 
methylation in any of the knockdown cells compared to control cells, indicating that de novo 
DNMTs are dispensable at these loci in primed hESCs. In the early transition, knockdown of 
DNMT3B and DNMT3L had little impact on the level of methylation, as the cells exhibited 
comparable levels of hypermethylation to control cells (Figure 4.4b). Knockdown of DNMT3A, 
however, was able to abolish hypermethylation, as these cells retain the levels of methylation 
present in primed hESCs (Figure 4.4b). To ensure that the effect of the DNMT3A knockdown 
was not restricted to this selection of genomic regions, we performed an Infinium 
MethylationEPIC BeadChip array to observe the impact of loss of DNMT3A across the genome. 
As the numbers of replicates used for this experiment were insufficient to perform DMP 
analysis between the knockdowns and controls in primed and early transition hESCs, we 
extracted methylation beta-values for the probes identified as hypermethylated (Δβ > 0.1, p < 
0.05) in wild-type early transition hESCs compared to primed hESCs (of which the top 10,000 
were presented in Figure 3.5 of Chapter 3), and plotted these as a heatmap. These data 
confirmed that in DNMT3A knockdown early transition hESCs, hypermethylation was not 
detected at any of the regions that gain methylation in control cells, while DNMT3B and 
DNMT3L early transition knockdown cells showed hypermethylation at comparable levels to 
the control (Figure 4.4c). This is despite comparable protein expression levels of DNMT3A and 
DNMT3B during the early transition of reprogramming, as measured by protein mass 
spectrometry (Figure 4.4d). Interestingly, with increased resolution across the genome 
compared to the targeted approach, it is evident that a knockdown of DNMT3A influences the 
level of methylation in primed hESCs too, as primed DNMT3A knockdown show a slight 
reduction in methylation compared to the control across all CpGs plotted. Collectively, this 
data indicates that hypermethylation during the early transition of reprogramming is carried 
out by DNMT3A and is independent of DNMT3L. 
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Figure 4.4. Knockdown of DNMT3A abolishes hypermethylation in the early transition of hESC reprogramming.  
a) qRT-PCR for the transcripts of the DNMT3 family in control and knock-down cell lines, in primed and early 
transition hESCs. Bars represent the mean of three technical replicates. Human GAPDH was used to normalise 
expression. b) Targeted bisulfite-sequencing of 4 regions of DNA. Each square represents the methylation % 
indicated by the colour key of a single CpG. Data is shown for 2 knockdown samples of DNMT3A/B/L and two non-
silencing (NS) controls in primed and early transition hESCs. c) Heatmap showing methylation levels for primed and 
early transition control and DNMT3A/B/L knock down samples. Heatmap is composed of the top 20,000 CpG probes 
that are differentially methylated (Δβ > 0.1, p < 0.05) in the wild-type early transition compared to primed hESCs. 
Methylation β-value is indicated by the colour key. d) Raw protein intensity values for DNMT3A and DNMT3B 
extracted from proteomics data, plotted in parts per million (ppm). Bars represent an average of 2 intensity values 
for each of the 3 replicates per sample, with error bars representing the SEM.  Statistical difference between 
samples was analysed by a two-tailed student’s t-test at each time point. ****P<0.0001. 
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DNMT3A is encoded by two main isoforms in human cells: a full length isoform DNMT3A1 that 
has an extended N-terminal region and is typically expressed in somatic cells, and a shorter 
isoform DNMT3A2, whose expression is typically restricted to early developmental cell types 
(Chen et al. 2002) (Figure 4.5a). A third transcript also exists but lacks the C-terminal that 
encodes the catalytic domain. A recent study demonstrated that the N-terminal of DNMT3A1 
can bind DNA and localizes specifically to the shores of bivalent CpG islands in mouse ESCs, 
where it can carry out de novo methylation (Manzo et al. 2017). We measured the transcript 
expression of the individual isoforms of DNMT3A and found that the two isoforms are 
differentially expressed during hESC reprogramming (Figure 4.5b). Both isoforms are 
transiently upregulated during the early transition, and DNMT3A2 is additionally upregulated 
in the naïve state, though the overall expression of DNMT3A2 across the period of 
reprogramming is much higher than that of DNMT3A1 (Figure 4.5b). To test whether 
DNMT3A1 is responsible for the hypermethylation of bivalent CpG islands upon hESC 
reprogramming, we generated a specific shRNA knockdown cell line of DNMT3A1 in primed 
hESCs by targeting its unique N-terminal domain, without affecting the expression of 
DNMT3A2 (Figure 4.5c).  We subjected the DNMT3A1 knockdown cell line and a control cell 
line to reprogramming until the early transition and used a targeted approach to measure DNA 
methylation at three regions known to be hypermethylated upon reprogramming. In primed 
hESCs, there was no impact of the DNMT3A1 knockdown on DNA methylation levels. Contrary 
to the study in mouse ESCs however (Manzo et al. 2017), DNMT3A1 knockdown hESCs also 
exhibited comparable levels of hypermethylation to the control at the target regions analysed 
during the early transition of reprogramming (Figure 4.5d), hence suggesting that the more 
dominantly expressed DNMT3A2 carries out de novo methylation upon hESC reprogramming.   
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Figure 4.5. Hypermethylation is carried out by the dominantly expressed DNMT3A2 isoform. a) Genome browser 
screenshot depicting the transcripts encoding the main isoforms of DNMT3A. The longer isoform, DNMT3A1 has an 
extended N-terminal domain compared to the shorter isoform, DNMT3A2. b) qRT-PCR for DNMT3A gene isoforms 
across the transition of hESC reprogramming. Bars are representative of the mean of three technical replicates and 
three independent biological replicates. Error bars represent the standard error of the mean. Statistical difference 
between samples was analysed by a two-tailed Student’s t-test, with a Bonferroni post-hoc test comparing each 
time point to primed hESCs. *P<0.05, **P<0.01 and ***P<0.001. Human GAPDH was used to normalise expression. 
c) qRT-PCR for the transcripts of the DNMT3A isoforms in primed and early transition hESCs for a control and a 
DNMT3A1 knockdown cell line. Bars represent the mean of three technical replicates. Human GAPDH was used to 
normalise expression. d) Targeted bisulfite-sequencing of 4 regions of DNA. Each square represents the methylation 
% indicated by the colour key of a single CpG. Data is shown for a non-silencing (NS) control and knockdown of 
DNMT3A1 in primed and early transition hESCs. 
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4.4 DNMT3A and DNMT3B contribute to hypermethylation during the late 
transition of reprogramming 
As our analysis thus far had been focused on the early transition of reprogramming, we next 
subjected the DNMT3A and DNMT3B knockdown cell lines to reprogramming until the late 
transition of reprogramming and measured the expression of the two genes to validate that 
the genes were still knocked down (Figure 4.6a). We then performed an Infinium 
MethylationEPIC BeadChip array to observe the impact of a knockdown of DNMT3A and 
DNMT3B on hypermethylation. Once again, as the numbers of replicates used for this 
experiment were insufficient to perform DMP analysis between the knockdowns and controls 
in primed and late transition hESCs, we extracted methylation beta-values for the probes 
identified as hypermethylated (Δβ > 0.1, p < 0.05) in wild-type early transition hESCs compared 
to primed hESCs (of which the top 10,000 were presented in Figure 3.5 of Chapter 3), and 
plotted these as a heatmap. Interestingly, at this stage of reprogramming, while DNMT3A 
knockdown cells show reduced levels of hypermethylation compared to the control (Figure 
4.6b), DNMT3A is not solely accountable for all the hypermethylation present. DNMT3B, which 
by this stage is transcriptionally expressed at a higher level than during the early transition 
(Figure 4.3), also contributes to hypermethylation, as DNMT3B knockdown cells also fail to 
hypermethylate to the same extent as control cells (Figure 4.6b).  
Collectively, these data show that DNMT3A, and more specifically the shorter isoform 
DNMT3A2, is responsible for de novo methylation during the early transition of hESC 
reprogramming. However, by the late transition of reprogramming at which point we detect 
the peak of hypermethylation and the strongest overlap with cancer hypermethylation (shown 
in chapter 3), both DNMT3A and DNMT3B seem to contribute to hypermethylation.  
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Figure 4.6. Both DNMT3A and DNMT3B contribute to hypermethylation during the late transition of 
reprogramming. a) qRT-PCR for the transcripts of DNMT3A and DNMT3B in primed and early transition hESCs for a 
control knockdown cell lines. Bars represent the mean of three technical replicates. Human GAPDH was used to 
normalise expression. b) Heatmap showing methylation levels for primed and late transition control and DNMT3A/B 
knock down hESCs. Heatmap is composed of the top 20,000 CpG probes that are differentially methylated (Δβ > 0.1, 
p < 0.05) in the wild-type late transition compared to primed hESCs. Methylation β-value is indicated by the colour 
key.  
 
 
4.5 Hypermethylation has a functional role in naïve pluripotency 
Given that both DNMT3A and DNMT3B knockdown cells display reduced hypermethylation 
compared to control cells by the late transition of reprogramming, we reasoned that we could 
use these cells to investigate whether hypermethylation plays a functional role during 
reprogramming or in naïve hESCs. We further reprogrammed the DNMT3A and DNMT3B 
knockdown cells to the stable naïve state, and measured the expression of the two genes to 
validate that the genes were still knocked down (Figure 4.7a). We performed an alkaline 
phosphatase assay on the naïve DNMT3A and DNMT3B knockdown cells, alongside the control 
hESCs. High alkaline phosphatase activity is a marker for an undifferentiated pluripotent stem 
cell state (O'Connor et al. 2008). We saw a reduction in the alkaline phosphatase activity of 
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both the DNMT3A and DNMT3B knockdown cells compared to control cells (Figure 4.7b), 
suggesting that pluripotency is impaired in the knockdown naïve cells. Additionally, while 
control cells form dome-shaped colonies as is typical of naïve hESCs, the DNMT3A and 
DNMT3B knockdown naïve hESCs grow in a mixture of both dome-shaped and more flattened 
colonies (Figure 4.7c). This may indicate either failure of the knockdown cells to successfully 
transition to the naïve state, or that the lack of hypermethylation in the absence of DNMT3A 
or DNMT3B impacts the stability of the naïve hESCs. We further measured the gene expression 
of a panel of genes that are markers of naïve pluripotency. While we did not see a consistent 
significant change in the expression of pluripotency markers in DNMT3A and DNMT3B 
knockdown hESCs compared to control cells, there seems to be a general trend of reduced 
expression of pluripotency markers, particularly in the DNMT3A knockdown cells, which may 
be more apparent with further biological replicates (Figure 4.7d). Collectively, these data 
indicate a putative role of de novo methylation by DNMT3A and DNMT3B either in the 
conversion to the naïve state or in stabilization of naïve pluripotency.  
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Figure 4.7. Knockdown of DNMT3A and DNMT3B impacts naïve pluripotency. a) qRT-PCR for DNMT3A and 
DNMT3B in control and knockdown naïve hESCs. Bars are representative of the mean of three technical replicates 
and two independent biological replicates. Error bars represent the standard error of the mean. Statistical 
difference between samples was analysed by one way ANOVA, with a Bonferroni post-hoc test comparing each time 
point to the non-silencing (NS) control cells. *P<0.05, N.S. denotes not significant. Human GAPDH was used to 
normalise expression. b) Alkaline phosphatase activity measured in DNMT3A and DNMT3B knock down and control 
naïve hESCs. Data shown are the mean of 2 biological replicates, each with 5 technical replicates. Error bars 
represent SEM. Statistical difference between samples was analysed by a one way ANOVA with a Bonferroni post-
hoc test compared to the control. **P<0.01. c) Brightfield images of non-silencing (NS) control, DNMT3A and 
DNMT3B knockdown naïve hESCs showing their different morphologies. Red arrows indicate naïve dome-shaped 
colonies and blue arrows indicate flattened colonies. Scale bars represent 125µm. d) qRT-PCR for naïve pluripotency 
markers in control and knockdown naïve hESCs. Bars are representative of the mean of three technical replicates 
and two independent biological replicates. Error bars represent the standard error of the mean. Statistical 
difference between samples was analysed by one way ANOVA, with a Bonferroni post-hoc test comparing each time 
point to the non-silencing (NS) control cells. N.S. denotes not significant. Human GAPDH was used to normalise 
expression. 
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4.6 Hypermethylation of bivalent loci correlates with loss of H3K4me3 
The interplay between bivalent chromatin and DNA methylation has been referred to many 
times, particularly in the context of cancer. Moreover, our data thus far had highlighted an 
enrichment of hypermethylated regions in genomic loci marked by H3K4me3 and H3K27me3 
in primed hESCs. To investigate any relationship between bivalent chromatin and DNA 
methylation upon hESC reprogramming, we used the grouping of bivalent regions generated in 
chapter 3 to address the intrinsic differences between the bivalent hypermethylated and 
bivalent non-hypermethylated groups, which both begin with the same chromatin states. As 
DNA methylation and H3K4me3 are known to be mutually exclusive (Ooi et al. 2007), we used 
a targeted approach to measure the enrichment of the modified histone at bivalent DNA 
regions. We performed ChIP-qPCR of H3K4me3, across the transition from primed to naïve 
pluripotency. We observed a loss of H3K4me3 at bivalent regions that become 
hypermethylated, whilst bivalent non-hypermethylated regions retain their levels of H3K4me3 
(Figure 4.8a). The loss of H3K4me3 is already apparent by the early transition of 
reprogramming. It is known that loss of H3K4me3 is permissive to the gain of DNA 
methylation, but this on its own cannot explain the specific gain of methylation at these 
regions, as both DNMT3A and DNMT3B possess an ADD domain capable of mediating the 
interaction of the enzymes with unmethylated H3K4 (Otani et al. 2009; Ooi et al. 2007; Guo et 
al. 2015; Zhang et al. 2010). Despite comparable absolute protein levels of DNMT3A and 
DNMT3B, as measured by mass spectrometry (Figure 4.4d), only DNMT3A deposits DNA 
methylation during the early transition of hESC reprogramming. In contrast to the reduction in 
H3K4me3, the levels of H3K27me3 exhibit little change at bivalent regions, despite the 
presence of DNA methylation (Figure 4.8b). While H3K27me3 and DNA methylation are 
considered to be mutually exclusive at CpG rich regions during development (Brinkman et al. 
2012), co-existence of the two modifications has previously been reported in the context of 
cancer (Gao et al. 2014).  
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Figure 4.8. A subset of bivalent loci lose H3K4me3 and gain DNA methylation. a) ChIP-qPCR enrichment of 
H3K4me3 and b) H3K27me3 are shown for candidate bivalent regions (possessing both H3K4me3 and H3K27me3 
histone modifications in primed cells) that do (6 regions) and do not (3 regions) become hypermethylated during 
reprogramming. Data is show as the signal enrichment relative to the input sample and error bars represent the 
minimum and maximum values from 2 independent experiments. Statistical difference between samples was 
analysed by a one way ANOVA test, with Bonferroni post-hoc test of each time point compared to primed hESC. * 
indicates p<0.05, N.S. denotes not significant.  
 
 
A recent study demonstrated that the binding of the DNA methylation reader protein, MECP2,  
to the ADD domain of DNMT3A inhibits the activity of the DNA methyltransferase by stabilising 
its auto-inhibitory confirmation (Rajavelu et al. 2018). At genomic sites with unmodified H3K4, 
the binding of H3 to the ADD domain of DNMT3A disrupts the interaction between DNMT3A 
and MECP2, thereby allosterically activating DNMT3A and enabling de novo DNA methylation 
(Rajavelu et al. 2018). Mass spectrometry based protein quantification showed that MECP2 is 
expressed in primed hESCs and is downregulated upon reprogramming, coinciding with the 
reduction of H3K4me3 at bivalent DNA loci (Figure 4.9a). To test whether the concomitant loss 
of MECP2 and H3K4me3 enable de novo DNA methylation upon hESC reprogramming, we 
generated a stable MECP2-overexpressing cell line in primed hESCs and subjected it to 
reprogramming until the early transition. We validated overexpression by measuring 
transcriptional expression of MECP2 in primed and early transition hESCs (Figure 4.9b). We 
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then used a targeted-bisulfite sequencing approach to measure DNA methylation at selected 
loci. We observed no impact of MECP2 overexpression on DNA methylation levels in primed or 
early transition hESCs (Figure 4.9c). These data indicate that hypermethylation of bivalent loci 
upon reprogramming occurs independently of MECP2 loss. 
 
 
Figure 4.9. Hypermethylation occurs independently of MECP2 loss. a) Raw protein intensity values for MECP2 
extracted from proteomics data, plotted in parts per million (ppm). Bars represent an average of 2 intensity values 
for each of the 3 replicates per sample, with error bars representing the SEM.  Statistical difference between 
samples was analysed by a one-way ANOVA with a Bonferroni post-hoc test comparing each early transition time 
point to primed hESCs. ****P<0.0001. b) qRT-PCR for TET1 in an empty vector control and overexpression cell line, 
in primed and early transition cells. Bars represent the mean of three technical replicates. Human GAPDH was used 
to normalise expression. c) Plot showing the % methylation in the early transition and primed state, for a MECP2 
overexpressing hESC line and empty vector control. Each dot represents the methylation % of single CpGs from 6 
genomic regions and the red bars represent the mean methylation level for each sample. Statistical difference 
between samples was analysed by a two way ANOVA test, with Bonferroni post-hoc test of the MECP2 
overexpressing sample compared to the control (empty vector). N.S. denotes not significant (p > 0.05). 
 
 
4.7 DNA hypermethylation is independent of TET1 loss 
We next sought to investigate the hypothesis that the loss of protective mechanisms that 
typically act to maintain CGIs in a hypomethylated state may result in hypermethylation. 
Bivalent loci in mice have been shown to be protected from DNA methylation through binding 
of ten-eleven translocation (TET) enzymes via their CXXC domains (Xu et al. 2011), and a recent 
study demonstrated that TET triple knock out in primed hESCs results in hypermethylation of 
bivalent loci (Verma et al. 2018). TET2 does not have a CXXC domain, and TET3 is expressed at 
very low levels in hESCs. TET1, however, which has a functional CXXC domain is expressed in 
primed hESCs and is subsequently downregulated at the protein level as hESCs progress 
through the early transition of reprogramming (Figure 4.10a). This protein expression pattern 
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appears to be uncoupled from the transcriptional expression of TET1 (Figure 4.10b), suggesting 
that the expression of TET1 protein is controlled by a post-transcriptional mechanism. To test 
whether loss of TET1-mediated antagonism of DNA methylation is responsible for 
hypermethylation of bivalent loci upon reprogramming, we generated a stable TET1-
overexpressing cell line in primed hESCs and subjected it to reprogramming until the early 
transition. We validated overexpression by measuring both transcriptional and protein 
expression of TET1 in primed and early transition hESCs (Figures 4.10c and 4.10d). We then 
used a targeted-bisulfite sequencing approach to measure DNA methylation at selected loci. 
We observed no impact of TET1 overexpression on DNA methylation levels in primed or early 
transition hESCs (Figure 4.10e). These data indicate that hypermethylation of bivalent loci 
upon reprogramming is independent of TET1 loss. 
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Figure 4.10. Hypermethylation occurs independently of TET1 loss. a) Western blot analysis of TET1 across the 
transition from primed to naïve pluripotency. * denotes degraded fragments of TET1 protein. GAPDH is used as a 
loading control. b) qRT-PCR for TET1 across the period of resetting. Bars are representative of the mean of two 
technical replicates and three biological replicates. Error bars represent the standard error of the mean. Statistical 
difference between samples was analysed by a one way ANOVA test. *P<0.05 and ***P<0.0001. Human GAPDH was 
used to normalise expression. c) Western blot analysis of TET1 in empty vector and TET1 overexpressing primed and 
early transition hESCs. * denotes degraded fragments of TET1 protein. GAPDH is used as a loading control. d) qRT-
PCR for TET1 in an empty vector control and overexpression cell line, in primed and early transition cells. Bars 
represent the mean of three technical replicates. Human GAPDH was used to normalise expression. e) Plot showing 
the % methylation in the early transition and primed state, for a TET1 overexpressing hESC line and empty vector 
control. Each dot represents the methylation % of single CpGs from 6 genomic regions and the red bars represent 
the mean methylation level for each sample. Statistical difference between samples was analysed by a two way 
ANOVA test, with Bonferroni post-hoc test of the TET1 overexpressing sample compared to the control (empty 
vector). N.S. denotes not significant (p > 0.05). 
 
 
4.8 DNA hypermethylation is coordinated by the transcription factor and core 
pluripotency networks. 
Having seen no evidence thus far for loss of protective mechanisms in facilitating DNA 
hypermethylation upon reprogramming, we hypothesized that an additional player, likely a 
DNA-binding factor, is involved in targeting DNMT3A-mediated hypermethylation in the early 
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stages of hESC reprogramming. We reasoned that a more thorough understanding of the 
unique properties of the bivalent hypermethylated group compared to the bivalent non-
hypermethylated group may provide insight into such a mechanism. We thus performed 
differential transcription factor-binding motif analysis of bivalent hypermethylated DNA 
regions, with the bivalent non-hypermethylated regions as a control set. This analysis performs 
a search of known DNA-binding motifs in the genomic sequences input, by searching against a 
database of human transcription factor motifs. We identified a large number of DNA-binding 
transcription factors with motifs enriched at regions that undergo hypermethylation. In order 
to play a role, these proteins must be expressed in the cells, particularly at the time at which 
hypermethylation occurs. We therefore analysed the total proteomics of primed hESCs and 
hESCs at two time points during the early transition of reprogramming. In total, we identified 
406 proteins that were significantly differentially expressed (Log2 FC > 1 or < -1, FDR < 0.05) 72 
hours into the early transition compared to primed hESCs, and 424 proteins that were 
significantly differentially expressed (Log2 FC > 1 or < -1, FDR < 0.05) 1 week into the early 
transition compared to primed hESCs (Figures 4.11a and 4.11b). Additionally, we were able to 
validate that the experiment had been successful technically, as we could detect 
overexpression of NANOG and KLF2 in early transition cells, as well as a significant 
upregulation of DNMT3L. We were also able to detect downregulation of both DNMT3A and 
DNMT3B, to varying degrees (Figures 4.11a and 4.11b). In order to identify proteins with a 
putative role in hypermethylation, we filtered the list of proteins identified to specifically look 
at those that are upregulated upon reprogramming. We next performed a cross-comparison of 
results of the motif analysis with the upregulated proteins from the proteomic analysis. We 
short-listed two candidate transcription factors, SRY-box 15 (SOX15) and Nuclear factor kappa 
B subunit 1 (NFKB1), which are upregulated during early reprogramming and show an 
enrichment of binding sites at hypermethylated regions (Figures 4.11a-c). We performed a 
similar cross-comparison of the results from the motif analysis with the RNA-seq data 
described in chapter 3. Through this analysis, we identified an additional two candidate 
transcription factors, Forkhead box C1 (FOXC1) and Zinc finger homeobox 3 (ZFHX3; Figure 
4.11c), which were transcriptionally upregulated during the early transition based on RNA-seq 
data (Figure 4.11d) but not detected in any samples by proteomic analysis, likely due to 
technical limitations of the method in detecting nuclear transcription factors (Simicevic and 
Deplancke 2017). We measured the expression of the transcripts of ZFHX3 and FOXC1 by qRT-
PCR to confirm their upregulation during the early transition of reprogramming (Figure 4.11e).  
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Figure 4.11. Transcription factors that bind hypermethylated loci are upregulated upon reprogramming. a&b) 
Volcano plots showing the difference in protein expression in early transition (72h and 1W) hESCs compared to 
primed hESCs (Supplementary Table 6). Each dot represents the log2 fold change based on three biological 
replicates. Statistical difference between samples was analysed by a student’s t-test, corrected for multiple testing. 
Red dots indicate statistically significant changes (adjP < 0.05). Proteins of interest are highlighted with coloured 
and labelled symbols. c) A selection of the transcription factors with motifs enriched in bivalent hypermethylated 
regions, with bivalent non-hypermethylated regions used as a background control. Motif analysis was performed 
using the analysis of motif enrichment (AME) tool on the MEME suite. d) Expression levels of FOXC1 and ZFHX3 
extracted from RNA-seq data, displayed in normalised counts per million (CPM). e) qRT-PCR for FOXC1 and ZFHX3 
across the period of reprogramming. Bars are representative of the mean of three technical replicates and three 
biological replicates. Error bars represent the standard error of the mean. Statistical difference between samples 
was analysed by a one way ANOVA test. *P<0.05, **P<0.01, ***P<0.001 and ***P<0.0001. Human GAPDH was used 
to normalise expression. 
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In order to determine whether our candidate transcription factors play a role in facilitating 
hypermethylation, we generated constitutive knockdown cell lines using two short hairpin 
RNAs (shRNAs) targeting each of the four candidate genes, and subjected each of the cell lines 
to reprogramming until the early transition. We validated the efficiency of the shRNA 
knockdowns by measuring expression of the target genes in both primed and early transition 
hESCs (Figure 4.12a). We then used a targeted-bisulfite sequencing approach to measure DNA 
methylation at selected loci, assaying both loci where the candidate transcription factors are 
predicted to bind and loci with no predicted binding sites. There was no effect on the level of 
methylation in primed hESCs in any of the knockdown cell lines compared to the control. 
Strikingly, however, upon reprogramming, knockdown of each of the transcription factors was 
able to reduce the level of hypermethylation at target loci analysed, suggesting that the early 
reprogramming transcription factor network coordinates bivalent promoter CGI 
hypermethylation (Figure 4.12b). The impact seems to be higher in regions where the highly 
expressed transcription factors are also predicted to bind, indicating a network synergy in 
preferentially mediating de novo methyltransferase recruitment to these sites (Figure 4.12c). 
These data support the hypothesis that a DNA-binding event may be the first step required in 
de novo DNA methylation, to actively target DNMT activity to specific genomic sites.  
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Figure 4.12. Knockdown of transcription factors reduces hypermethylation at target loci. a) qRT-PCR for the 
transcripts of 4 transcription factors in control and knock-down cell lines, in primed and early transition cells. Bars 
represent the mean of three technical replicates. Human GAPDH was used to normalise expression. b&c) Plots 
showing the % methylation in the early transition and primed state, for 4 different transcription factor knock downs 
and a non-silencing control. Data for each sample are an average of 2 independent shRNA knock downs. Each dot 
represents the methylation % of single CpGs from 12 genomic regions (with TF binding sites) or 4 genomic regions 
(without TF binding sites) and the red bars represent the mean methylation level for each sample. Statistical 
difference between samples was analysed by a two way ANOVA test, with Bonferroni post-hoc test of each TF knock 
down compared to the control. *P<0.05, **P<0.01, and ***P<0.001, ****P<0.0001. N.S. denotes not significant. 
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As reprogramming hESCs to the naïve state is a multifaceted process involving a number of 
inhibitors and growth factors that affect the signalling network of hESCs, we sought to test 
whether signalling changes associated with factors required for induction of the naïve state 
induction could influence hypermethylation. We conducted hESC reprogramming until the 
early transition, each time removing one of the factors required for reprogramming (Figure 
4.13a). We then used a targeted approach to measure DNA methylation at loci that become 
hypermethylated upon reprogramming. Reprogramming in the absence of the ERK pathway 
inhibitor or GSK3β inhibitor (also a WNT pathway agonist) or concomitant removal of both 
inhibitors still resulted in hypermethylation at target loci analysed (Figure 4.13b). As the factor 
common to all the conditions tested is doxycycline, this suggests that hypermethylation may 
be coordinated by the overexpressed NANOG and KLF2 or the associated pluripotency 
network. Collectively, these data indicate that upon reprogramming hESCs to the naïve state, 
hypermethylation is driven by the transcription factor network that becomes active upon 
reprogramming, and that this may be synchronised by the core pluripotency network. 
 
 
Figure 4.13. Hypermethylation occurs independently of the 2i inhibitors. A) Schematic showing the experimental 
setup to test the impact of the 2i inhibitors on hypermethylation during the early transition of hESC reprogramming. 
b) Targeted bisulfite-sequencing of 3 genomic regions. Each square represents the methylation % indicated by the 
colour key of a single CpG. The first column represents data from primed hESCs, and the subsequent columns 
represent data from early transition hESCs cultured in a variety of culture conditions indicated by the +/- symbols 
above. 
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4.9 Discussion 
The data presented in this chapter detail the DNA methylation machinery involved in 
mediating the changing patterns of DNA methylation upon primed to naïve hESC 
reprogramming. We observed downregulation of the maintenance methylation proteins 
DNMT1 and UHRF1, and upregulation of the TET enzymes, both of which temporally coincided 
with the global demethylation that occurs upon reprogramming. To this end, it has been 
demonstrated in mESCs that TET1-/- and TET2-/- ESCs are still able to demethylate their 
genomes, (Ficz et al. 2013) and that TET1/2/3 triple knock out only affects a limited specific 
number of loci (von Meyenn et al. 2016). This suggests that TET enzymes are dispensable for 
global demethylation. In mESCs, the primary cause of global demethylation has been 
attributed to impaired methylation maintenance as a result of downregulated UHRF1 protein 
and a global loss of the H3K9me2 mark, which is responsible for the recruitment of DNMT1 to 
replicating DNA (von Meyenn et al. 2016). We hypothesize that impaired methylation 
maintenance due to downregulated UHRF1 protein and the resulting alteration in targeting 
and regulation of DNMT1 activity and stability is primarily responsible for the global 
demethylation induced upon hESC reprogramming. This is supported by the observation that a 
disruption of the interactions in the DNMT1/UHRF1/PCNA complex can result in tumorigenesis 
associated with global demethylation (Hervouet et al. 2010; Pacaud et al. 2014). 
We identified DNMT3A as the de novo DNA methyltransferase responsible for the deposition 
of DNA methylation early during hESC reprogramming and we demonstrate loss of H3K4me3 
specifically from bivalent regions that become hypermethylated. Intriguingly, the levels of 
H3K27me3 exhibit little change at bivalent regions, despite the presence of DNA methylation. 
H3K27me3 and DNA methylation are considered to be mutually exclusive at CpG rich regions 
during development (Brinkman et al. 2012), however co-existence of the two modifications 
has previously been reported in the context of cancer (Gao et al. 2014). It is known that loss of 
H3K4me3 is permissive to the gain of DNA methylation, but this on its own cannot explain the 
specific gain of methylation at these regions, as both DNMT3A and DNMT3B possess an ADD 
domain capable of mediating the interaction of the enzymes with unmethylated H3K4 (Otani 
et al. 2009; Ooi et al. 2007; Guo et al. 2015; Zhang et al. 2010). Interestingly, during the early 
transition of reprogramming, our proteomics data shows that both DNMT3A and DNMT3B are 
downregulated to varying degrees. Despite comparable absolute protein levels of DNMT3A 
and DNMT3B, as measured by mass spectrometry, only DNMT3A deposits DNA methylation 
during the early transition of hESC reprogramming. Generating a stable DNMT3B 
overexpression primed hESC cell line and reprogramming it to the early transition would 
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provide verification that protein expression levels of DNMT3B are not the limiting factor 
preventing the enzyme from contributing to DNA hypermethylation during the early transition 
of reprogramming.  
We deduced that the shorter isoform of DNMT3A, DNMT3A2, is specifically responsible for de 
novo methylation upon reprogramming, as we observed no impact on levels of 
hypermethylation when we knocked down DNMT3A1. Due to the lack of unique exons in 
DNMT3A2, we were unable to knock down this isoform and show a direct impact on DNA 
hypermethylation. An alternative to confirm the unique role of DNMT3A2 would be to 
generate a DNMT3A knockout cell line and re-introduce specifically the expression of 
DNMT3A2 and measure DNA methylation at bivalent CGIs upon reprogramming. 
The data indicate that DNMT3B also contributes to hypermethylation by the late transition of 
reprogramming, as is often observed in the context of cancer cells (Roll et al. 2008). In line 
with this, naïve hESCs generated from either DNMT3A or DNMT3B knockdown primed hESCs 
exhibit reduced stability of naïve pluripotency. It is difficult to distinguish whether this is 
reflective of an inability to successfully transition to naïve pluripotency in the absence of the 
DNMT3s, or whether there is a direct impact on the stability of the naïve pluripotent state. 
Additionally, it is unclear whether the impact is dependent on the hypermethylation 
associated with the catalytic activity of the two enzymes, or is a result of a non-catalytic role of 
DNMT3A and DNMT3B. This could be further tested by using an independent method to erase 
DNA hypermethylation at bivalent CGIs, such as treatment of naïve hESCs with the DNA 
demethylating agent 5-azacytidine, and then evaluating of the impact of lack of 
hypermethylation on the stability of the naïve pluripotent state. Moreover, it would be useful 
to validate the findings of both DNMT3A and DNMT3B knockdowns by generating double 
knockout cell lines of the two enzymes, in order to be sure that any residual protein in the 
knockdown cell lines is not influencing the cellular phenotype, or that the two proteins are not 
compensating for each other. 
We investigated the potential role of loss of protective mechanisms in facilitating DNA 
hypermethylation upon reprogramming. Specifically, we looked at the impact of TET1 
overexpression on hypermethylation during the early transition of reprogramming. To validate 
overexpression of TET1, we measured both gene and protein expression of the enzyme in 
TET1-overexpressing and control cells. The gene expression data showed only a modest 2-fold 
increase in TET1 transcript levels at the early transition, compared to a 10-fold increase 
observed in MECP2 transcript levels in an MECP2-overexpression cell line generated using the 
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same overexpression system. Western blot analysis of the protein also showed a modest 
overexpression of TET1 in the overexpressing cells compared to the control, particularly when 
taking into account all the bands on the blot, which likely correspond to degradation products 
or isoforms of the protein. As the gene and protein expression of TET1 are uncoupled during 
hESC reprogramming, it is plausible that despite trying to overexpress TET1 mRNA, post-
transcriptional or post-translational mechanisms retain overarching control over TET1 protein 
expression. This may explain the lack of impact seen on levels of DNA hypermethylation upon 
reprogramming in cells containing a TET1-overexpression construct. Further verification of 
TET1 protein expression by western blotting, or measurement of global levels of 5hmC as a 
readout of TET1 overexpression would enable more firm conclusions to be drawn with regards 
to the impact of TET1 loss on DNA hypermethylation.  
We explored the hypothesis that hypermethylation of bivalent CGIs occurs as a result of active 
targeting of DNMT activity by chromatin or DNA-interacting proteins. It has been 
demonstrated that PRC2, which is responsible for deposition of H3K27me3, can directly 
regulate DNA methylation (Vire et al. 2006), however recent studies suggest that while PRC2 
can recruit DNMT3A to the DNA, it is not sufficient to trigger de novo DNA methylation, 
indicating that additional factors are required (Rush et al. 2014). Our data points towards the 
transcription factor network established upon reprogramming playing a role in the targeting or 
recruitment of DNMT3A to loci that gain methylation. We identified four candidate 
transcription factors that were upregulated during the early transition of reprogramming and 
had motifs enriched at bivalent regions that become hypermethylated, of which SOX15 and 
NFKB1 were found to be upregulated as measured by mass spectrometry, while FOXC1 and 
ZFHX3 were not detected in any samples by mass spectrometry but were transcriptionally 
upregulated based on RNA-seq data. It is likely that as we performed total proteomics on 
whole cell lysates, technical limitations of the method in detecting nuclear transcription factors 
(Simicevic and Deplancke 2017) can explain why we did not detect FOXC1 and ZFHX3. 
Subcellular fractionation and subsequent proteomics of the nuclear fraction of proteins may 
provide a more accurate measure of the transcription factor network active upon 
reprogramming. Additionally, the expression of each of the candidate proteins can be 
validated by western blotting.  
Whilst we cannot currently differentiate between a direct interaction of DNMT3A with 
transcription factors or an indirect transcription factor network-driven effect on targeting of 
the enzyme, loci-specific recruitment of DNMT3A via transcription factors has been previously 
demonstrated (Brenner et al. 2005) and in vitro data supports the ability of DNMT3A to 
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interact directly with numerous transcription factors (Hervouet, Vallette, and Cartron 2014). 
Moreover, this data is in support of the notion that underlying DNA sequence is important in 
the establishment of DNA methylation patterns (Long et al. 2016; Krebs et al. 2014; Lienert et 
al. 2011). Targeted ChIP of the transcription factors at bivalent DNA regions, and a co-
immunoprecipitation of the transcription factors bound to DNMT3A would be useful to 
confirm whether the transcription factors actually bind their predicted binding sites during 
reprogramming, and whether they exhibit a direct interaction with DNMT3A.  
Our approach for shortlisting candidate transcription factors with a putative role in the 
mechanism of hypermethylation relied on identifying transcription factors that were 
upregulated either at the level of mRNA or protein upon reprogramming. This approach is 
based on the assumption that an increase in the expression of a transcription factor is 
correlated with an increase in its activity or function. However, there is much evidence in the 
literature that transcription factors can undergo post-translational modifications that may 
alter their activity, localisation or ability to interact with other co-factors (Tootle and Rebay 
2005; Filtz, Vogel, and Leid 2014). It may therefore be of additional value to investigate the 
impact on reprogramming-associated hypermethylation of transcription factors whose 
expression levels are not significantly altered upon hESC reprogramming. 
Our data are also indicative of the overexpressed NANOG and KLF2 coordinating de novo 
methylation, however studies have shown that KLF2 is not expressed in vivo in the human 
inner cell mass (Yan et al. 2013; Blakeley et al. 2015), where we also observed 
hypermethylation (detailed in chapter 3). Additionally, we observed comparable 
hypermethylation in naïve hESCs generated using two transgene-independent methods of 
reprogramming (detailed in chapter 3). This collectively suggests that the core pluripotency 
network, to which NANOG belongs, is likely responsible for coordinating the transcriptional 
changes that drive DNA hypermethylation. There is growing evidence in the literature 
regarding the acquisition of stem-like properties and expression of pluripotency genes in 
cancers (Ben-Porath et al. 2008; Chen and He 2016). This makes it intriguing to speculate that a 
transcriptional programme associated with the pluripotency network could drive a shared 
mechanism of hypermethylation during reprogramming to naïve pluripotency and in cancer 
development, either preceding or in conjunction with genetic mutations. Additional molecular 
features of the primed to naïve state transition appear analogous to cancer hallmarks 
(Hanahan and Weinberg 2011), such as altered metabolism (Takashima et al. 2014), loss of 
imprints (Pastor et al. 2016), loss of DNA hydroxymethylation (Ficz and Gribben 2014) and 
genomic instability (Pastor et al. 2016; Liu et al. 2017). Whether they are related to the 
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changing epigenetic landscape remains unexplored, but further use of this model system may 
shed light on the emergence of these characteristics during cellular transformation. We 
propose that this may provide a good model system to understand whether the molecular 
processes associated with cellular reprogramming play a role in tumourigenesis. To this end, 
the next chapter will explore the genomic stability of hESCs upon reprogramming, as well as 
any potential relationship between the changing DNA methylation patterns and the genomic 
stability of the cells.  
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Chapter 5. Results 3: Investigating genome stability during primed 
to naïve reprogramming 
 
5.1 Introduction 
CpG sites are underrepresented globally across the genome due to the high mutation rate of 
methylated cytosines. As CpG residues within CGIs are commonly unmethylated, CpG islands 
remain protected from the depletion of CpGs (Bird 1980; Bird et al. 1985). Cytosine can 
deaminate spontaneously to give uracil, and the resulting U:G mismatch is recognised by uracil 
DNA glycosylases and the uracil base is efficiently eliminated and replaced with cytosine. 5mC, 
however, is deaminated to give thymine (Bird 1980), and the resulting T:G mismatch is 
repaired with reduced efficiency (Schmutte et al. 1995). Compared to unmodified C, 5mC has 
increased susceptibility to spontaneously deaminate (Shen, Rideout, and Jones 1994). Aside 
from spontaneous deamination, the activation-induced cytidine deaminase (AID) is thought to 
mediate hydrolytic deamination of 5mC into T and C to U. The T is repaired if AID activity is 
coupled to DNA repair, resulting in active demethylation. The U:G mismatch, if replicated over 
will give rise to C to T mutations unless it is excised by UNG (Perez-Duran et al. 2012). Unlike U, 
however, because T is a natural base, the mutant base can persist through DNA replication, 
and upon cell division, it can be passed on to daughter cells as a C to T transition mutation 
(Schmutte et al. 1995). Despite the existence of MBD4, a dedicated thymine DNA glycosylase 
that can selectively remove T from a T:G mismatch, these mismatches are repaired with 
reduced efficiency (Schmutte et al. 1995; Hendrich et al. 1999).  
Methylated CpGs are considered to be hotspots for DNA mutation, supported by the fact that 
C to T mutations are the most frequent in human disease, constituting a third of all point 
mutations (Cooper and Youssoufian 1988; Pfeifer 2017). In particular, it has been shown for 
the p53 gene, which is frequently mutated across many cancers, that the mutations frequently 
occur within the methylated CGIs within the gene promoter (Denissenko et al. 1997; 
Greenblatt et al. 1994). C to T mutations may occur in the coding regions of genes (Rideout et 
al. 1990), or on regulatory regions of DNA, hence altering binding sites of transcription factors 
and other proteins (Zemojtel et al. 2011). When the mutations occur in early-replicating DNA, 
they are typically repaired by BER machinery, but mutations can also occur in late-replicating 
DNA where BER operates with reduced efficiency, thereby resulting in mutation (Blokzijl et al. 
2016; Tomkova et al. 2018).  
While 5mC shows increased mutability compared to unmethylated C, its oxidised derivative, 
5hmC (Tahiliani et al. 2009), has in fact been shown to be protective against mutagenesis 
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(Tomkova et al. 2016), and enrichment of 5hmC at sites of DNA damage has been shown to 
promote genome stability by ensuring chromosome segregation occurs correctly (Kafer et al. 
2016).  
Some of the most frequently seen mutational signatures in human cancers feature high rates 
of C to T mutations, and are attributed to the deaminase hyperactivity of AID or APOBEC 
enzymes at methylated CpG dinucleotides, possibly coupled with inefficient BER pathway 
activity (Alexandrov et al. 2013). Recent reports suggest that tissue-specific mutations 
accumulate in normal adult stem cells during life. These patterns are similar between the 
normal stem cells of a given tissue and cancers that arise from those tissues, suggesting that 
intrinsic, non-random mutational processes such as that described above may be responsible 
for initiating tumorigenesis (Blokzijl et al. 2016). 
While DNA methylation may promote mutation due to the mutability of 5mC, its presence 
across the genome is beneficial in maintaining genomic and chromosomal stability (Chen et al. 
1998). Recently, it has been reported that hypomethylation of late-replicating regions of the 
DNA begins during foetal development and is linked to cell division, such that cancer 
hypomethylation reflects the mitotic history of the cells (Zhou et al. 2018). Several studies 
have reported chromosomal breakages, fusions, and aneuploidy in relation to DNA 
hypomethylation and downregulation or mutations of the DNMTs, and such instability may 
promote tumour initiation or progression (Eden et al. 2003; Gaudet et al. 2003; Sheaffer, 
Elliott, and Kaestner 2016; Dodge et al. 2005; Karpf and Matsui 2005). As DNA methylation is 
involved in the silencing of retrotransposons during development (Bestor 2004),  
hypomethylation may also result in increased retrotransposition and re-expression of such 
elements, which may play an active role in tumorigenesis (Daskalos et al. 2009). The absence 
of DNA methylation at certain genomic regions such as heterochromatic repetitive elements 
may lead to incorrect chromosome segregation that gives rise to chromosomal aberrations 
and resulting aneuploidy, which is found across many tumour types (Monier, Mouradian, and 
Sullivan 2006; Duijf, Schultz, and Benezra 2013). Such chromosomal instability has been 
detected early on in the process of carcinogenesis and is a common feature of cancers (Shih et 
al. 2001; Kops, Weaver, and Cleveland 2005). A number of different types of chromosomal 
aberrations can be detected depending on the underlying molecular cause, which include 
various mitotic abnormalities that often arise as a result of cellular replication stress (Burrell et 
al. 2013). The aberrations can manifest as multipolar spindles arising from multiple centrioles, 
lagging chromosomes during anaphase, or ultrafine anaphase bridges, among others (Burrell 
et al. 2013; Kops, Weaver, and Cleveland 2005; Thompson, Bakhoum, and Compton 2010). 
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Chromosomal aberrations such as those mentioned above can be detected in cells in vitro 
through a variety of methods including immunofluorescent staining of proteins that are 
associated with or bind to the various structural aberrations, as well as staining for 
centromeres. Additionally, as genomic instability can activate DNA damage pathways, 
detection of proteins associated with the DNA damage response are also used as a proxy for 
the level of DNA damage occurring in a cell. In particular, one of the most frequently used 
markers is the phosphorylation of the histone H2A variant H2AX at Ser 139 (γ-H2AX), as this 
phosphorylation is induced rapidly and abundantly upon the detection of a DNA double-
stranded break (DSB) in a cell (Ji et al. 2017). 
Primed to naïve hESC reprogramming is associated with large-scale changes in DNA 
methylation patterns, as detailed in chapter 3. Both global demethylation of the genome and 
regional hypermethylation may facilitate altered genomic stability of the cells. To this end, 
recent studies have reported reduced long-term genomic stability in naïve hESCs generated 
using alternative reprogramming methods, with naïve hESCs generated using the 5iLAF 
method particularly displaying abnormal karyotypes following multiple passages (Liu et al. 
2017; Pastor et al. 2016; Guo et al. 2017). Such karyotypic instability has also been observed 
upon the generation of naïve human stem cells generated through iPS reprogramming (Kilens 
et al. 2018), in addition to increased chromosomal aberrations, somatic mutations and copy 
number variation (Hussein et al. 2011; Ji et al. 2012; Mayshar et al. 2010; Gore et al. 2011). 
Additionally, it has been previously reported that de novo point mutations occur during iPS 
reprogramming in a manner that indicates that they are attributable to oxidative stress-
induced DNA damage (Yoshihara et al. 2017). However, it has also been demonstrated that 
limiting replication stress during cellular reprogramming either through genetic or chemical 
manipulation can reduce genomic instability (Ruiz et al. 2015). 
This chapter will explore the genomic stability of hESCs during the reprogramming of primed to 
naïve hESCs, in the context of changing DNA methylation patterns. In particular, a potential 
relationship between global demethylation and structural genomic instability will be 
investigated with preliminary experiments, as well as a potential relationship between DNA 
demethylation and an increased mutation frequency. Additionally, a relationship between CGI 
hypermethylation and increased mutability of the CpG dinucleotide will be tested. 
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5.2 Levels of DNA damage markers remain constant across the transition from 
primed to naïve pluripotency 
The DNA damage response (DDR) is typically activated in response to stress signals 
encountered during physiological processes. In particular, DSBs rapidly result in the 
accumulation of γ-H2AX, and the specific phosphorylation of serine 139 on H2AX is used as a 
marker for DNA damage (Ji et al. 2017). To understand whether hESCs undergo DNA damage 
upon reprogramming, we used immunofluorescence to measure the number of γ-H2AX foci 
present in hESCs across the transition from primed to naïve pluripotency. We observed no 
significant difference in the number of interphase nuclei positive for γ-H2AX at any point 
during the reprogramming transition compared to primed hESCs, though the basal level of γ-
H2AX positive nuclei is high (Figure 5.1). This may be a reflection of human stem cells being 
highly sensitive to DNA damage and activating robust DNA repair responses against even low 
levels of DNA damage in order to maintain their genomic integrity (Fu et al. 2017; Seifert, 
Dejosez, and Zwaka 2017). 
We next stained primed and naïve hESCs for p53 binding protein 1 (53BP1), which is also 
involved in DSB repair. Specifically, 53BP1 is known to regulate the DSB repair pathway choice, 
favouring non-homologous end joining (NHEJ) over homologous recombination (HR) (Panier 
and Boulton 2014). We observed a small difference from 59.26% to 77.5% in the percentage of 
53BP1-positive interphase nuclei in naïve compared to primed hESCs (Figure 5.2). However, as 
the levels of DSBs remain unchanged between primed and naïve hESCs based on the γ-H2AX 
staining, it is possible that the increased 53BP1 is attributable to its role in responding to 
replication stress, which may occur during reprogramming (Lukas et al. 2011; Harrigan et al. 
2011). 
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Figure 5.1. Levels of γ-H2AX remain unchanged upon primed to naïve reprogramming. a) A representative 
microscope image of hESCs grown on iMEFs stained with an antibody against γ-H2AX (phosphorylated S139; green) 
and DAPI (blue). Irradiated mouse feeder cells act as an internal positive control for staining as they contain several, 
large γ-H2AX foci. The white box highlights an example of a hESC nucleus with a γ-H2AX foci. Scale bar represents 
10µm. b) Quantification of the percentage of nuclei that have at least one γ-H2AX foci during each stage of 
reprogramming. The number at the top of each bar represents the total number of nuclei analysed for each time 
point. Error bars represent the standard deviation of three technical replicates for primed and naïve hESCs. A semi-
automated spot count approach was used to score γH2AX positive nuclei and to quantify the number of foci/cell. 
Statistical significance was determined using a one-way ANOVA comparing each time point to each other. N.S. 
denotes not significant.  
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Figure 5.2. Levels of 53BP1 show a slight increase in naïve compared to primed hESCs. a) A representative 
microscope image of hESCs grown on iMEFs stained with an antibody against 53BP1 (green) and DAPI (blue). The 
white box highlights an example of a hESC nucleus with a 53BP1 foci. Scale bar represents 5µm. b) Quantification of 
the percentage of nuclei that have at least one 53BP1 foci during each stage of reprogramming. The number at the 
top of each bar represents the total number of nuclei analysed for each time point. A semi-automated spot count 
approach was used to score γH2AX positive nuclei and to quantify the number of foci/cell.  
 
 
5.3 hESC reprogramming is associated with increased chromosome errors during 
mitotic anaphase and increased ultrafine bridges 
In order to maintain genomic stability, cells must ensure that the DNA is correctly replicated 
and repaired prior to mitosis, and that chromosomes are properly segregated during cell 
division, the latter being the most critical for maintenance of genomic stability. Cells have 
mechanisms in place to ensure that these processes occur efficiently, however these 
mechanisms can be defective for a variety of reasons and can result in genomic instability. 
Defects during DNA replication as a result of endogenous or exogenous damage as well as 
inefficient DNA repair often result in the stalling of DNA replication forks (Lecona and 
Fernandez-Capetillo 2014). Such defects may arise as a result of replication stress, which can 
be a major contributor of structural abnormalities that arise during mitosis (Burrell et al. 2013). 
Replication stress can occur for a variety of reasons such as insufficient levels of 
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deoxynucleotides or DNA replication factors, or due to the misregulation of DNA repair 
pathways (Bester et al. 2011; Lecona and Fernandez-Capetillo 2014; Ruiz et al. 2015).  
Many of the chromosomal abnormalities that arise as a result of DNA replication errors can be 
detected during anaphase if they bypass the mitotic checkpoint (Kops, Weaver, and Cleveland 
2005). Moreover, defective chromosome segregation during mitosis can manifest as a number 
of structural abnormalities. One such abnormality is the presence of lagging chromosomes 
during anaphase, which can arise as a result of sister chromatid mis-segregation that can be 
attributed to pre-mitotic processes or defective chromosome attachments during mitosis 
(Bizard and Hickson 2018). Lagging chromosomes, or laggards, are fragments of chromosomes 
that are not physically connected to the rest of the segregating chromosomes and remain near 
the equatorial plate during anaphase (Bizard and Hickson 2018). Lagging chromosomes can be 
sub-divided further as either centric or acentric chromatin fragments. Acentric laggards lack a 
centromere and are therefore unable to interact with the mitotic spindle and segregate 
correctly during mitosis. Such fragments typically arise as a result of incorrect processing of 
DNA damage. Centric laggards, on the other hand, are typically full chromosomes containing a 
centromere, which arise as a result of defective microtubule attachment such as merotelic 
attachments during mitosis (Bizard and Hickson 2018; Cimini et al. 2001). 
In order to determine whether chromosomes are correctly segregated through mitosis during 
hESC primed to naïve reprogramming, cells at various stages of reprogramming were stained 
with DAPI and anti-CREST, which stains all centromeres. The hTERT-RPE1 cell line, which is a 
karyotypically stable diploid human epithelial cell line, was used as a control. Primed hESCs 
exhibited very small number of lagging chromosomes, however we detected a transient 
increase in the percentage of anaphase nuclei with lagging chromosomes as cells progressed 
through the early transition of reprogramming, with 42% of anaphase nuclei containing 
laggards at the late transition of reprogramming. No lagging chromosomes were detected in 
the stable naïve cells, however this may be due to the very low numbers of anaphase nuclei 
present in the sample. Interestingly, the majority of lagging chromosomes detected were 
acentric, based on the absence of signal from anti-CREST staining. This is indicative of the 
majority of the instability being attributable to errors during DNA replication in the lead up to 
mitosis, rather than errors during mitosis.  
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Figure 5.3. There is a transient increase in the detection of lagging chromosomes during primed to naïve hESC 
reprogramming. a) Representative image of hESCs stained with DAPI (blue) and anti-CREST which stains centromeres 
(red). Image shows an example of a cell in anaphase with lagging chromosomes. Scale bar represent 5µm. b) 
Quantification of the % of cells in anaphase with errors based on the detection of lagging chromosomes, at each stage 
of reprogramming. The RPE1 cell line was used as a control. The number at the top of each bar represents the total 
number of anaphase nuclei analysed for each time point. c) % of cells with lagging chromosomes, split into those with 
centric laggards (containing a centromere) or acentric laggards (not containing a centromere) based on anti-CREST 
staining.  
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Another class of abnormal structures that can arise during anaphase are ultrafine bridges 
(UFBs), which are distinct from chromatin bridges that also form during mitosis, and can be 
distinguished by the fact that they cannot be detected using conventional DNA dyes such as 
DAPI, due to the presence of single-stranded DNA (ssDNA) (Liu et al. 2014). Instead, UFBs 
consist of de-chromatinised single-stranded DNA filaments coated with UFB-associated 
proteins (Liu et al. 2014). These bridges are a potential source of genomic instability. UFBs can 
arise from interlocked DNA at centromeres, from late replication intermediates induced by 
replication stress, from telomeres, or from intertwined DNA generated by HR (Chan and West 
2018). The common feature between the majority of UFBs is that they are typically associated 
with defects that occur during DNA replication that result in un-replicated DNA, or abnormal 
DNA structures which are carried over into mitosis. However, some UFBs may also arise from 
defects during mitosis such as improper sister chromatid cohesion (Liu et al. 2014). Once UFBs 
have formed, the replication protein A (RPA) is one of a number of proteins that is recruited to 
these bridges through its association with ssDNA, and plays a role in their resolution (Chan and 
Hickson 2009). 
To detect the presence of ultrafine bridges, we stained hESCs at each stage of reprogramming 
with DAPI, anti-CREST to detect the centromeres, and an antibody against the replication 
protein A 70kDa DNA-binding subunit (RPA70). The number of anaphase nuclei with ultrafine-
bridges was counted based on RPA70 staining. We did not detect the presence of any UFBs in 
the hTERT-RPE1 control cell line. Primed hESCs exhibited very small number of UFBs, however 
we detected a transient increase in the percentage of nuclei with UFBs as cells progressed 
through the early transition of reprogramming, with a peak of 24.4% of anaphase nuclei 
containing UFBs at the late transition of reprogramming. Interestingly, no UFBs were detected 
in the stable naïve cells, however this may be due to the very low numbers of anaphase nuclei 
present in the sample.   
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Figure 5.4. There is a transient increase in the number of ultrafine bridges detected during primed to naïve hESC 
reprogramming. a) Images of hESCs at various stages during reprogramming stained with DAPI (blue), anti-CREST 
(red) and anti-RPA70 (green). Images show representative examples of cells in anaphase with ultrafine bridges 
(UFBs) which stain negatively for DAPI and positively for RPA70 which associates with single-stranded DNA at UFBs. 
b) Quantification of the percentage of cells with UFBs at each stage of reprogramming. The RPE1 cell line was used 
as a control. The number at the top of each bar represents the total number of anaphase nuclei analysed for each 
time point.  
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The chromosomal aberrations detected during the transition from primed to naïve 
pluripotency include primarily acentric lagging chromosomes and ultrafine bridges during 
anaphase, both of which are typical of pre-mitotic defects (Gisselsson 2008). Only a small 
percentage of the laggards contained centromeres, indicating that mitotic errors involving 
incorrect attachment of chromosomes to the mitotic spindle cannot account for the instability 
observed upon reprogramming (Burrell et al. 2013). Collectively, this points to a putative role 
of replication stress induced by reprogramming in mediating the genomic instability detected 
during reprogramming.  
 
5.4 hESC reprogramming is associated with centrosome amplification and 
increased multipolar spindles 
In addition to lagging chromosomes and UFBs, multipolar mitotic spindles are another type of 
mitotic error that can be detected by staining mitotic cells. Multipolar spindles are strongly 
associated with supernumerary centrosomes that may arise as a result of centrosome 
amplification. Multipolar spindles can perturb balanced separation of sister chromatids and 
can often result in random segregation to daughter cells, hence giving rise to aneuploid cells 
(Gisselsson 2008). 
In order to determine whether the phenomenon of centrosome amplification and multipolar 
spindles was associated with primed to naïve hESC reprogramming, cells from various time 
points during reprogramming were stained with DAPI, anti-centrin3 which stains centrosomes, 
and anti-β-tubulin which stains microtubules. Across the period from primed to naïve hESCs, a 
number of different types of multipolar spindles could be detected (Figure 5.5a). While nearly 
100% of primed and early transition hESCs typically displayed 4 centrioles as expected (Figure 
5.5b), there were an elevated number of naïve hESCs with more than 4 centrioles (figure 5.5c), 
corresponding to mitotic cells with multipolar spindles. This suggests that there may be an 
increased likelihood of an aneuploid population of cells in the naïve state as a result of random 
chromosome segregation associated with multipolar spindles. 
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Figure 5.5. Spindle abnormalities can be detected in naïve hESCs. a) Images of cells stained with DAPI (blue), anti-
centrin 3 (green) which stains centrioles, and β-tubulin (red), which allows the visualisation of spindle fibres. The 
first row represents an example of a normal spindle, with 4 centrioles and an organised spindle. The second two 
rows show representative examples of abnormal multi-polar spindles, each with more than 4 centrioles. Scale bars 
represent 5µm. b) Quantification of the percentage of cells with less than 4 centrioles, 4 centrioles, or more than 4 
centrioles at each stage of reprogramming. c) Centriole number per cell (black dots) during reprogramming. Red 
lines represent the mean. The number at the top of each bar represents the total number of nuclei analysed for 
each time point.  
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5.5 Long-term naïve hESCs exhibit increased aneuploidy  
Having observed signs of chromosomal instability, we next investigated the potential 
outcomes of these aberrations by using various techniques to measure the chromosomal 
content of individual cells during reprogramming.  
We first performed DAPI staining of fixed cells followed by flow cytometry simply to measure 
the DNA content of cells. As hESCs are grown on a layer of iMEF feeder cells, the flow 
cytometry staining protocol required a separation strategy to eliminate the feeder cells from 
the analysis. The most common published method for this involves dissociating the mixture of 
hESCs and iMEFs, and performing serial plating to allow separation of the two cell types on the 
basis that iMEFs adhere to plastic surfaces faster than hESC. In our hands, this was only able to 
eliminate 50% of feeder cells. We therefore used an anti-feeder antibody for positive 
discrimination of iMEFs and to test whether this could efficiently separate iMEFs from hESCs, 
we further stained the cells with an antibody for human Thy1/CD90 which is a cell surface 
marker that is highly expressed in primed hESCs but is absent in naïve hESCs (Chapter 3; Figure 
3.1c). We performed flow cytometry to visualise the separation of primed and naïve hESCs 
from each other and from feeder cells and confirmed that the anti-feeder antibody was 
successfully able to separate iMEFs from hESCs (Figure 5.6a). We repeated the staining in the 
absence of the anti-CD90 antibody, instead staining cells with anti-feeder and DAPI and 
analysed the DNA content of primed and naïve hESCs by comparing levels of DAPI. Primed 
hESCs have a DAPI profile that is considered normal, whereby there is a peak of cells in the G1 
phase of the cell cycle with a single copy of the genome, a smaller number of cells in S phase 
with intermediate levels of DNA content, and a second peak of cells in the G2/M phase of the 
cell cycle with duplicated DNA content (Figure 5.6b). The naïve hESCs also retain this profile, 
but in addition, there is an additional tail and peak on the histogram, depicting cells with an 
abnormal DNA content greater than that of cells undergoing mitosis. This is indicative of 
aneuploid and tetraploid cells in the naïve hESC population (Figure 5.6b).  
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Figure 5.6. Aneuploidy can be detected in naïve hESCs through analysis of cellular DNA content. a) Representative 
flow cytometry plots of anti-feeder/CD90 stained primed and naïve hESCs, with iMEFs as a control. Plots shown 
have already filtered out debris and doublets. Plots are shown for forward scatter area (FSC-A) against anti-feeder 
APC and for forward scatter height (FSC-H) against CD90-PE. Mouse feeder cells can be separated from a mixed 
population to give primed (CD90+) and naïve (CD90-) hESC populations with 96.2% and 98.4% purity respectively. b) 
DAPI-area histogram for primed and naïve hESCs following removal of debris, doublets and iMEFs from the analysis. 
The histogram shows a normal cell cycle profile for primed hESCs, with an expected distribution of cells in G1, S, or 
G2/M phase of the cell cycle. In the naïve hESCs, an abnormal aneuploidy/tetraploid population can be detected in 
addition to this profile.  
 
 
159 
 
We next performed immunofluorescence staining of cells across the transition from primed to 
naïve hESCs to determine how early on during reprogramming these abnormalities are 
apparent. Cells were stained with DAPI and the anti-CREST antibody as an indication of 
chromosome number. As a control, we used the hTERT-RPE1 cell line which is expected to 
have normal numbers of chromosomes. Figure 5.7a depicts examples of aneuploid cells 
detected with abnormal numbers of chromosomes. The number of centromeres stained by the 
anti-CREST antibody was used as a readout of the number of chromosomes present in each 
cell. We counted the number of chromosomes per cell and used a threshold of 41-51 to define 
a cell with a normal diploid chromosome number to allow for staining error. Cells with less 
than 41 or more than 51 chromosomes were considered to be aneuploid (Figure 5.7b). 
Compared to the hTERT-RPE1 cell line which has a very stable diploid genome with no signs of 
aneuploidy, the hESCs generally display higher levels of variability in the number of 
chromosomes per cell. However, the mean chromosome number per cell for primed hESCs and 
hESCs in the early transition of reprogramming remains within +/- 5 of the expected 46 
chromosomes in a diploid genome, and then begins to deviate from the expected mean during 
the late transition (Figure 5.7c). The stable naïve hESCs which have been passaged 20 times 
exhibit higher levels of aneuploidy, showing a significant increase in chromosome number per 
cell compared to primed hESCs.  
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Figure 5.7. Abnormal chromosome numbers are more prevalent in naïve compared to primed hESCs. a) A 
representative microscope image of a primed and naïve hESC stained with the CREST antibody which stains all 
centromeres (red) and DAPI (blue), in each case depicting a cell with more than the normal number of 
chromosomes. Scale bar represents 5µm. b) Quantification of the percentage of cells with less than 41 
chromosomes, between 41 and 51 chromosomes, or more than 51 chromosomes at each stage of reprogramming. 
The RPE1 cell line was used as a control. c) Chromosome number per cell (black dots) during reprogramming. Red 
lines represent the mean. The number at the top of each bar represents the total number of nuclei analysed for 
each time point. Statistical significance between the time points was analysed using a one-way ANOVA with 
multiple testing. Significant difference between primed and naïve hESCs is indicated with a p-value. 
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5.6 p53 protein expression is stabilised in naïve hESCs 
The mitotic checkpoint is a mechanism employed by cells to ensure that chromosome 
segregation occurs accurately during mitosis, and is one of a number of cell cycle checkpoints 
that act to regulate cell cycle progression. The mitotic checkpoint should prevent the majority 
of structural aberrations that have been detected during primed to naïve hESC 
reprogramming. One of the key proteins associated with each of the cell cycle checkpoints is 
p53. P53 is implicated during each of the cell cycle checkpoints, and in the response to DNA 
damage, where it mediates cell cycle arrest of programmed cell death in response to various 
signals (Giono and Manfredi 2006). In normal cells, p53 is maintained at low levels by proteins 
that regulate its expression, but it is stabilised and activated in response to various cellular 
stresses and stimuli (Shieh et al. 1997; Kubbutat, Jones, and Vousden 1997). P53 plays a role in 
preventing the propagation of aneuploid cells that result from incorrect mitosis, thereby 
playing a role in maintaining genomic stability (Giono and Manfredi 2006).  
P53 is one of the most frequently mutated tumour suppressor genes across multiple cancer 
types, and mutations in p53 are also positively selected for in some human pluripotent stem 
cells (Merkle et al. 2017). Moreover, it has recently been suggested that p53 may contribute to 
DNA methylation homeostasis in ESCs by regulating the expression of DNMT3A and DNMT3B 
(Tovy et al. 2017). Additionally, there is evidence to suggest that p53 acts as a barrier to 
efficient cellular reprogramming, and that mutations to p53 enhance cellular reprogramming 
and increase the malignant potential of the reprogrammed cells (Marion et al. 2009; Sarig et 
al. 2010).  
We measured both gene and protein expression of p53 across the transition from primed to 
naïve pluripotency in hESCs. At the level of gene expression p53 is highly expressed in primed 
hESCs and is downregulated upon the early transition of reprogramming and maintained at 
reduced levels throughout reprogramming to naïve hESCs (Figure 5.8a). At the protein level, 
however, p53 is initially downregulated as cells go through the early stages of reprogramming, 
but the protein appears to be later stabilised as cells go through the late transition of 
reprogramming, and is particularly abundant in stable naïve hESCs (Figure 5.8b). It is worth 
nothing that the antibody used for detection is able to detect both wild-type and mutant forms 
of the p53 protein. 
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Figure 5.8. p53 protein expression is stabilised in naïve hESCs. a) Counts per million (CPM) from RNA-seq data of 
p53 across the transition of hESC reprogramming. Bars are representative of the mean of three biological replicates. 
b) Western blot analysis of p53 across the transition from primed to naïve pluripotency. GAPDH is used as a loading 
control. 
 
 
5.7 Loss of DNMT3B does not enhance genomic instability upon reprogramming 
The centromeres that hold sister chromatids together and ensure proper chromosome 
segregation during mitosis are composed primarily of repetitive DNA satellites. The 
centromeric proteins B and C (CENP-B and CENP-C) localise to alpha satellite or minor satellite 
DNA at the centromeres (Guenatri et al. 2004; Muro et al. 1992; Politi et al. 2002). Centromeric 
regions also exhibit distinct epigenetic modifications, including dense DNA hypermethylation 
and histone lysine di- and trimethylation, particularly at H3K9 (Lehnertz et al. 2003).  
A major link between DNA methylation and genomic stability comes from the study of patients 
with ICF syndrome which is caused by mutations in DNMT3B and is characterised by mitotic 
defects (Ehrlich 2003). One of the key defining features of the disease is the DNA 
demethylation of centromeric and pericentromeric repeats and loss of chromosome 
condensation during mitosis (Ehrlich 2003). It has been demonstrated that DNMT3B interacts 
with CENP-C and that CENP-C recruits DNMT3B and DNA methylation to centromeric and 
pericentromeric satellite repeats, which further regulates the characteristic histone code at 
these regions (Gopalakrishnan et al. 2009). In this context, loss of either CENP-C or DNMT3B 
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through experimental manipulation led to increased chromosomal segregation defects and 
genomic instability (Gopalakrishnan et al. 2009).  
Using the DNMT3B knock down hESC lines generated in chapter 3, we sought to investigate a 
potential role of diminished DNMT3B expression on the chromosomal and genomic instability 
detected early during reprogramming. Our hypothesis was that in the absence of DNMT3B, we 
may see an increase of cells with abnormal chromosomal structures as a result of loss of 
DNMT3B-mediated epigenetic regulation of centromeres. Using cells stained with DAPI and 
anti-CREST, we once again used the number of CREST positive foci as a readout of 
chromosome number in primed and early transition wild-type (WT) and DNMT3B knock down 
cells (Figure 5.9a). We also counted the number of chromosomes per cell and used a threshold 
of 41-51 to define a cell with a normal diploid chromosome number to allow for staining error. 
Cells with less than 41 or more than 51 chromosomes were considered to be aneuploid (Figure 
5.9b). The mean chromosome number per cell for WT and DNMT3B knock down primed and 
early transition hESCs remains within +/- 5 of the expected 46 chromosomes in a diploid 
genome, indicating that reduced expression of DNMT3B does not influence chromosomal 
stability in the early stages of hESC reprogramming. Additionally, we quantified the percentage 
of anaphase cells with lagging chromosomes and UFBs in WT and DNMT3B knock down hESCs 
(Figure 5.9c and 5.9d). Once again, there was no significant difference between the 
percentages of mitotic cells with laggards or UFBs in the DNMT3B knock down cells compared 
to the WT in either primed or early transition hESCs. Collectively, these results indicate that a 
reduction in the expression of DNMT3B does not affect chromosomal instability in the early 
stages of primed to naïve hESC reprogramming.  
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Figure 5.9. Downregulation of DNMT3B does not enhance genomic instability during early reprogramming. a) 
Chromosome number per cell (black dots) during early reprogramming in wild-type (WT) and DNMT3B knock down 
(KD) hESCs. Red lines represent the mean. The number at the top of each bar represents the total number of nuclei 
analysed for each time point. b) Quantification of the percentage of cells with less than 41 chromosomes, between 
41 and 51 chromosomes, or more than 51 chromosomes at each stage of reprogramming. The RPE1 cell line was 
used as a control. c) Quantification of the % of cells in anaphase with errors based on the detection of lagging 
chromosomes during early reprogramming in WT and DNMT3B KD hESCs. The RPE1 cell line was used as a control. 
The number at the top of each bar represents the total number of anaphase nuclei analysed for each time point. 
Bars represent the mean of 2 biological replicates. Error bars represent SEM. Statistical significance was calculated 
using a one-way ANOVA with a post-hoc test comparing each KD sample to the WT for each time point. N.S. 
denotes not significant. d) Quantification of the percentage of cells with ultrafine bridges (UFBs) during early 
reprogramming in WT and DNMT3B KD hESCs. The RPE1 cell line was used as a control. The number at the top of 
each bar represents the total number of anaphase nuclei analysed for each time point. Bars represent the mean of 
2 biological replicates Error bars represent SEM. Statistical significance was calculated using a one-way ANOVA with 
a post-hoc test comparing each KD sample to the WT for each time point. N.S. denotes not significant. 
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5.8 The genomic mutation frequency is unaffected by global demethylation upon 
reprogramming 
The assays detailed above indicated that reprogramming is associated with genomic instability. 
We were next interested in determining whether the demethylation that occurs during 
reprogramming affects the global mutation frequency in hESCs, as has been reported in other 
contexts (Chen et al. 1998). We used a whole-genome sequencing approach to measure the 
mutation frequency during hESC reprogramming. We opted to measure hESC in the late 
transition of reprogramming and in naïve hESCs grown for 20 passages following induction of 
the stable naïve state, with primed hESCs used as a basal measure of the ongoing mutation 
rate. The cells in the late transition of reprogramming were used as an intermediate time point 
to detect any potential increase in mutation frequency directly influenced by the ongoing 
genomic demethylation, while the naïve hESCs were used to try to detect any change in the 
mutation frequency that accrued over time in the population as a result of the cells having a 
global demethylated genome. For both time points, we were interested in detecting all 
mutations with a low variant allele frequency (VAF), irrespective of the genomic location of the 
mutation, as hESCs in culture are unlikely to face any specific selective pressures that would 
select for certain mutations.  
We performed WGS for primed, late transition and naïve hESCs, and obtained whole genome 
sequencing reads at a coverage of 5x per sample. We counted the total number of C to T 
variants per sample and normalised this value to either the total read count per sample (Figure 
5.10a) or the total number of single nucleotide variants detected (Figure 5.10b), and 
additionally calculated the ratio between C to T and A to G variants (Figure 5.10c). We 
observed no significant difference in the frequency of C to T mutations between primed, late 
transition and naïve hESCs, indicating that global demethylation upon reprogramming does not 
affect the mutation frequency in the cells. However, due to the low coverage of the data, the 
low level of variability between the different time points is comparable to the low variability 
between replicates. This suggests that the variability is attributable to the background error 
rate that arises as a result of PCR and sequencing errors. It is therefore difficult to distinguish 
true variation between samples from background noise, suggesting that a considerably higher 
coverage of sequencing reads would be required to detect true variation in the frequency of 
mutations.  
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Figure 5.10. Global demethylation does not affect the C to T mutation frequency. a) The total number of C to T 
mutations per sample, normalised to the total read count per sample. Bars are representative of two biological 
replicates, and error bars represent SEM. Statistical significance between samples was calculated using a one-way 
ANOVA. N.S. denotes not significant. b) The total number of C to T mutations per sample, normalised to the total 
number of single nucleotide variants per sample. Bars are representative of two biological replicates, and error bars 
represent SEM. Statistical significance between samples was calculated using a one-way ANOVA. N.S. denotes not 
significant. c) The total number of C to T mutations per sample, divided by the total number of A to G variants, 
displayed as a C to T/ A to G ratio. Bars are representative of two biological replicates, and error bars represent 
SEM. Statistical significance between samples was calculated using a one-way ANOVA. N.S. denotes not significant. 
 
5.9 Hypermethylation of CGIs during reprogramming is not associated with an 
increased mutation frequency 
Methylated CpGs are considered to be more prone to spontaneous deamination than 
unmethylated CpGs, and T:G mismatches generated through both spontaneous deamination 
or AID-induced deamination undergo less efficient repair (Shen, Rideout, and Jones 1994; 
Schmutte et al. 1995). We used rt-qPCR to measure the expression of AID/AICDA across the 
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time course of reprogramming and detected a transient upregulation of its expression during 
the early stages of reprogramming (Figure 5.11).  
 
 
Figure 5.11. AID is transiently upregulated during the early transition of reprogramming. qRT-PCR for AID across 
the transition of hESC reprogramming. Bars are representative of the mean of three technical replicates and three 
independent biological replicates. Error bars represent the standard error of the mean. Statistical difference 
between samples was analysed by a two-tailed Student’s t-test, with a Bonferroni post-hoc test comparing each 
time point to primed hESCs. *P<0.05, **P<0.01 and ***P<0.001. Human GAPDH was used to normalise expression. 
 
 
We subsequently set out to determine whether the CGI hypermethylation that accumulates 
during primed to naïve reprogramming increases the mutability of CpG residues at CGIs. To 
allow the cells enough time to undergo multiple divisions following de novo methylation, we 
opted to study the effect of CGI hypermethylation on DNA mutation in cells in the late 
transition of reprogramming and in naïve hESCs grown for 20 passages following induction of 
the stable naïve state. The cells in the late transition of reprogramming were used as an 
intermediate time point to detect any potential early mutations at CGIs which are not 
subsequently maintained in the population following multiple rounds of cell division, while the 
naïve hESCs would allow us to detect mutations that accrued over time in the population. Both 
time points were compared to primed hESCs, which contain primarily unmethylated CGIs.  
We used our WGBS analysis (detailed in chapter 3) to identify two control regions within CGIs 
that are unmethylated in primed hESCs and remain unmethylated throughout the process of 
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reprogramming to the naïve state. We also selected three test CGI regions that are 
unmethylated in primed hESCs that become hypermethylated during reprogramming and 
remain hypermethylated in naïve hESCs. Each of regions selected contained at least 6 CpG 
sites. We amplified DNA from the five regions at each of the three time points using and then 
used a targeted sequencing approach to obtain high-depth sequencing of each of the regions 
for our analysis.  
 
 
Figure 5.12. DNA hypermethylation at CGIs does not impact the frequency of C to T mutations. a) The percentage 
variant allele frequency (% VAF) for C to T mutations compared to all other single nucleotide variants in primed, 
naïve, and late transition hESCs, at regions that become hypermethylated during reprogramming and b) regions 
that remain unmethylated during reprogramming. Bars are representative of the mean of two independent 
biological replicates. Error bars represent the standard error of the mean. Statistical significance between samples 
was calculated using a two-way ANOVA, comparing the time points of reprogramming and the type of variant, with 
a post-hoc test comparing C to T mutations and all variants for each time point. N.S. denotes not significant, *** 
denotes p < 0.001. c) The %VAF of C to T mutations for primed, naïve and late transition hESCs for hypermethylated 
and non-hypermethylated regions. Bars are representative of the mean of two independent biological replicates. 
Error bars represent the standard error of the mean. Statistical significance between samples was calculated using a 
two-way ANOVA, comparing the time points of reprogramming and the methylation status of the region, with a 
post-hoc test comparing C to T mutations at hypermethylated and non-hypermethylated regions for each time 
point. N.S. denotes not significant. 
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Using an analysis pipeline that enabled the calculation of VAFs of all single nucleotide variants, 
we compared the average VAFs of C to T mutations compared to all variants at each time 
point. We used a minimum threshold of 0.001 (0.1%) to identify variants. This threshold is 10-
fold lower than the 1% cut-off typically used to variant calling, however as we were interested 
in comparing rare variants between samples with two replicates per time point, and because 
the non-hypermethylated regions and the primed hESCs both act as controls, we reasoned 
that this cut-off was sufficient to test our hypothesis. Moreover, as with the WGS analysis, 
hESCs in culture are unlikely to face any particular selective pressures that would select for 
specific mutations and increase their VAFs. We observed no significant difference between the 
VAFs of C to T mutations compared to all variants at the regions that become hypermethylated 
upon reprogramming (Figure 5.12a). For the control regions that remain unmethylated during 
reprogramming, there was a statistically significant difference between the VAFs of C to T 
mutations compared to all variants, however this was observed at all time points (Figure 
5.12b). Moreover, when we looked specifically at C to T mutations and compared the VAFs 
across the time points at both hypermethylated and non-hypermethylated regions, we found 
no significant differences between any of the average VAFs, indicating that there was no 
difference between regions that become hypermethylated compared to those that remain 
unmethylated throughout the reprogramming process (Figure 5.12c). Altogether, we observed 
that C to T mutations were not more frequent than other substitutions at any regions or at any 
time point, and that hypermethylation did not increase the VAFs of C to T mutations in a site-
specific manner. This suggests that the CGI hypermethylation associated with reprogramming 
does not influence the intrinsic mutability of CpGs and that the upregulation of AID detected 
early during the reprogramming process does not have an impact of the rate of C to T 
mutations, or that the AID protein is not actually expressed despite the mRNA being present, 
though this remains to be tested.  
 
5.10 Discussion 
The data presented in this chapter demonstrate preliminary evidence of some genomic 
instability in cells as they undergo reprogramming from the primed to the naïve state of 
human pluripotency. The genomic instability observed appears to be related to the 
reprogramming process, but largely independent of the global DNA demethylation and 
regional CGI hypermethylation that occurs upon reprogramming, though this remains to be 
explored further due to their temporal overlap.  
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Our data showed that upon primed to naïve hESC reprogramming, the levels of DNA DSBs 
based on γ-H2AX positive foci remain constant, which may either be due to steady levels of 
DNA damage, or the lack of activation of the DDR. Interestingly, while we did not observe 
evidence of an increased frequency of DNA DSBs, we observed evidence of a number of 
different manifestations of chromosomal segregation errors, such as lagging chromosomes, 
UFBs in anaphase nuclei, and multipolar mitotic spindles with extra centrosomes. The 
correlation between the frequencies of these mitotic segregation errors is expected, as a 
mitotically unstable population will typically display different types of errors, likely in a similar 
fraction of cells (Gisselsson 2008), though this is difficult to infer from staining of fixed cells. 
Moreover, we observed a significant increase in the number of aneuploid or tetraploid cells in 
the naïve hESC population, which is likely the outcome of the chromosomal errors that bypass 
the various check points in the cell cycle. This increased karyotypic instability is in line with 
previous studies that have reported abnormal chromosomal content in certain naïve hESC lines 
generated either from primed hESCs or through iPS reprogramming of somatic cells (Pastor et 
al. 2016; Kilens et al. 2018).  
The specific types of chromosomal aberrations observed such as UFBs and primarily acentric 
lagging chromosomes are indicative of pre-mitotic defects and suggest that replication stress 
may play a role in generating instability. Replication stress has previously been associated with 
similar chromosomal aberrations, and has been implicated as a potential cause of genomic 
instability in other types of cellular reprogramming (Burrell et al. 2013; Ruiz et al. 2015). To 
ascertain whether replication stress is indeed a contributing factor to chromosomal instability 
during reprogramming, one possible experimental approach would be to induce 
reprogramming of primed hESCs in the presence of additional exogenous nucleotide 
supplements in case exhaustion of the nucleotide pool results in DNA replication defects and 
the associated chromosomal instability (Bester et al. 2011).  
Genome alterations such as those detected upon primed to naïve hESC reprogramming only 
become a threat to the cell once they pass anaphase. It has been shown in other contexts that 
if such chromosome structures are left unresolved, they can give rise to chromosomal 
aberrations such as those typically found in cancer. In line with this, the stabilisation of p53 
protein in naïve hESCs is an interesting observation as it could reflect stabilisation of the wild-
type p53 protein, indicating that damaged naïve hESCs may be undergoing apoptosis. The 
apoptosis of damaged naïve hESCs could be a possible explanation for the lower percentage of 
cells with lagging chromosomes and ultrafine bridges in the stable naïve hESC population 
compared to the cells in the early and late transition of reprogramming. Alternatively, as the 
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antibody used recognises both wild-type and mutant forms of the protein, accumulation of 
p53 in naïve hESCs could reflect stabilisation of a mutant form of p53, as has previously been 
observed in hESC lines and is a frequent observation in cancer where mutant p53 favours 
cancer cell survival (Merkle et al. 2017; Mantovani, Collavin, and Del Sal 2019).  
Our data indicated that a reduction in the expression of DNMT3B did not affect the levels of 
abnormal mitotic structures observed early during hESC reprogramming. As we did not 
explicitly assess the DNA methylation status of centromeric DNA in DNMT3B knock down 
hESCs however, we cannot conclude whether the expected demethylation of centromeric and 
pericentromeric DNA repeats occurred upon knock down of DNMT3B. Moreover, we did not 
assess chromosomal instability in the DNMT3B knock down cells at later stages of 
reprogramming or in naïve hESCs lacking DNMT3B, which correspond to the time points where 
the most instability was evident in wild type hESCs. However, from the data we have, we can 
conclude that diminished expression of the DNMT3B protein does not acutely influence 
chromosomal instability during the early stages of primed to naïve hESC reprogramming.  
We tested a putative relationship between DNA demethylation and the frequency of ongoing 
mutations in hESCs during the late transition of reprogramming and in naïve hESCs. Our data 
showed no detectable change in the mutation frequency between primed, late transition and 
naïve hESCs. The experimental approach used enabled us to sequence the genome at 5x 
coverage for each sample, with duplicate samples of primed, naïve and late transition hESCs, 
each of which represent a heterogeneous population of cells. The average mutation rate in 
normal human somatic cells is estimated to range between 3x10-7 and 3x10-8 mutations per 
nucleotide per generation of cells, equating to roughly 10 to 100 mutations per genome per 
generation for the human genome that is made up of 3x109 base pairs (Xue et al. 2009; 
Genomes Project et al. 2010; Milholland et al. 2017) . With the 5x coverage we obtained, it is 
difficult to differentiate between true mutations and false positives, as the VAFs for each of 
the variants identified were below the estimated 1% error rate that is a limitation of the next-
generation sequencing process. This 1% error rate constitutes polymerase errors, bias during 
PCR amplification as well as errors during cluster amplification and sequencing (Fox et al. 
2014). It is therefore difficult to draw strong conclusions from this experiment. An improved 
approach for future studies would be to employ sequencing techniques that are designed to 
minimise the background error rate, such as duplex sequencing, which is reported to have an 
error rate of less than 1 artefactual mutation per billion nucleotides by operating on the 
premise that true mutations must be found on both strands of the DNA (Schmitt et al. 2012). 
Additionally, as hESCs in culture may not undergo any selective pressure that would facilitate 
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the accumulation of mutations, it may also be beneficial to grow up single cell clones of hESCs 
and perform sequencing on the resulting cell populations in order to be able to detect variants 
at a sufficient depth. 
We also tested the differential susceptibility of C to T mutations arising from methylated and 
unmethylated cytosine nucleotides, through either spontaneous deamination or deamination 
by AID. We saw no significant difference in the VAFs of C to T mutations across the time course 
of reprogramming as CGIs become hypermethylated, or between regions that are 
hypermethylated compared to those that remain unmethylated. Despite using a targeted 
sequencing approach that enabled a greater depth of sequencing for each region analysed, the 
VAFs of the mutations identified were all once again below 1%, thereby making it difficult to 
differentiate them from background noise and to draw strong conclusions with regards to the 
relationship between DNA methylation and mutation susceptibility. Moreover, the primed to 
naïve hESC in vitro reprogramming system is unlikely to be subjected to specific selective 
pressures that would enable the clonal selection and outgrowth of cells with specific mutations 
as is the case for clonal mutations in cancer. However, given the high depth of sequencing 
using a targeted approach (a minimum of 10,000 reads per region), it is likely that the low VAFs 
of below 1% indicate that there is no increase in the frequency of C to T mutations as a result 
of hypermethylation during reprogramming. Once again, employing a sequencing technique 
such as duplex sequencing may be a better approach to ascertain any relationship between 
DNA methylation and mutation.  
The preliminary characterisation of genomic instability and altered mutation frequency upon 
primed to naïve hESC reprogramming detailed in this chapter indicates that some degree of 
genomic instability is associated with reprogramming to the naïve state of pluripotency. The 
instability appears to be associated with replication stress and manifests as structural 
chromosomal aberrations that are detectable in mitotic cells during anaphase. On the 
contrary, the mutation rate of primed, naïve and late transition hESCs appears to be 
comparable, indicating that reprogramming and the associated DNA methylation changes do 
not affect the cellular mutation rate. Due to limitations of the experimental and sequencing 
approaches used, however, further experiments using more sensitive technologies are 
necessary to enable firm conclusions to be drawn with regards to reprogramming, DNA 
methylation and mutation frequency.  
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Chapter 6. Conclusions and Future Directions 
 
6.1 Discussion & Future Directions 
 
6.1.1 Dynamics and functions of DNA methylation in hESCs and cancer 
In this thesis, we demonstrate that upon reprogramming of primed hESCs to the naïve state of 
pluripotency, cells acquire DNA methylation at a subset of CGI promoters associated with 
developmental genes, while globally, the genome undergoes demethylation. By performing a 
temporal analysis of DNA methylation levels during the transition between the two pluripotent 
states, we show that the acquisition of DNA hypermethylation is gradual, and that global 
erasure of DNA methylation also occurs at a late stage of reprogramming, despite several 
changes in gene and protein expression occurring rapidly upon induction of reprogramming. 
This is consistent with the profile of iPS reprogramming of somatic cells, where global 
demethylation occurs at a late stage, after several waves of transcriptional reprogramming and 
global chromatin remodelling (Polo et al. 2012; Mikkelsen et al. 2008).  The level of 
hypermethylation accrued at each CGI varies, with some CGIs gaining 10% methylation, while 
others gain up to 80-90% methylation. This indicates that not all the cells in the population of 
reprogramming hESCs are gaining DNA methylation at each region, pointing to population 
heterogeneity in the epigenetic landscape of cells upon reprogramming. Moreover, only a 
subset of the hypermethylated sites retain the hypermethylation in stable naïve hESCs, 
suggesting that the reprogramming process may be selecting for cells with a particular DNA 
methylation profile. To verify whether primed to naïve hESC reprogramming involves active 
reprogramming of cells or the selection of a subset of cells, hESCs could be labelled with 
bromodeoxyuridine (BrdU) and the rate of loss of BrdU monitored upon induction of 
reprogramming to determine the rate of actively proliferating cells. Additionally, it would also 
be of interest to determine whether cells that become hypermethylated during the transition 
phase are those that successfully transition to the naïve state, by sorting cells during the early 
transition of reprogramming based on positive staining for the cell surface marker Sushi 
domain containing 2 (SUSD2), which has recently been reported to be a reliable marker for the 
purification of naïve hESCs (Bredenkamp et al. 2019). 
The DNA methylation landscape that results upon primed to naïve hESC reprogramming 
mirrors the human cancer DNA methylome, where aberrant CGI hypermethylation is 
frequently observed amidst a globally hypomethylated genome. Such parallels to the cancer 
DNA methylome have been drawn previously in other mammalian species and developmental 
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contexts, such as in mouse trophoblast cells (Smith et al. 2017). However, the data we present 
here demonstrates a hypermethylation phenomenon conserved across in vitro and in vivo 
human pluripotency (Guo et al. 2014), strengthened by its reproducibility across multiple in 
vitro reprogramming methods (Theunissen et al. 2014; Guo et al. 2017). Moreover, it is 
notable that we do not observe comparable hypermethylation in the mouse ICM or in in vitro 
mouse ESCs cultured in the presence of 2i inhibitors. This observation may reflect the fact that 
hESCs and mESCs in vitro represent different pluripotent states, which is further highlighted by 
the differences in their gene expression (Davidson, Mason, and Pera 2015). Of particular 
relevance for this study, it is notable that naïve human and mouse ESCs exhibit varied 
expression of DNMTs, in particular DNMT3L which is highly upregulated in naïve hESCs as 
demonstrated in our data, but is downregulated in mESCs cultured in 2i (Ficz et al. 2013; von 
Meyenn et al. 2016). In recent years, the emergence of novel sequencing technologies that 
allow for more detailed characterisation of the molecular processes underlying mouse and 
human early development have exposed a number of differences between the two, likely with 
functional consequences (Hanna, Demond, and Kelsey 2018; Boroviak et al. 2018). Such 
differences have potential implications for making inferences with regards to epigenetic 
processes between species, both in development and in the study of cancer, as has been noted 
previously (Diede et al. 2013).  
The presence of methylated CGIs both in naïve hESCs in vitro and in human ICM cells in vivo 
suggests that the hypermethylation may play a functional role in the maintenance of naïve 
pluripotency. This is supported by the finding that similar developmental pathways undergo 
hypermethylation and gene repression, perhaps further attenuating the expression of lowly 
expressed genes and maintaining cells in a naïve state. We observed that naïve hESCs 
generated from either DNMT3A or DNMT3B knockdown primed hESCs exhibited reduced 
stability in the naïve pluripotent state. It is currently difficult to distinguish whether this is 
reflective of an inability of the primed hESCs to successfully transition to the naïve state in the 
absence of the DNMT3s, or whether the lack of de novo DNA methylation directly impacts the 
stability of the naïve pluripotent state. Additionally, it is unclear whether the impact on naïve 
hESCs is dependent on the catalytic de novo methylation activity of the two enzymes, or is a 
result of a non-catalytic role of DNMT3A and DNMT3B. This could be further tested by using an 
independent method to erase DNA hypermethylation at bivalent CGIs, such as treatment of 
naïve hESCs with the DNA demethylating agent 5-azacytidine, followed by evaluation of the 
impact of lack of hypermethylation on the stability of the naïve pluripotent state. Moreover, it 
would be useful to validate the findings of both DNMT3A and DNMT3B knockdowns by 
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generating CRISPR knockout primed hESC lines of the two enzymes and reprogramming them 
to the naïve state, in order to be sure that any residual protein in the knockdown cell lines is 
not influencing the cellular phenotype. In parallel, it would also be of interest to generate 
CRISPR knockout cell lines directly in naïve hESCs, in order to clarify whether DNMT3A and 
DNMT3B and their de novo methylation activity are required for the process of reprogramming 
or for the stable naïve state. In addition to assessing the impact of DNMT3A and DNMT3B 
knockout on the naïve pluripotent state in knockout cell lines generated using both strategies, 
it would also be interesting to evaluate the differentiation potential of the knockout hESCs to 
ascertain whether the de novo methylation is functionally important during the process of 
differentiation. The SUSD2 cell-surface marker could also be used in this context to verify how 
efficiently the DNMT knockdown or knockout hESCs transition to naïve pluripotency 
(Bredenkamp et al. 2019). Current protocols for differentiating naïve hESCs require the cells to 
be transitioned through the primed state in vitro conditions before they differentiate into 
progenitors of various cell lineages (Takashima et al. 2014), suggesting that a molecular barrier 
which may involve DNA methylation restricts their ability to differentiate directly from the 
naïve state. To this end, the abnormal morphology detected in naïve hESCs generated from 
DNMT3A and DNMT3B knockdown hESCs may be indicative of spontaneous differentiation 
occurring in the absence of such a barrier and this could be further explored by staining for 
cellular markers of differentiation.  
The relationship between a bivalent histone signature at developmental gene promoters and 
the acquisition of DNA methylation that we observe upon primed to naïve hESC 
reprogramming is consistent with reports of hypermethylated bivalent CGIs identified upon iPS 
reprogramming (Ohm et al. 2010; Doi et al. 2009). Moreover, it mirrors the wealth of literature 
that has detailed a similar predisposition of CGIs marked by polycomb or bivalent histone 
modifications in stem cells to exhibit DNA hypermethylation in cancer (Easwaran et al. 2012; 
Widschwendter et al. 2007; Ohm et al. 2007; Schlesinger et al. 2007; Bernhart et al. 2016). 
Additionally, our observation that bivalent regions that become hypermethylated upon 
reprogramming lose H3K4me3 but retain H3K27me3 is consistent with studies in cancer that 
have also reported the co-occurrence of H3K27me3 and DNA methylation (Gao et al. 2014). 
Conversely, H3K27me3 and DNA methylation are considered to be mutually exclusive during 
mammalian development, and genome-wide analysis of histone modifications in naïve hESCs 
generated using the 5iLAF reprogramming protocol showed a reduction of H3K27me3 at 
developmental gene promoters (Brinkman et al. 2012; Theunissen et al. 2014). A more 
comprehensive global analysis of histone modifications upon reprogramming to the naïve 
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state may improve our understanding of the relationship between bivalency and DNA 
methylation.  
We observed a striking overlap between the CpGs that become hypermethylated upon 
reprogramming and those hypermethylated in a range of cancer types. The data also revealed 
that a number of the reprogramming-associated hypermethylated CpGs that exhibit high levels 
of DNA methylation in cancer also show moderate levels of methylation in the matched 
normal tissue. This may be because the normal tissue used on TCGA is typically healthy tissue 
neighbouring the site of the tumour, which may also be undergoing some aberrant molecular 
processes despite being considered non-malignant. Moreover, the majority of the patients 
from which the tissues are taken on TCGA are elderly individuals, and the CGI methylation 
observed may be attributable to ageing-associated DNA methylation which has also been 
shown to overlap with cancer hypermethylation (Rakyan et al. 2010). To ascertain more 
comprehensively the degree of overlap between reprogramming-associated hypermethylation 
and hypermethylation associated with both ageing and cancer, it would be of value in future 
analyses to compare the data to samples from the NIH Roadmap Epigenomics Project 
(Bernstein et al. 2010), which comprises DNA methylation data of various tissue types from 
both young and old healthy individuals.  
 
6.1.2 Mechanisms of aberrant DNA methylation 
The global demethylation that occurs upon primed to naïve hESC reprogramming is 
accompanied by a downregulation of the DNMT1 binding partner UHRF1, which is responsible 
for recruiting DNMT1 to replicating DNA. This downregulation occurs at the protein level but 
not at the mRNA level, indicating post-transcriptional or post-translational regulation of the 
protein. While we did not experimentally test whether this is the primary mechanism 
responsible for the global loss of DNA methylation upon hESC reprogramming, the finding is in 
line with data from mESCs converted from serum to 2i conditions, where downregulation of 
UHRF1 protein and the resulting impairment of maintenance methylation has been reported 
as the major mechanism resulting in a hypomethylated genome in 2i mouse ESCs (von Meyenn 
et al. 2016). Further exploration is required in future studies to verify whether impaired 
maintenance methylation is the primary cause of DNA demethylation upon hESC 
reprogramming.  
The DNA loci that are hypermethylated upon reprogramming of primed hESCs to the naïve 
state exhibit a high degree of overlap with CpGs that are hypermethylated across a variety of 
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different cancer types. Despite some degree of tissue-specific DNA hypermethylation in 
cancers from distinct tissue types (Sproul et al. 2012), studies that have performed pan-cancer 
DNA methylation analysis have reported a considerable overlap in the regions that are 
hypermethylated across cancer types (Easwaran et al. 2012). Moreover, these studies have 
highlighted an enrichment of these pan-cancer hypermethylated loci in developmental 
pathways, often more specifically in pathways associated with neuronal development (Kim et 
al. 2012; Easwaran et al. 2012). Collectively, the findings of these studies suggest that aberrant 
DNA methylation does not occur through a stochastic process, as only a subset of genomic loci 
are affected by this phenomenon, with substantial similarity across cancer types, independent 
of their underlying genetic mutations. Instead, they point toward an instructive mechanism 
controlling DNA methylation, relying on the interaction of DNMTs with trans-acting protein 
complexes and specific DNA sequences (Keshet et al. 2006). 
Our data indicates that DNMT3A, and particularly the shorter isoform DNMT3A2 is responsible 
for the deposition of de novo DNA methylation at bivalent promoter CGIs during the early 
stages of reprogramming primed hESCs to the naïve state of pluripotency. This finding is not in 
line with a study performed in mouse extraembryonic tissues, where DNMT3B has been 
identified as the DNMT responsible for depositing DNA methylation at bivalent CGI promoters 
associated with developmental genes (Smith et al. 2017). It is also not consistent with a study 
performed in differentiating mESCs, where the longer isoform of DNMT3, DNMT3A1, was 
found to control de novo DNA methylation at bivalent CGIs. Additionally, two independent 
studies investigating the function of a mutant form of DNMT3A with a point mutation in the 
PWWP domain have reported aberrant DNA hypermethylation of DNA regions marked by 
polycomb or bivalent histone modifications, but in each case, hypermethylation is observed 
upon differentiation when DNMT3A1 becomes more dominantly expressed (Heyn et al. 2018; 
Sendzikaite et al. 2019). It is likely that the precise roles of DNMT3A and DNMT3B are 
dependent on the cellular context and the specific isoforms expressed. We observed that 
during the late transition of reprogramming, as the gene expression of DNMT3B increases and 
we detect the peak of hypermethylation, both DNMT3A and DNMT3B appear to contribute to 
the hypermethylation. This finding is in support of correlations drawn in cancer settings 
between increased DNMT3B expression and gene hypermethylation (Roll et al. 2008; Linhart 
et al. 2007). To verify whether both enzymes contribute to hypermethylation in the later 
stages of reprogramming or to ascertain whether one is able to compensate for the other, a 
DNMT3A and DNMT3B double knockout cell line could be transitioned to the naïve state and 
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DNA methylation measured to assess whether the absence of both enzymes abrogates de 
novo methylation altogether.  
The data presented in this thesis demonstrates that CGIs marked by bivalent histone 
modifications in primed hESCs are prone to deposition of de novo DNA methylation upon 
reprogramming to the naïve state. However, while the bivalent state appears to be predictive 
of regions that are hypermethylated during primed to naïve hESC reprogramming and of 
aberrant DNA hypermethylation in cancer, many bivalent regions do not become 
hypermethylated, indicating that bivalency is not sufficient to prime a region for 
hypermethylation. This suggests that other factors may also contribute to this phenomenon. 
To this end, it has been found that the proximity of a CGI to retrotransposon elements can 
influence their predisposition to DNA methylation independently of other chromatin features 
(Estecio et al. 2010). More recently, it has been shown that partially methylated domains 
which undergo demethylation in cancer acquire intermediate DNA methylation levels, 
regardless of the underlying functional genomic elements, such that CGIs become 
hypermethylated (Brinkman et al. 2019). Additionally, a number of studies have identified 
short DNA motifs that discriminate between DNA loci that are sensitive or resistant to DNA 
methylation (Keshet et al. 2006; Feltus et al. 2006; Lienert et al. 2011). It is possible that a 
simple unifying mechanism of aberrant DNA methylation does not exist, but that various 
determinants and are reconciled to generate the DNA methylation patterns that are 
characteristic of cancer genomes.  
Our data points towards the transcription factor network established upon reprogramming 
playing a role in the targeting or recruitment of DNMT3A to loci that gain methylation. In 
particular, our validation of four transcription factors NFKB1, SOX15, ZFHX3 and FOXC1 implies 
that they may each play a role in regulating de novo methylation. Based on the current 
literature, the four transcription factors are not involved in common pathways. However, 
SOX15 is associated with a stem cell phenotype and is also upregulated upon iPS 
reprogramming (Nishino et al. 2010; Maruyama et al. 2005). FOXC1 is upregulated in many 
cancer types and is considered to play a role in conferring stem-like properties in cancer cells 
(Yang et al. 2017). The NKFB1 gene encodes the 105 kDa protein p105, which undergoes 
further processing to produce the 50 kDa protein p50, which is a DNA-binding subunit of the 
NFKB protein complex. Specifically, p50 can form a p50-p50 homodimer or can form a p50-p65 
heterodimer, and each of these combinations have been reported to act as transcriptional 
repressors or to drive tumour-promoting inflammation in a context-dependent manner 
(Concetti and Wilson 2018). Moreover, p50 has previously been shown to interact with the 
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H3K4me3 demethylase KDM5A and recruit it to gene promoters to maintain a repressive 
chromatin state (Zhao et al. 2016). While none of these studies directly report a relationship 
between the transcription factors and DNA methylation, their roles in stem cells, cancer, and 
in transcriptional repression suggest that they may also play a role in DNA methylation. The 
combinations of transcription factors active in different cell types or cancer types may result in 
the tissue-specific variation observed among the DNA methylomes of different cancer types 
(Sproul et al. 2012). It would be useful in future studies to evaluate the effect of the knock 
down of a transcription factor that it not overexpressed during reprogramming to determine 
whether the high expression of these transcription factors is related to their role in controlling 
de novo methylation. Moreover, although our data suggests that the effect of the transcription 
factor knockdown may be independent of their binding, the data is based on predicted binding 
sites and may not be reflective of the true binding profile of each transcription factor in hESCs. 
Therefore, if each transcription factor plays a role in controlling de novo methylation at a 
subset of sites, it is plausible that generating a multi-knockdown cell line and assessing the 
impact on DNA methylation may produce a similar effect to the knockdown of DNMT3A. 
Finally, it would also be of value to reprogram the transcription factor knock down cell lines 
beyond the early transition through to the stable naïve state to confirm whether or not they 
successfully reprogram, to distinguish whether the reduction in DNA methylation is due to 
reduced de novo methylation or inefficient reprogramming. Furthermore, whilst we cannot 
currently differentiate between a direct interaction of DNMT3A with transcription factors or an 
indirect effect  on the targeting of the enzyme by the active transcription factor network, it has 
previously been demonstrated that DNMT3A can be recruited to the DNA in a loci-specific 
manner by transcription factors (Brenner et al. 2005) and in vitro data supports the ability of 
DNMT3A to interact directly with numerous transcription factors (Hervouet, Vallette, and 
Cartron 2014). Future studies could test the putative protein-protein interaction by performing 
co-immunoprecipitation of DNMT3A and the various transcription factors. Additionally, 
targeted or global ChIP analysis of the transcription factors would aid the interpretation of the 
data by clarifying which of the predicted binding sites is actually bound by each of the 
transcription factors in hESCs and how this is altered upon reprogramming.  
Although we did not find evidence of a role for TET1 in protecting CGIs from DNA methylation 
upon primed to naïve hESC reprogramming, further verification is required in future 
experiments to confirm whether TET1 was successfully overexpressed at the protein level. 
Moreover, several other CXXC domain-containing proteins have been implicated in playing a 
protective role against DNA methylation in other cellular contexts (Long, Blackledge, and Klose 
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2013), and these proteins may be relevant for the mechanism of hypermethylation in naïve 
hESCs and in cancer. The selection criteria used to identify candidate proteins that may be 
involved either in site-specific targeting of DNMTs to the DNA, or in protection of CGIs from 
DNA methylation was the changing expression levels of the proteins. However, this does not 
take into account mechanisms such as post-translational modifications or protein localisation 
that may impact their activity and functions upon reprogramming. It remains possible that the 
protection of CGIs by CXXC domain-containing proteins acts alongside the transcription factor 
mediated recruitment of de novo DNMTs to the DNA to regulate DNA hypermethylation and 
this should be addressed further in future studies. 
Our data are also indicative of the overexpressed pluripotency factors NANOG and KLF2 
coordinating de novo methylation, however studies have shown that KLF2 is not expressed in 
vivo in the human ICM (Yan et al. 2013; Blakeley et al. 2015), where we also observe 
hypermethylation. Additionally, we observe comparable hypermethylation in naïve hESCs 
generated using two transgene-independent methods of reprogramming. This collectively 
suggests that the core pluripotency network, to which NANOG belongs, may be responsible for 
coordinating the transcriptional changes that drive DNA hypermethylation. Figure 6.1 depicts 
the model of de novo methylation during reprogramming that emerges through the 
intersection of various lines of evidence from the data in this thesis, including the de novo 
DNMTs, bivalent histone modifications, the transcription factor network and pluripotency 
factors. There is growing evidence in the literature regarding the acquisition of stem-like 
properties and expression of pluripotency genes in cancers, which contribute to intratumour 
heterogeneity and plasticity and may facilitate the formation of cancer stem cells (Ben-Porath 
et al. 2008; Chen and He 2016; Friedmann-Morvinski and Verma 2014). This makes it intriguing 
to speculate that a transcriptional programme associated with the pluripotency network could 
drive a shared mechanism of hypermethylation during reprogramming to naïve pluripotency 
and in cancer development, either preceding or in conjunction with genetic mutations.   
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Figure 6.1. Model of de novo DNA hypermethylation upon primed to naïve hESC reprogramming. The model that 
emerges from the data in this thesis is that upon reprogramming of primed hESCs to the naïve state, DNMT3A, and 
later DNMT3B carry out de novo methylation at bivalent CGI promoters, which concomitantly lose H3K4me3. The 
de novo DNMTs are targeted to these loci by DNA-binding transcription factors (TFs) which act either through a 
direct or indirect interaction with the DNMTs. This process is further regulated by NANOG and the naïve 
pluripotency network. 
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6.1.3 Reprogramming of hESCs as a model system for cancer development 
Alongside the epigenetic, transcriptional, and metabolic changes occurring during the 
transition from primed to naïve human pluripotency, our data shows preliminary evidence of 
multiple manifestations of chromosomal instability upon reprogramming, resulting in the 
accumulation of aneuploid cells in the naïve hESC population. Similar to frequent aberrant 
DNA methylation patterns, aneuploidy is a common feature of human cancers (Gordon, Resio, 
and Pellman 2012). Whether or not the genomic instability is related to the changing 
epigenetic landscape cannot be inferred from the current data, but it is evident that both 
processes are induced as cells acquire a more primitive pluripotent state. These processes may 
be analogous to those that occur in differentiated somatic cells, as they acquire enhanced self-
renewal and proliferative capacity during iPS reprogramming and in cancer development. In 
line with this, there is now early evidence of in vivo processes that resemble reprogramming, 
such as the recently described process of paligenosis (Willet et al. 2018). In this process, fully 
differentiated stomach cells regain plasticity and proliferative potential and re-enter the cell 
cycle in response to tissue injury, with the potential to result in dysplasia in the context of 
chronic injury or inflammation that enables the accumulation of mutations (Jin and Mills 
2019). Similar processes involving the plasticity of differentiated cells and their ability to 
undergo dedifferentiation and reprogramming of their cellular identity in response to tissue 
injury or stress have been reported in several other tissue types (Puri, Folias, and Hebrok 2015; 
Wang et al. 2017; Boerboom et al. 2017; Yu et al. 2018; Desai, Brownfield, and Krasnow 2014; 
Miyajima, Tanaka, and Itoh 2014). Moreover, signalling pathways such as the MAPK pathway 
and Wnt signalling which are involved in primed to naïve hESC reprogramming and stem cell 
maintenance have also been implicated in the regulation of such processes (Boerboom et al. 
2017), and these pathways are some of the most frequently misregulated signalling pathways 
in cancer (Zhan, Rindtorff, and Boutros 2017; Dhillon et al. 2007). While the epigenetic 
landscape during these in vivo dedifferentiation processes has not yet been assessed, the 
change in cellular state implies that epigenetic changes are involved as cellular identity is 
epigenetically regulated. As with partial reprogramming induced by transient expression of the 
OSKM factors in vivo which results in dysplasia, the improper regulation of in vivo 
dedifferentiation processes in response to tissue injury, particularly chronic conditions, may 
increase the likelihood of the generation of dysplastic cells, as increased cellular and epigenetic 
plasticity can facilitate the hallmarks of cancer (Ohnishi et al. 2014; Flavahan, Gaskell, and 
Bernstein 2017). Figure 6.2 summarises these ideas into a model depicting dedifferentiation 
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and reprogramming as potential routes to cancer formation through shared molecular 
processes, including DNA methylation. 
The understanding of the development and early stages of cancer is limited by the scarcity of 
suitable model systems. Cancer has long been considered a genetic disease, with the clonal 
model of cancer having prevailed in the literature, but the initial processes that facilitate 
mutations at specific sites in specific tissues of origin and result in the transformation of a 
normal cell into a cancer cell remain ambiguous (Polak et al. 2015; Feinberg, Ohlsson, and 
Henikoff 2006). There is growing evidence that clonal expansion of cancer driver mutations 
exists at low frequencies in the healthy ageing population, indicating that additional processes 
are required for disease initiation (Xie et al. 2014; Young et al. 2016; Blokzijl et al. 2016). 
Whether epigenetic changes precede mutations and prime cells for genomic instability or 
whether aberrant epigenetic changes are the result of DNA mutations also remains an area 
that requires further study, as both possibilities have been proposed previously (Feinberg, 
Ohlsson, and Henikoff 2006; Youn et al. 2018). The majority of cancer studies focus on 
comparing cancer cells to normal tissue of the closest analogous tissue type. As a result, much 
of the data regarding aberrant epigenetic modifications in cancer is correlative, while causal 
relationships have been more difficult to demonstrate. Moreover, the molecular processes 
that underlie many of the aberrations that are detected in cancer remain poorly characterised 
as they may no longer be active in the cancer cells of patients at the time of study. A recent 
technological advance that has enabled the modification of the epigenome in a targeted 
manner in vitro using CRISPR technology has facilitated the demonstration of 
hypermethylation driving aberrant molecular processes in the absence of cancer driver 
mutations (Saunderson et al. 2017). Moreover, using organoid models which are a closer 
representation of in vivo tissues compared to cell lines, it has been shown that 
hypermethylation can accelerate oncogene-driven transformation in vitro (Tao et al. 2019). 
While these studies represent major advances in our understanding of the role of DNA 
methylation in cancer by indicating that DNA hypermethylation can play a driving role in 
carcinogenesis, the underlying molecular mechanisms that bring about aberrant 
hypermethylation still have not been elucidated.  
The primed to naïve hESC reprogramming system is unique in that it enables thorough 
temporal characterisation of the molecular processes that give rise to the abnormal epigenetic 
patterns observed in both naïve hESCs and across many cancer types. Despite hESCs being far 
removed from somatic cells which form the bulk of human tumours, the parallels between the 
epigenetic landscapes of naïve hESCs and cancer cells suggest that reprogramming and the 
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transformation of normal cells into cancer cells may share common epigenetic trajectories. 
Moreover, it is also plausible that the MEK1/2 and GSK3β pathway inhibition, along with the 
overexpression of NANOG and KLF2 act to phenocopy the signalling effects of cancer driver 
mutations, thus resulting in comparable DNA methylomes. Molecular mechanistic insight 
gained from studying primed to naïve reprogramming may be relevant for understanding 
cancer formation. Mechanisms deciphered in stem cells could be further tested in more 
physiological model systems such as organoids to enhance the understanding of the epigenetic 
and mutational trajectories that facilitate transformation.    
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Figure 6.2. Reprogramming and cancer. During normal human development, stem cells give rise to various lineages 
of differentiated/somatic cells through the process of differentiation, which involves epigenetic changes that 
modulate changes in cell identity. Differentiation can be reversed in vivo in response to tissue injury that results in 
dedifferentiation, or through induced pluripotent stem cell reprogramming, and these stem cells can be further 
reprogramming to a more primitive naïve state of pluripotency in vitro. The molecular processes underlying these 
changes in cellular state, particularly the epigenetic reprogramming, may parallel processes occurring during 
malignant transformation. Of particular relevance to this thesis, both naïve hESCs and cancer cells exhibit genome-
wide DNA hypomethylation and promoter CpG islands (CGI) hypermethylation, while somatic cells and primed 
hESCs exhibit a globally hypermethylated genome with unmethylated CGIs. 
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6.2 Concluding Remarks 
The commonality in DNA methylation patterns across cancer types, each harbouring different 
driver mutations, suggests that DNA methylation changes occur early in tumourigenesis, and 
this has been demonstrated previously (Hanley et al. 2017), though models of early cancer 
development are limited. In line with this, the notion that cancer cells follow an evolutionary 
trajectory towards a stem cell state (Chen and He 2016; Ben-Porath et al. 2008) makes the 
transition from primed to naïve pluripotency an interesting model to study biological 
processes such as DNA methylation and DNA damage that results in chromosomal and 
genomic instability, as these processes likely occur early during cellular transformation or 
cancer initiation, and may be analogous to dedifferentiation. Using this system, we have 
demonstrated that upon reprogramming primed hESCs to the naïve state, transcription factors 
and the pluripotency network facilitate de novo DNA methylation amidst global demethylation 
that likely results from impaired maintenance methylation. In parallel, chromosomal instability 
accumulates in the cells and results in aneuploidy. Whether or not additional molecular 
features of the primed to naïve state transition that appear analogous to cancer hallmarks 
(Hanahan and Weinberg 2011) - such as altered metabolism (Takashima et al. 2014), loss of 
imprints, and loss of DNA hydroxymethylation (Ficz and Gribben 2014) - are related to the 
changing epigenetic landscape remains unexplored, but further use of this model system may 
shed light on the emergence of these characteristics during cellular transformation. Primed to 
naïve hESC reprogramming may provide a good model system to understand whether cellular 
reprogramming and the molecular processes associated with it play a role in tumourigenesis. 
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